The molecular determinants and consequences of recombination in the evolution of human enteroviruses by Lowry, Kym
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
A Thesis Submitted for the Degree of PhD at the University of Warwick
http://go.warwick.ac.uk/wrap/38168
This thesis is made available online and is protected by original copyright.
Please scroll down to view the document itself.
Please refer to the repository record for this item for information to help you to
cite it. Our policy information is available from the repository home page.
 The Molecular Determinants and Consequences 
of Recombination in the Evolution of Human 
Enteroviruses 
 
 
Kym Sheree Lowry  
 
A thesis submitted for the degree of Doctor of Philosophy  
 
University of Warwick 
 
School of Life Sciences  
 
March 2011 
Table of Contents 
 
List of Tables .............................................................................................................. 3 
List of Figures ............................................................................................................. 4 
Acknowledgements..................................................................................................... 6 
Declaration.................................................................................................................. 8 
Summary..................................................................................................................... 9 
Abbreviations ........................................................................................................... 10 
CHAPTER ONE: Introduction .............................................................................. 14 
1.1 Classification.............................................................................................. 14 
1.2 Virus Structure and Life Cycle .................................................................. 21 
1.3 Enterovirus Evolution ................................................................................ 35 
1.4 Aims ........................................................................................................... 47 
CHAPTER TWO: Materials and Methods ........................................................... 48 
2.1 Cell Culture and Virological Methods ....................................................... 48 
2.2 Molecular Genetic Techniques .................................................................. 52 
2.3 Stock Solutions and Buffers....................................................................... 58 
2.4 List of DNA plasmids ................................................................................ 60 
2.5 Restriction Enzymes to Linearise Plasmids ............................................... 61 
2.6 List of Oligonucleotides............................................................................. 62 
CHAPTER THREE: RNA-mediated Interference to Enrich Recombinants .... 63 
3.1 Introduction................................................................................................ 63 
3.2 Construction of anti-PV miRNA Expressing Plasmid ............................... 70 
3.3 Transient Expression of miRNA to Reduce Virus Replication ................. 76 
3.4 Transient Expression of siRNA to Reduce Virus Replication................... 80 
3.5 Discussion .................................................................................................. 93 
CHAPTER FOUR: In vitro Recombination .......................................................... 99 
4.1 Introduction................................................................................................ 99 
4.2 Proposed Methodology ............................................................................ 102 
4.3 Recovery of Intratypic Recombinants...................................................... 105 
4.4 Recovery of Intertypic Recombinants...................................................... 108 
4.5 Recovery of Intraspecies Recombinants .................................................. 109 
4.6 Co-transfections with RNA Partners Belonging to Species B................. 115 
4.7 Discussion ................................................................................................ 121 
CHAPTER FIVE: Characterisation of Recombinants....................................... 124 
5.1 Introduction.............................................................................................. 124 
5.2 PV3/PV1 Recombinants .......................................................................... 125 
5.3 Intraspecies Recombinants....................................................................... 155 
5.4 Comparative Bioinformatic Analysis of RNA Partner Sequences .......... 164 
5.5 Discussion ................................................................................................ 185 
CHAPTER SIX: Construction of RNA Partners for Co-transfections............. 190 
6.1 Introduction.............................................................................................. 190 
6.2 Generation of a Full-length Infectious E30 cDNA .................................. 193 
6.3 Generation of a Full-length EV7 CRE Mutant cDNA............................. 206 
6.4 Discussion ................................................................................................ 212 
CHAPTER SEVEN: General Discussion............................................................. 215 
Bibliography: .......................................................................................................... 224 
 -2-
List of Tables 
Table 1.1 Classification of Picornavirus family ........................................................ 16 
Table 1.2 Clinical symptoms associated with certain enteroviruses ......................... 19 
Table 1.3 Some enterovirus serotypes and their receptors ........................................ 23 
Table 2.1 List of subgenomic replicon and full-length clones used in this study ..... 60 
Table 2.2 Restriction sites used to linearise plasmids for RNA transcriptions ......... 61 
Table 2.3 Oligonucleotides used throughout this study ............................................ 62 
Table 3.1 Summary of RNAi and delivery methods ................................................. 66 
Table 3.2 Synthesised miRNA oligonucleotides (DNA) and corresponding 
nucleotide positions in PV1 and PV3 genome .......................................... 71 
Table 3.3 Synthesised siRNA oligonucleotides (RNA) and corresponding nucleotide 
positions in PV1 and PV3 genome............................................................ 82 
Table 4.1 Combinations of interspecies co-transfections performed ...................... 118 
Table 5.1 Characterisation of PV3/PV1 recombinants by crossover region from 
single co-transfection............................................................................... 130 
Table 5.2 Characterisation of PV3/PV1 recombinants by crossover region from an 
independent co-transfection in L929 cells............................................... 138 
Table 5.3 Characterisation of PV3/PV1 recombinants by crossover region after 
continuous passage through HeLa cells .................................................. 150 
Table 5.4 Recombinant viruses recovered from three intraspecies co-transfections
................................................................................................................. 158 
 
 
 -3-
List of Figures 
Figure 1.1 Genome structure of enteroviruses. ......................................................... 25 
Figure 1.2 Summary of the PV life cycle.................................................................. 29 
Figure 1.3 Poliovirus negative-strand synthesis........................................................ 31 
Figure 1.4 Poliovirus positive-strand RNA synthesis. .............................................. 33 
Figure 1.5 Current replication-dependent template switching models for RNA 
recombination. ........................................................................................ 43 
Figure 3.1 RNAi silencing of mRNA in cells. .......................................................... 68 
Figure 3.2 RNAi regimes to enrich recombinants in a virus population................... 69 
Figure 3.3 The expression vector kit used to deliver virus specific miRNA to cells.75 
Figure 3.4 Immunofluorescence of GFP expressing plasmids in cells. .................... 77 
Figure 3.5 Effects of miRNA on PV replication....................................................... 79 
Figure 3.6 Intra-assay variation using miRNA. ........................................................ 81 
Figure 3.7 Effects of siRNA on PV replication. ....................................................... 84 
Figure 3.8 Effects of MET-2C siRNA dose-response on PV replication. ................ 87 
Figure 3.9 Effects of si-6243PV3 siRNA dose-response on PV3 replication........... 88 
Figure 3.10 Effects of combinations of siRNA on PV replication............................ 90 
Figure 3.11 Optimisation of siRNA transfection and infection time points. ............ 92 
Figure 3.12 Challenging siRNA transfected HeLa cells at higher MOIs of PV. ...... 94 
Figure 4.1 Generating recombinant virus in the absence of infectious parental virus.
.............................................................................................................. 103 
Figure 4.2 Method used to generate recombinant viruses by co-transfection......... 104 
Figure 4.3 Virus recovered from L929 cells co-transfected with PV3 RNA 
molecules. ............................................................................................. 107 
Figure 4.4 Virus recovered from BsrT7 cells co-transfected with PV1 and PV3 RNA 
partners. ................................................................................................ 110 
Figure 4.5 Intraspecies C recombinants constructed by Dr. Claire Blanchard. ...... 112 
Figure 4.6 Virus recovered from intraspecies RNA co-transfections. .................... 114 
Figure 4.7 Virus recovered from pT7EV7luc + pT7EV7ΔCRE co-transfections. . 116 
Figure 4.8 Plaque assays of interspecies co-transfection supernatant..................... 120 
Figure 5.1 Identification and biological cloning of 100 PV3/PV1 recombinant 
viruses. .................................................................................................. 126 
Figure 5.2 An example of a non-clonal recombinant virus mixture. ...................... 129 
Figure 5.3 Chromatogram of sequenced recombinant virus 105B.......................... 131 
Figure 5.4 Sixteen distinct crossover junctions identified from 100 cloned PV3/PV1 
recombinants......................................................................................... 133 
Figure 5.5 Sites of crossover junctions in recovered PV3/PV1 recombinants. ...... 135 
Figure 5.6 Origin of the inserted 15 nt sequence in recombinant 25A at the crossover 
site......................................................................................................... 137 
Figure 5.7 Four distinct crossovers identified from 31 cloned PV3/PV1 
recombinants in a repeated independent experiment............................ 139 
Figure 5.8 Single-step growth curves...................................................................... 141 
Figure 5.9 Plaque phenotypes of parent and two selected recombinant viruses. .... 143 
Figure 5.10 Competition assays between recombinant and wild-type viruses in the 
same infection. ...................................................................................... 145 
 -4-
Figure 5.11 Changes in crossover regions from passaged PV3/PV1 recombinants.
.............................................................................................................. 147 
Figure 5.12 Crossover regions of PV3/PV1 recombinants after serial passage 
through HeLa cells................................................................................ 149 
Figure 5.13 Sites of the recombination junctions in the passaged recombinants 51G 
and 36B. ................................................................................................ 152 
Figure 5.14 New crossover sites for serially passaged recombinants. .................... 153 
Figure 5.15 RT-PCR product of biologically cloned intraspecies C recombinants.156 
Figure 5.16 Single intraspecies recombinant formed from RNA partners.............. 159 
Figure 5.17 Crossover junctions of intraspecies C recombinants formed from 
replicons and Dr. Blanchard’s constructed recombinants. ................... 160 
Figure 5.18 Changes in crossover region of serially passaged intraspecies 
recombinants......................................................................................... 163 
Figure 5.19 Imprecise and precise recombination junctions and correlation to 
sequence identity between RNA partners............................................. 166 
Figure 5.20 Mononucleotide composition of RNA partners................................... 168 
Figure 5.21 Comparison of junction sites and homopolymers located in 
recombination regions of PV1 and PV3. .............................................. 169 
Figure 5.22 Palindromic sequences identified within targeted recombination region 
of PV1 and PV3. ................................................................................... 171 
Figure 5.23 Local secondary structures using MFED analysis for PV1 and PV3 
regions of recombination. ..................................................................... 173 
Figure 5.24 Amino acid similarity scan between PV1 and PV3............................. 175 
Figure 5.25 Comparing 2Apro domain structures to precise junction sites.............. 178 
Figure 5.26 Amino acid similarity scans comparing PV1, PV3, and CVA21 protein 
sequences across the recombination region. ......................................... 180 
Figure 5.27 Crossover sites in PV3 and PV1 recombinants from this study and from 
the literature. ......................................................................................... 181 
Figure 5.28 Correlation coefficients for locations of junction sites in recombinants 
recovered............................................................................................... 184 
Figure 5.29 Distance of template switching from original displacement from donor 
template................................................................................................. 187 
Figure 6.1 Overview of proposed E30 full-length infectious clone construction. .. 192 
Figure 6.2 Amplification and restriction digests of E30 cDNA.............................. 195 
Figure 6.3 Construction of pT7E30 full-length infection clone for E30................. 197 
Figure 6.4 Phylogenetic analysis of cloned E30 strain GB37................................. 200 
Figure 6.5 Recovery of infectious E30 from RNA transfections............................ 201 
Figure 6.6 Growth characteristics of infectious full-length pT7E30 GB37 clone. . 203 
Figure 6.7 Overview of construction of E30 subgenomic replicon encoding 
luciferase............................................................................................... 205 
Figure 6.8 Predicted secondary structure of wild-type and mutagenised EV7 CRE 
stem loop............................................................................................... 207 
Figure 6.9 Strategy for mutagenising CRE in full-length infectious clone pT7EV7.
.............................................................................................................. 209 
Figure 6.10 Overlapping PCR of EV7 CRE fragments. ......................................... 210 
Figure 7.1 Production (and restrictions) of a viable recombinant RNA virus. ....... 218 
 
 -5-
List of Appendices 
Appendix 1 Potential cleavage products of selected imprecise recombinants........ 233 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -6-
Acknowledgements 
 
This work was funded by a University of Warwick Studentship, to which I am 
extremely grateful for making this research project possible. I have appreciated the 
opportunity to gain valuable experience in such a rich research environment and have 
enjoyed all that Warwick University (including an outstanding virology section) has 
to offer. 
 
I would like to thank my supervisor Professor David J. Evans for awarding me a 
scholarship – thank you for taking that leap of faith having never met the potential 
student on the other side of the world. I appreciate the endless time, help, and support 
throughout my PhD and realise how lucky I was to have such an approachable 
supervisor.  
 
I need to thank the members of the Evan’s lab for making it such an enjoyable work 
environment. I’ll miss the cheeky sports banter, the constant laughs, and the wealth 
of knowledge and experience that made it so enriching. 
  
Thanks must go to my family and friends who have offered constant support 
throughout and always provided help or a sympathetic ear. I can’t wait to spend more 
time with you all. 
 
I would like to dedicate this thesis to my mother, Judy, who overcame serious illness 
during the course of my study and taught me what it was to ‘knuckle down’ and keep 
going when the times were tough. You are brave and always look to the future. 
 
Finally, I would like to acknowledge the unwavering support, direction, patience, 
understanding, occasional prodding, computer expertise, and shoulder to lean on, of 
my husband Mark. What more can I say? Thank you so much. 
 
 -7-
Declaration 
 
This work was completed at the University of Warwick between July 2007 and 
November 2010 and has not been submitted for another degree. The work is original 
and unless otherwise stated in the text, has been completed by the author. 
 
 
 
Signed 
 
 
 
 
Date
 -8-
Summary 
Recombination is an important biological process in a diverse range of viruses, 
particularly those with single-stranded ribonucleic acid (RNA) genomes including 
the enteroviruses. Mutations caused by the error-prone RNA-dependent RNA 
polymerase (RdRp) and the vast population size of these virus populations are 
evolutionary mechanisms that generate genetic diversity – this allows viruses to 
survive under changing environmental pressures (e.g. adaptive host immunity). 
Ribonucleic acid recombination has been identified as another contributing 
mechanism involved in diversification, by removing interfering or lethal mutations 
from a virus genome, and by establishing new viruses.  
 
Virus RNA recombination is well documented and is identified in several virus 
families including picornaviruses. However, recombination is a rare event and the 
study of the molecular mechanisms behind virus recombination is complicated by 
our ability to isolate and analyse recombinants from a mixed virus population 
including the parental viruses. 
 
The objectives of this study were to firstly devise a method for generating 
populations of natural recombinant viruses, and secondly, to study the molecular 
processes that determine where and when recombination occurred in the enteroviral 
genome.  
 
During this project, an in vitro system was developed to allow the recovery of 
recombinant enteroviruses in the absence of their parental viruses. Two virus RNA 
molecules containing “lesions” rendering them unable to generate viable virus on 
their own were co-transfected into mouse L929 cells. The method required two 
parental virus RNA molecules to be present in a single cell to produce a viable 
recombinant virus. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and 
sequencing analysis confirmed the recombinant nature of progeny virus genomes. 
Experimental data confirmed the effectiveness of the method and provided evidence 
that recombination occurs in at least two phases. Initial template switching, referring 
to the transfer of RdRp from one RNA template to another mid-replication, occurred 
apparently indiscriminately and with the addition of extra virus and non-virus 
sequence at the junction sites. In the second phase, any additional sequence was lost 
during subsequent rounds of replication and selection. The approach was expanded 
to incorporate viruses from different enterovirus species to investigate intra- and 
interspecies recombination events.  
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CHAPTER ONE: Introduction 
Evolution requires genetic variation. Positive-sense single stranded RNA viruses 
including important human pathogens like poliovirus (PV) and rhinovirus have error 
prone polymerases, short replication cycles, and high yields that together contribute 
to genetic diversity. Far greater genetic variation is achieved by chance 
recombination events than is possible in a single round of genome replication, and 
this is an important biological process that accelerates virus evolution further.  
 
Although the result of many separate recombination events have been observed and 
characterised in nature, other than an understanding of the underlying principle, little 
is known about the mechanisms (viral and host) that establish the location of 
recombination breakpoints across the virus genome. Recombination is a rare event 
(possibly only one per million progeny), so this complicates isolation and analysis of 
recombinants from a mixed population. To this end, a method has been developed to 
recover recombinant viruses in vitro in the absence of infectious parental viruses.  
 
This review will briefly consider the mechanisms of enteroviral evolution, methods 
of RNA recombination and evidence of recombination in enteroviruses both 
naturally and in the laboratory. Poliovirus, being the prototype strain of 
picornaviruses, is one of the best studied viruses and is used extensively during this 
project. As such, the majority of this literature review will focus on this virus. 
1.1 Classification 
Virus classification and the species concept 
Classifying viruses into a taxonomic system is primarily performed by the 
International Committee on Taxonomy of Viruses (ICTV). The classification of a 
new virus into a family is based on morphology of the virion, the type of genomic 
nucleic acid it contains (e.g. single- or double stranded deoxyribonucleic acid [DNA] 
or RNA), the method of replication, and in some cases, the host organism (Hyypiä et 
al., 1997). A collection of genera form a family and these are generally defined on 
the basis of virion density, acid sensitivity, and host organisms. A virus “species” is a 
group of viruses that share similar morphological characteristics, can recombine 
amongst themselves to produce viable progeny, and can infect the same range of host 
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species. A group of species, in turn, comprise a genus. The term virus species implies 
a single genotype whereas RNA viruses, due to their large population sizes and high 
mutation rates, are in fact a diverse population of genotype variants or quasispecies 
(Lauring & Andino, 2010). Virus species are further subdivided into serotypes, 
which are classically defined as antigenically distinct viruses that are incapable of 
being neutralised to a significant extent by other serotype antibodies from the same 
species. Genetic variation within serotypes leads to the identification of virus strains, 
which are the limit to virus classification.  
 
The picornavirus family 
The picornaviruses are small (pico is a very small unit of measure), single stranded 
positive-sense RNA viruses belonging to the family Picornaviridae. Poliovirus is the  
type species (Flint et al., 2004) and the family includes 12 genera that are responsible 
for morbidity in both humans and animals (summarised in table 1.1). After 
poliomyelitis, probably the most notable disease-causing picornavirus is foot-and-
mouth disease virus (FMDV) (genus aphthovirus), which infects cloven-hoofed 
animals such as cattle and swine (Bachrach, 1968). This highly infectious virus has 
devastating financial effects on the agricultural industry through the necessary 
elimination of millions of animals and containment/sanitation measures. Other 
picornaviruses that greatly impact public health comprise enteroviruses (including 
PV and echoviruses); rhinoviruses (causing the majority of cases of the common 
cold); and hepatoviruses (hepatitis A virus [HAV]).  
 
The enterovirus genus 
Human enteroviruses are currently subgrouped into seven species, Human 
Enterovirus (HEV) A-D and Human Rhinovirus (HRV) A-C (Arden & Mackay, 
2009). Over 100 distinct human enterovirus serotypes exist at present and these were 
mainly grouped according to pathogenicity in experimental animals before the 
introduction of more modern molecular methods for classification (Hyypiä et al., 
1997). Recently, over 70 identified serotypes were assigned or reassigned to various
 -15-
 Table 1.1 Classification of Picornavirus family 
Genus Species Serotype 
Aphthovirus Equine rhinitis A virus ERAV 
 Bovine rhinitis B virus BRV-2 
 Foot-and-mouth disease virus FMDV-A, FMDV-Asia1,  
    FMDV-C, FMDV-O, FMDV-SAT1-3 
Avihepatovirus Duck hepatitis A virus DHV-1 
Cardiovirus Encephalomyocarditis virus EMCV 
  Theilovirus TMEV, VHEV, TLV, RTV-1 
Enterovirus Bovine enterovirus BEV-1, BEV-2 
 Human enterovirus A CVA2-8, 10, 12, 14, 16, EV71, 76, 89-92,  
  SV46 
 Human enterovirus B CVA9, CVB1-6, E-1-9, 11-21, 24-27, 29-33,  
  EV69, 73-75, 77-88, 95, 97, 100, 101, 
  SVDV, unclass HVB 
 Human enterovirus C CVA1, 11, 13, 15, 17-22, 24, EV96, PV1-3,  
  unclass EVC 
 Human enterovirus D EV68, 70, 94 
 Human rhinovirus A HRV-1, 2, 7-13, 15, 16, 18-25, 28-34, 36,  
  38-41, 43-47, 49-51, 53-68, 71, 73-78,  
  80-82, 85, 88-90, 94-96, 98 
 Human rhinovirus B HRV-3-6, 14, 17, 26, 27, 35, 37,42, 48, 52,  
  69, 70, 72, 79, 83, 84, 86, 91-93, 97, 99  
 Human rhinovirus C HRV-1-3, HRV-4-6, 8, 10, 12, 13, 17-20,  
 (not defined) 22-28, 30-35, 37, 38, 40-48, 51-57, 59-61, 
  63, 64, 66-71, 73-84, 86-88, 90-100 
 Porcine enterovirus B PEV-9, 10, J10 
  Simian enterovirus A A-2PV, SVSA4, SVSV4, SVSV28, SPV7 
Erbovirus Equine rhinitis B virus ERV-2 
Hepatovirus Hepatitis A virus HAV, SAV 
Kobuvirus Aichi virus AiV, unclass KV 
  Bovine kobuvirus BKV 
Parechovirus Human parechovirus E1-8, 10, 11 
  Ljungan virus LV87-012, LV145SL, LV174F 
Sapelovirus Avian sapelovirus ASV 
  Porcine sapelovirus PV8, PVJ4, PVJ6 
Senecavirus Seneca Valley virus SVV 
Teschovirus Porcine teschovirus PTV1-11, PV11, PVJ1-3, 5, 7, 9 
Tremovirus Avian encephalomyelitis virus AEMV 
As of 21 Jan 2011 
Virus abbreviations are outlined on page 10 
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enterovirus species through partial or complete genome sequencing and phylogenetic 
analysis (Lukashev, 2005; Oberste et al., 2004a; Oberste et al., 2004b). Molecular 
typing has been adopted for the identification of enterovirus isolates, and this is 
based on comparisons of a portion of the VP1 capsid gene (Oberste et al., 1999). 
Enterovirus serotypes within a species typically share > 75% nucleotide sequence 
identity (> 85% amino acid identity) (Oberste et al., 2007).  
 
Poliovirus was recently reclassified as a member of HEV-C as a result of 
phylogenetic analysis which showed that members of this species were closely 
related in the non-capsid coding region (Benschop et al., 2008; Brown et al., 2003). 
Previous separation of PVs from HEV-C was based on disease manifestations, 
specifically the ability of PV to cause poliomyelitis, and to bind to the specific 
poliovirus receptor (PVR; CD[cluster differentiation]155) (Lukashev, 2005; Minor, 
2004). There is generally little correlation between the virus serotype and the 
resulting disease in the host, as in virus serotypes belonging to different enterovirus 
species can cause similar symptoms. 
 
Transmission 
Enteroviruses infect the host by two main routes namely; (1) faecal-oral transmission 
(such as PV) and (2) respiratory routes (most predominantly with rhinoviruses). 
Faecal-orally transmitted viruses such as PV are acid-stable (pH 3.0 to 5.0) for 1 to 
3 hours (hrs), and replicate at 37°C which makes them suited to enteric infection. 
These faecal-orally transmitted enteroviruses are also resistant to inactivation by 
many common disinfectants and soaps (Sutter et al., 2008). In contrast, rhinoviruses 
are acid-labile and replicate more efficiently at 33°C (hence their preference for the 
upper respiratory tract) (Kistler et al., 2007; Pallansch & Roos, 2001).  
 
Diseases associated with enterovirus infection 
Human enterovirus infections are usually asymptomatic or cause mild illness (such 
as a rash or a “common cold”); however some enteroviruses can cause a range of 
more severe illness in the host including respiratory diseases, acute hemorrhagic 
conjunctivitis, myocarditis, and undifferentiated rash. Rarer conditions such as 
aseptic meningitis and irreversible paralytic poliomyelitis can lead to death (Huang et 
al., 1999; Khetsuriani et al., 2006; Melnick, 1984; Pallansch & Roos, 2001). 
 -17-
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Table 1.2 outlines a number of enteroviruses and their clinical symptoms (adapted 
from Flint et al., 2004). The patient age also influences the severity of disease 
experienced after infection by enterovirus serotypes. For example, children tend to 
have mild or asymptomatic symptoms following PV infection while older children 
and adults experience more severe symptoms. Neonates are at higher risk of disease 
caused by non-poliovirus enteroviruses (44% of total infections by age group) 
(Khetsuriani et al., 2006) presumably due to underdeveloped immunity, while all 
ages are at risk of rhinovirus infection (causing predominantly upper and lower 
respiratory illness).  
 
Overview of PV pathogenesis and eradication strategy 
Poliovirus was discovered by Landsteiner and Popper in 1909 and was the cause of 
extensive poliomyelitis disease outbreaks up to the 1950s (Wimmer et al., 1993). 
Infection with PV can lead to one of the following outcomes: (1) asymptomatic 
infection which is the most common outcome (72%); (2) minor illness such as fever, 
vomiting, constipation, or sore throat; (3) non-paralytic poliomyelitis (aseptic 
meningitis); or (4) paralytic poliomyelitis which is a rare outcome (usually <1% of 
cases) (reviewed in Sutter et al., 2008). Poliovirus progressively penetrates other 
tissues after escaping the tonsils and gut following initial infection and can cause 
symptoms elsewhere, e.g. myalgia, vomiting, and pain in the limbs. Studies in the 
1940s and 1950s determined that this form of disease lasted from 5 to 25 days, and 
resulted in complete recovery (reviewed in Nathanson & Kew, 2010). Progression to 
severe symptoms occurs if the virus penetrates the blood brain barrier of the central 
nervous system (CNS) by infecting motor neurons (Minor, 2004), as the name 
suggests – (polio = grey, myelitis/myelo = marrow). Virus replicates and destroys 
motor neurons in the grey matter of the spinal cord, brain stem, or motor cortex, and 
can ultimately lead to paralysis or even death (reviewed in Sutter et al., 2008).  
 
There are three antigenically distinct serotypes of PV (serotypes 1, 2, and 3) and 
infection with one serotype does not confer protection against the other serotypes 
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Table 1.2 Clinical symptoms associated with certain enteroviruses 
Virus Paralytic  Encephalitis, Carditis Neonatal Hand-foot- Rash Acute  Respiratory Fever Diarrhea, Diabetes, Orchitis Congenital 
 Disease Meningitis  disease and-mouth  hemorrhagic Tract   GI disease pancreatitis  anomalies 
          disease   conjunctivitis infections           
Poliovirus 1-3 + +      + +     
Coxsackieviruses A1-24 + + +  + + + + +    + 
Coxsackieviruses B1-6 + + + +  +   +  + + + 
Echovirus 1-33 + + + +  +  + + +    
Enterovirus 70 +      +       
Enterovirus 71 + +   +         
Parechoviruses 1-3 + +      + + +    
Rhinoviruses 1-100               +           
(Adapted from Flint et al., 2004) 
 
(Bodian, 1951; Toyoda et al., 1984). The introduction of trivalent, inactivated polio 
vaccine (IPV) (Salk) and trivalent, live attenuated (Sabin) oral poliovirus vaccine 
(OPV) (Wimmer et al., 1993) reduced the incidence of poliomyelitis between 1950 
and 1970. The former was a formalin trivalent IPV developed by Dr. Jonas Salk and 
licensed in 1955 (Salk, 1953). In 1963, an attenuated oral vaccine containing all three 
serotypes was developed and licensed by Dr. Albert Sabin (Sabin & Boulger, 1973). 
Oral polio vaccine contained attenuated strains of PV and was developed by rapidly 
passaging neurovirulent strains at suboptimal temperatures in simian cells and 
tissues. Numerous studies have since identified the multiple genetic determinants of 
Sabin vaccine strain attenuation, and Kew et al have summarised the critical 
mutations responsible in all three strains (Kew et al., 2005). Briefly, Sabin-1 vaccine 
strain was distinguishable from its neurovirulent progenitor by 55 nucleotide (nt) 
substitutions which were located throughout the genome (McGoldrick et al., 1995). 
Through reverse genetics, it was determined that the most important attenuating 
substitution occurred in the internal ribosome entry site (IRES) at position 480 
(Kawamura et al., 1989) while four other substitutions in the capsid region 
contributed to the attenuating phenotype. Sabin-2 contained only two substitutions 
(in the IRES and VP1 coding region) from the original P712 strain that contributed to 
the attenuated phenotype (Macadam et al., 1993). Lastly, the attenuated Sabin-3 
strain differed from the neurovirulent Leon strain by 10 nt substitutions, with the 
principal attenuating nts located in the IRES, VP3, and VP1 coding regions (Stanway 
et al., 1984). The attenuation of the neurovirulent phenotype in PV vaccine strains 
provides one of the best model for rapid virus evolution and how we exploited it for 
the generation of highly effective vaccines.  
 
Poliovirus vaccines are included in the national paediatric vaccine schedules of most 
developed countries. In 1988, the World Health Organisation (WHO) implemented 
the global eradication target to improve vaccination efforts in developing countries 
where PV infections resulted in annual cases of poliomyelitis in sub-optimally 
vaccinated or other vulnerable populations (WHO, 1988). To date, only four 
countries (Afghanistan, India, Nigeria, and Pakistan) still have wild PV transmission 
(CDC, 2006). However, the rapid evolution of PV during replication (with particular 
reference to mutation rates of the viral polymerase mentioned later) means that 
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vaccine strains are inherently unstable and occasionally mutate to cause PV 
infections in vaccinated individuals or close contacts.  
 
Cases of vaccine-associated paralytic poliomyelitis (VAPP) are rare independent 
events that occur following administration of OPV (Kew et al., 2005). The risk is 
low - approximately one case per 2.4 million doses delivered - and is a direct 
consequence of genetic mutation of OPV strains (CDC, 1997; Kew et al., 2005). 
During virus replication in a vaccinee, Sabin vaccine strains can spontaneously revert 
to enhanced virulence by key nt substitutions that conferred attenuation in the first 
place (outlined above). Sabin-3 contributes to the highest rates of VAPP post-
vaccination, with low genetic stability of critical substitutions the main cause 
(Chumakov et al., 1992; Kew et al., 2005). Such vaccine-derived outbreaks of VAPP 
arise as a direct result of OPV replication in vaccinees, and highlights the role of 
rapid genetic evolution within these virus populations. 
 
Several outbreaks caused by vaccine-derived polioviruses (VDPVs) have been 
identified in recent years due to more modern sequencing methods. Vaccine-derived 
PVs differ from 1% to 15% of VP1 sequence from the original Sabin vaccine strains 
indicating longer circulation post-vaccination (Kew et al., 2005). These VDPVs may 
circulate within a population, especially in areas where wild PV no longer occurs and 
where there is low vaccine coverage (CDC, 2006; Rousset et al., 2003). There are 
several categories of VDPVs including circulating-VDPVs (cVDPVs) that arise from 
recombination events between VDPVs and species C enteroviruses (Kew et al., 
2002; Rousset et al., 2003; Shimizu et al., 2004; Yang et al., 2003), 
immunodeficiency-associated VDPVs (iVDPVs) which are excreted from 
immunodeficient recipients usually over the long term, and ambiguous-VDPVs 
(aVDPVs) which do not fall into either of the previous categories and have no 
defined origin (CDC, 2006).  
1.2 Virus Structure and Life Cycle 
Virus morphology 
Enteroviruses consist of a ~7.5 kilobase (kb) RNA genome encapsulated in a non-
enveloped icosahedral capsid with a diameter of approximately 30 nanometres (nm) 
(Putnak & Phillips, 1981). The capsid shell is formed from 60 copies of each of the 
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viral capsid proteins (VP4, VP2, VP3, and VP1) and forms a virion with a single 
virus protein genome (VPg)-linked positive-sense RNA (Hogle et al., 1985; Lee et 
al., 1977; Rossmann et al., 1985). Each heteromeric structural unit comprises one 
copy of VP1, VP2, and VP3, while one copy of VP4 lies on the inner surface of the 
viral capsid, purportedly to support the capsid interior and interact with the RNA 
genome (Guttman & Baltimore, 1977; Lee et al., 1993). Each of the 12 five-fold axes 
of the capsid (with prominent peaks) is surrounded by a surface depression, or 
“canyon”, where the host receptor CD155 docks (Bernhardt et al., 1994; Colston & 
Racaniello, 1994).  
 
Tissue tropism  
Pathogenesis of enteroviruses is influenced by extracellular factors including the 
presence of cellular receptors required for virus attachment and cell infection, and 
this largely determines tissue tropism. As well as requirements for cellular entry, 
viruses must also be able to replicate within the cell by utilising the cell’s own 
machinary. 
 
Experimental studies suggest that many enteroviruses exploit more than one cell 
surface protein in order to infect host cells (Evans & Almond, 1998). However, PV 
and the major group of HRV are exceptions in that they only require one receptor, 
CD155 and the intracellular adhesion molecule type-1 (ICAM-1) respectively (Greve 
et al., 1989; Mendelsohn et al., 1989). Other enteroviruses use different 
immunoglobulin-like molecules and adhesion proteins for attachment, and a current 
list of identified receptors used by a selection of enteroviruses is outlined in table 1.3.  
 
Tissue tropism of PV is predominantly determined by expression of CD155, also 
known as poliovirus receptor (PVR), therefore natural PV infection is only supported 
by human and simian cells in culture (McLaren et al., 1959). These observations 
suggest that PV did not emerge from an animal reservoir, nor do they circulate in 
such hosts. In 1989, Mendelsohn and colleagues cloned the human PVR gene and as 
a result, were able to express PVR on the surface of mouse cells 
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 Table 1.3 Some enterovirus serotypes and their receptors 
Serotype Receptor Reference 
Poliovirus 1-3 CD155 (PVR) (Mendelsohn et al., 1989) 
Coxsackievirus A21 ICAM-1, DAF (Shafren et al., 1997) 
Rhinovirus (major group) ICAM-1 (Greve et al., 1989) 
Coxsackievirus B1, B3, B5 DAF (Shafren et al., 1995) 
(Bergelson et al., 1994) 
(Powell et al., 1998) Echovirus 3, 6, 7, 11-13, 20, 21, 24, 29, 33 DAF 
(Ward et al., 1994) 
Echovirus 22 αvβ3 vitronectin  (Roivainen et al., 1994) 
(Nishimura et al., 2009) Enterovirus 71 
  
SCARB2, PSGL-1 
  (Yamayoshi et al., 2009) 
CAR, coxsackievirus and adenovirus receptor; DAF, decay accelerating factor; ICAM-1, intracellular  
adhesion molecule 1; PVR, poliovirus receptor; SCARB2, scavenger receptor class B member 2;  
PSGL-1, human P-selectin glycoprotein ligand-1 
(L cells) which ordinarily do not support PV infection (Mendelsohn et al., 1989). As 
a result, L cells also became susceptible to PV infection, and not just permissive to 
PV replication. In further experiments, transgenic mice containing the human PVR 
gene in the germ line were established for PV studies (Koike et al., 1991; Ren et al., 
1990). Both groups observed that transgenic mice were susceptible to either infection 
by PV1 (Mahoney) or all PV serotypes, and presented with the same clinical 
symptoms identified in humans and monkeys. PVR transcripts were shown to be 
expressed in a wide range of transgenic mouse tissues, and this was also observed in 
humans (e.g. CNS) (Koike et al., 1991; Mendelsohn et al., 1989).  
 
Genome organisation 
The enterovirus genome consists of a single stranded, non-segmented positive-sense 
RNA molecule approximately 7500 nts long. The genome encodes a long single open 
reading frame preceded by a highly structured 5’ non-coding region (NCR) and 
followed by a short 3’ NCR with a poly(A)-tail. The polyprotein is cleaved co- and 
post-translationally by the virus’s own encoded proteases (2Apro and 3Cpro/3CDpro). 
The enterovirus genome encodes four structural (capsid) proteins and seven non-
structural proteins (figure 1.1A). The P1 region encodes the proteins necessary for 
the virion capsid, proteins from the P2 region are involved in host cell membrane 
rearrangement, protein processing and RNA replication, and P3 proteins are required 
for immune response interference and virus RNA replication. Figure 1.1B 
demonstrates how the cleavage products from P1, P2, and P3 regions are processed 
from the polyprotein.  
 
A series of fast and slow proteolytic cleavages occur throughout the polyprotein in 
order to release virus proteins necessary for disrupting host cell processes and for 
fulfilling virus replication. Cleavage of the polyprotein initially occurs at the 
P1/P2 junction in cis by 2Apro at a Tyr/Gly pair, while the second processing step 
also occurs in cis to release P3 from P2 by 3Cpro/3CDpro at a Gln/Gly pair (Lawson & 
Semler, 1992; Toyoda et al., 1986). The remaining cleavage events (except one) 
occur in trans by 3Cpro/3CDpro at Gln/Gly pairs to generate mature proteins 
(Kitamura et al., 1981; Semler et al., 1981). It remains to be determined the 
mechanism that cleaves VP0 to yield VP4 and VP2  
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Figure 1.1 Genome structure of enteroviruses. (A) The virus RNA genome 
contains the essential signals for viral translation, replication, virion assembly and 
release of viral progeny from the host cell and is divided into 3 regions, P1-P3 
(Source: Jiang et al., 2007). (B) Genome structure and cleavage products of 
picornavirus coding sequence. The red triangle indicates cleavage performed by 2A; 
the blue triangles are cleaved by 3C; the black triangle is cleaved by an unknown 
protease (Source: Flint et al., 2004). 
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(Basavappa et al., 1994). Not only do virus proteases cleave the polyprotein, they are 
also involved in cleaving host cell proteins in order to inactivate cellular targets and 
inhibit host defences. Virus proteinase 2Apro plays an essential role in disrupting cap-
dependent translation in the cell, by cleaving subunit p220 of the eukaryotic 
translation initiation factor 4 (eIF-4) (Kräusslich et al., 1987). Likewise, PV 3Cpro 
has been implicated in many host cell processes. In one instance, 3Cpro cleaves a 
cellular factor (G3BP), which is involved in the formation of cellular messenger 
(m)RNA stress granules (SGs) (White et al., 2007). Stress granules are thought to 
regulate mRNA metabolism during stress and favour the translation of stress 
response proteins. Additionally, 3Cpro mediates cleavage of transcriptional activator 
p53 with the help of cellular factors, thereby regulating the transcription of cellular 
genes (Weidman et al., 2001). 
 
The enterovirus genome also consists of cis-acting features required for translation 
and replication, and are discussed in further detail in the following section.  
 
Regulatory elements in enterovirus/picornavirus genomes 
The picornavirus replication cycle relies not only on virally encoded proteins, but is 
also mediated by cis-acting elements within the genome that drive translation and 
replication.  
 
The 5’ NCR contains cis-acting features required for translation and replication 
including the IRES, responsible for recruiting ribosomal subunits to translate the 
single polyprotein from which mature virus cleavage products are derived – these are 
essential for subsequent RNA replication and virion packaging (Pelletier & 
Sonenberg, 1988). An 88 nt cloverleaf structure is also located in the 5’ NCR 
upstream of the IRES. This is crucial for RNA replication and plays a role in forming 
a ternary complex with virus protein 3CD, cellular poly(rC)-binding protein (PCBP), 
and poly(A)-binding protein (PABP), which circularises the genome and initiates 
replication from the 3’ poly(A)-tail (Andino et al., 1990; Herold & Andino, 2001; 
Parsley et al., 1997). 
 
The 3’ NCR and poly(A)-tail are involved in RNA synthesis, as this is the site for 
initiation of negative-strand synthesis mentioned above. A pseudoknot structure has 
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been identified in this region (Melchers et al., 1997; Mirmomeni et al., 1997; Rohll 
et al., 1995), and although the role of the 3’ NCR in general is not clear, it may 
provide a role in stabilising spatial interactions during replication (Pilipenko et al., 
1996). Rohll and colleagues found that extensive mutagenesis of the single stem-loop 
structure formed by the HRV-14 3’ NCR and replaced in a PV3 replicon, severely 
debilitated virus replication, indicating that this structure was essential for 
replication. Herold and Andino suggest that the 3’ NCR plays a regulatory role, but 
is not an origin of replication, as PVs are still viable if this region is interchanged 
with another enterovirus (HRV14) or if the region is deleted (Herold & Andino, 
2001; Rohll et al., 1995; Todd et al., 1997). Similarly, the poly(A)-tail is an 
important cis-acting element for RNA replication, since removal or significant 
shortening results in defects in replication (Herold & Andino, 2001; Spector et al., 
1975). 
 
Within the coding region itself, a further cis-acting replication element (CRE) is 
located in the 2C coding region of PV and all other enteroviruses, and is a conserved 
61 nt stem-loop structure (Goodfellow et al., 2000). The CRE acts as a template for 
VPg uridylylation and VPg-pUpU functions as a primer for RNA synthesis by 3Dpol. 
Uridylylation is the process of covalently linking two uridine nts to a tyrosine residue 
(Crawford & Baltimore, 1983; Kuhn et al., 1988) and this process relies on an 
A1A2A3CA motif in the terminal loop of the CRE structure (Goodfellow et al., 2003) 
. It has been demonstrated using a cell-free in vitro translation and replication 
reaction with PV that 2CCRE is not required for negative-strand synthesis, even 
though both positive- and negative-strand synthesis are primed by VPg (Goodfellow 
et al., 2003). In this case it is possible that the poly(A)-tail functions to template VPg 
uridylylation prior to negative-strand synthesis, as shown in in vitro assays (Paul et 
al., 1998).  
 
Similar CRE structures have been identified in various regions of other non-
enterovirus genomes, including the VP1 encoding region of HRV14 (McKnight & 
Lemon, 1998), the 5’ NCR of FMDV (Mason et al., 2002), and 2A of HRV2 (Gerber 
et al., 2001), indicating that the CRE location is not conserved. Goodfellow et al 
later demonstrated that the CRE could be relocated to the 5’ NCR (from its original 
2C position in PV) without this impacting on activity (Goodfellow et al., 2003). 
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Likewise, the FMDV CRE can be moved to the 3’ end of the genome without 
affecting replication (Mason et al., 2002).  
 
In a competitive intracellular environment, virus genomes contain cis-acting 
elements, including the cloverleaf, CRE, and componants of the 3’ NCR, to allow 3D 
polymerase (3Dpol) to differentiate between viral and cellular RNAs (reviewed in 
Bedard & Semler, 2004). 
 
Overview of the enterovirus life cycle  
Enteroviruses share similar genome structure and morphology, and as a result, have a 
similar life cycle. The following overview describes the PV life cycle as this is well 
studied and the subject of research presented in this thesis. Many aspects of PV 
infection have been mentioned, therefore will be shortened for brevity. A 
diagrammatic summary of the life cycle is shown in figure 1.2. 
 
Poliovirus infection is initiated by the attachment of virus particles to PVR, and this 
triggers conformational changes in the virus particle. Upon cell attachment, both VP4 
and the amino terminus of VP1 are externalised and are subsequently inserted into 
the host cell membrane (Levy et al., 2010). This results in the formation of 
pores/channels that allow for the movement of virus RNA into the cell’s cytoplasm. 
Viral RNA is translated under the control of the IRES, by recruitment of ribosomes 
to the site, into a single polyprotein by a cap-independent mechanism (Pelletier & 
Sonenberg, 1988). The long polyprotein is cleaved co- and post-translationally by the 
virus’s encoded proteases to yield 11 virus proteins, some of which are necessary for 
virus replication (Kräusslich et al., 1988; Toyoda et al., 1986). The switch from 
translation to transcription occurs once sufficient viral proteins (such as 3CDpro and 
3Dpol) have been synthesised, and these associate with cellular proteins to the 
5’ NCR to begin this process. Host cell endoplasmic reticulum membranes are 
rearranged and associate with non-structural virus proteins and cellular proteins to 
form replication complexes where viral RNA synthesis takes place (Bienz et al., 
1983, Bienz et al., 1990). Newly synthesised negative-sense strands of PV serve as 
template for positive-sense strand synthesis, of which a proportion are further 
translated to increase the number of virus RNA capsid proteins in the cytoplasm. 
Virus capsid proteins are required to encapsidate single copies of VPg-linked virus  
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Figure 1.2 Summary of the PV life cycle. A brief outline is described in the text. © 
represents the m7G cap which is present on most host mRNAs, but not on PV. 
Negative-strand RNA is purple, while positive-strand RNA is red. (Source: Whitton 
et al., 2005). 
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RNA genomes before mature virions are released from the cell following lysis 
(Novak & Kirkegaard, 1991). In all, PVs have a short growth cycle which takes 
approximately 8 hrs from cell attachment to virus release (Mueller et al., 2005).  
 
Poliovirus RNA replication 
Although PV RNA synthesis is an intricate process, it has been examined extensively 
to provide a clear understanding of the viral and cellular proteins involved. Once the 
virus genome is released into the cytoplasm, VPg is cleaved by a cellular enzyme 
(Ambros et al., 1978). The genome is translated and virus proteins necessary for 
RNA replication and for inhibiting host cell processes are produced. Virus RNA 
replication proceeds in a replication complex, formed by the rearrangement of 
cellular membranes, and involves virus and cellular proteins that initiate negative-
strand RNA synthesis by genome circularisation (Ansardi et al., 1996; Herold & 
Andino, 2001).  
 
Replication complexes have been studied extensively, including their role in virus 
replication (Bienz et al., 1980; Bienz et al., 1990). The P2 virus proteins are found to 
be associated with the endoplasmic reticulum from 3 to 3.5 hrs post-infection, and 
RNA synthesis begins to decline approximately 1 hr later (Ansardi et al., 1996, Bienz 
et al., 1987). These virus-induced vesicles are described as closed ‘entities’ which 
limit or prevent the exchange of viral protein, RNA, or membranes, in order to 
concentrate necessary components (Egger et al., 2000; Miller & Krijnse-Locker, 
2008). They may also protect newly synthesised virus RNA from cellular factors and 
competing processes (Ahlquist, 2002).  
 
Virus proteins 2C and 3AB are responsible for binding virus RNA to membranes 
during replication, as 3Dpol cannot associate with membranes (Plotch & Palant, 1995; 
Semler et al., 1982; Teterina et al., 1997). Figure 1.3 outlines PV negative-strand 
RNA synthesis. Virus precursor protein 3CDpro, together with poly(rC)-binding 
protein 2 (PCBP2) facilitates the formation of a ribonucleprotein complex as both 
bind to the 5’ terminal cloverleaf structure on the positive-strand RNA (Andino et 
al., 1990; Andino et al., 1993; Gamarnik & Andino, 1997). Poly(A)-binding protein 
1 (PABP1), which is bound to the 3’ poly(A)-tail also interacts with the 
ribonucleoprotein complex to circularise the genome (Wang et al., 1999). The CRE  
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 Figure 1.3 Poliovirus negative-strand synthesis. Once the virus genome is released 
into the cytoplasm, VPg, a virus protein covalently linked to the 5’ terminal of RNA, 
is cleaved by a cellular enzyme. The genome is translated and virus proteins 
necessary for RNA replication are produced. Virus RNA replication proceeds in a 
replication complex, which incorporates cellular membranes associated with initial 
translation, and virus and cellular proteins that initiate negative-strand RNA 
synthesis by genome circularisation. (Source: Flint et al., 2004). 
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structure also binds 3Dpol, 3CDpro, and VPg in which the latter serves as a protein 
primer for RNA synthesis. Negative-strand RNA synthesis proceeds by 3Dpol 
elongation once the complex is transferred to the 3’ end of the genome. As a result, a 
double stranded replicative form (RF) is produced, containing a positive- and 
negative-strand virus genome. 
 
Following synthesis of negative RNA strands, membrane-associated virus protein 2C 
anchors this RNA strand to replication membranes (Banerjee & Dasgupta, 2001) 
(figure 1.4). It has been demonstrated that guanidine inhibits initiation of negative-
strand synthesis and mutants resistant to guanidine contain mutations mapped to the 
2C region (Barton & Flanegan, 1997). Binding to protein 2C might aid recruitment 
of uridylylated VPg-containing complexes to the 3’ end of the negative-strand to 
initiate positive-strand RNA synthesis. VPg-pUpU (bound to the 3’ end of negative-
strand) is uridylylated by 3Dpol using 3’ terminal A residues, and serves as the primer 
for positive-sense RNA synthesis. VPg-pUpU is elongated by 3Dpol to synthesise 
multiple copies of positive-sense strands (Barton & Flanegan, 1997; Richards et al., 
1984) and allows for suitable genome packaging with structural proteins prior to 
virion release.  
 
The use of reverse genetics (infectious virus clones and subgenomic replicons) 
The study of viruses, such as their genome structure, functions, and interactions (both 
internally and with the host cell) has benefited greatly from the ability to make 
mutations in cDNA and then determine the phenotype by recovery of virus in cell 
culture. Engineered PV genomes, for example, have been a powerful tool for 
investigating the critical substitutions that attenuate neurovirulent vaccine strains 
during development of the OPV (reviewed in Almond, 1987). The sequencing and 
characterisation of virus RNA genomes was originally difficult due to instability of 
the nucleic acid as well as its susceptibility to ribonucleases, and this limited virus 
studies. The molecular study of RNA viruses was only improved in the last 30 years 
when groups were able to recover infectious virus from cloned cDNA copies. 
Briefly, these clones comprise partial- or full-length virus cDNA genomes inserted 
into self-replicating vectors that allow for the generation of multiple copies through 
culture in transformed bacteria. Ribonucleic acid genomes that are transcribed from 
cDNA clones in vitro are shown to generate infectious virus upon transfection into  
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Figure 1.4 Poliovirus positive-strand RNA synthesis. Following synthesis of 
negative RNA strands, it is hypothesised that membrane-associated virus protein 2C 
anchors this RNA strand to replication membranes. This might aid recruitment of 
uridylated VPg-containing complexes to the 3’ end of the negative-strand to initiate 
positive-strand RNA synthesis. VPg-pUpU (attached to the 3’ end of negative-
strand) is synthesised by 3Dpol using 3’ terminal A residues, and serves as the primer 
for positive-sense RNA synthesis. VPg-pUpU is elongated by 3Dpol to synthesise 
multiple copies of positive-sense strands and allows for suitable genome packaging 
with structural proteins prior to virion release. (Source: Flint et al., 2004). 
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permissive cells that are able to support infection. This was first achieved by 
Taniguchi and colleagues with the recovery of an RNA bacteriophage, Qβ, from 
cloned cDNA  (Taniguchi et al., 1978). The cloning of the first animal RNA virus, 
PV, occurred only a few years later. Racaniello and Baltimore initially cloned three 
fragments spanning the PV1 genome into plasmids before combining these into one 
final clone to make the first infectious PV clone (Racaniello & Baltimore, 1981a; b).  
 
Likewise, the HRV14 genome was cloned in its entirety and infectious virus was 
recovered from RNA transcripts transfected in HeLa cells (Mizutani & Colonno, 
1985). Subsequently, the coxsackievirus B3(CVB3) genome was cloned directly into 
pBR322, and the entire coxsackievirus B4 (CVB4) (strain JVB) genome was cloned 
also into pBR322, both by the cDNA:RNA hybrid method to construct a first full-
length infectious clone for sequence comparison (Jenkins et al., 1987; Tracy et al., 
1985). Since then, molecular techniques have improved to construct complete 
enterovirus cDNA plasmids, especially using amplification by polymerase chain 
reaction (PCR) and cloning of entire genomes (Lindberg et al., 1997). 
 
Infectious cDNA in plasmid form allows for genetic manipulations that cannot be 
performed on an RNA genome alone. Mutations or modifications can be introduced 
into the cDNA in order to characterise the properties of subsequently recovered virus 
in vitro. One such example was the disruption of the CRE structure by site-directed 
mutagenesis, which led to the inhibition of positive-strand RNA synthesis and 
ultimately a lack of recovered virus in cell culture (Goodfellow et al., 2000).  
 
Virus cDNA plasmids are also useful in order to map spontaneous mutations that 
arise when wild-type viruses are able to grow under restrictive conditions (selective 
pressures). Mutations that allow viruses to escape such restrictive conditions can 
therefore be identified by sequencing and used for recombination studies. One such 
example was the mapping of PV mutants that were resistant to 2 millimolar (mM) 
guanidine, which usually inhibits replication (Emini et al., 1984). Resistance to 
guanidine was mapped to mutations in the 2C region, and similar studies have 
identified genetic markers linked to selection by temperature, escape from 
monoclonal antibody neutralisation, and actinomycin D (Dewalt et al., 1990; Kean et 
al., 1989; Reynolds et al., 1992).  
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Subgenomic replicons emerged as a powerful tool in the mid 1980s when researchers 
became interested in the mechanism of PV replication and the role of defective 
interfering (DI) particles during virus infection. Defective interfering particles are 
shown to replicate in cells but due to missing portions of their genome, are not able 
to propagate virus unless in the presence of helper virus (Kuge et al., 1986). Minimal 
genome elements required for replication and signals necessary for virion packaging 
can be determined as a result of such particles. Poliovirus DI particles have been 
isolated from virus populations propagated in cell culture and results indicate that the 
locations of deletions were limited to the capsid coding region (Hagino-Yamagishi & 
Nomoto, 1989; Kajigaya et al., 1985). This suggests that such incomplete genomes 
retain the ability to replicate and package due to cis-acting non-structural proteins, in 
the presence of infectious virus. This knowledge was applied to the construction of 
subgenomic replicons in which large fragments of the P1 region were deleted from 
infectious PV cDNA clones (Kaplan & Racaniello, 1988). Enterovirus cDNA 
genomes can be altered by the replacement of the capsid region with a reporter gene 
(e.g. luciferase) to create subgenomic replicons. The capsid can be removed without 
any consequences to RNA synthesis and allows for accurate quantitative detection of 
RNA, replication, and translation by in vitro assay. A subgenomic replicon for PV3 
was constructed by the removal of the capsid region and replacement by a reporter 
gene encoding chloramphenicol acetyltransferase (CAT) (Percy et al., 1992). A 
luciferase-expressing Mahoney strain of PV1 replicon was also engineered to study 
the ribonucleoprotein complex during virus replication (Andino et al., 1993). These 
are a few of the several virus clones that exist for picornaviruses.  
1.3 Enterovirus Evolution 
Virus evolution  
Evolution requires genetic variation. Positive-sense single-stranded RNA viruses 
including important human pathogens like PV and hepatitis C virus (HCV) have 
error prone polymerases, short replication cycles, and high virus yields that together 
contribute to genetic diversity. The small genome of PV ultimately allows for it to 
replicate quickly so that more progeny RNA can be generated, and this has 
advantages when adaptation to host conditions is required. 
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Virus genome adaptability in a host depends on three broad factors; (1) the genetic 
heterogeneity of the population (or quasispecies) or the number of stable mutations 
in individual genomes compared to the consensus sequence; (2) the population size; 
and (3) the complexity of the viral genome (Domingo & Holland, 1997). 
Consequently, a viral population can contain genomes with one or several mutations 
that make mutants dissimilar from the type species or reference genomes (Bouslama 
et al., 2007). This high level of variation allows RNA viruses to exist as a 
heterogeneous population and is the reason why viruses are constantly changing, 
with the continuous emergence of new strains from a quasispecies population. 
Mutations within viral populations lead to variations in virulence and possibly 
modifications in host cell tropism as a result of selective pressures imposed by the 
host.  
 
Mechanisms of evolution in enteroviruses 
Most genetic diversity in positive-sense RNA virus populations arise from mutations 
caused by the error-prone nature of the virus’s own RdRp (Domingo & Holland, 
1997, Steinhauer et al., 1992). As a result, enteroviruses (and indeed all positive-
sense RNA viruses), exist as quasispecies; a collection of non-identical but related 
genomes (Lauring and Andino, 2010; Domingo & Holland, 1997). This is significant 
given the size of such quasispecies genome populations. Virally encoded RdRps lack 
exonucleolytic editing ability (Ishihama et al., 1986), and it has been shown that PV 
polymerases have an estimated mis-insertion error rate ranging from 1.2 x 10-4 to 
1 x 10-6 for transition mutations and 3.2 x 10-5 to 4.3 x 10-7 for transversion 
mutations (Freistadt et al., 2007). As a result, repeated passages of large populations 
of virus over time enrich those mutant genomes that replicate more efficiently, and 
can also alter virulence by modifying host cell tropism (Domingo & Holland, 1997). 
The best example of this is the attenuation of the three serotypes of PV to create the 
OPV. Strains of PV were repeatedly passaged through monkey cells (in vivo and ex 
vivo) to eventually select viruses with multiple spontaneous point mutations that led 
to the inability of these strains to replicate as efficiently in human neurons while 
retaining the ability to replicate in the human gut cells where they were capable of 
inducing the desired protective immune response (Kew et al., 2005, Sabin & 
Boulger, 1973). Conversely, reversion to a virulent phenotype by point mutation is a 
risk associated with oral polio vaccination (Rezapkin et al., 1995; Taffs et al., 1995) 
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and was demonstrated by Westrop et al., when they showed that attenuation of PV3 
Sabin vaccine strain from its neurovirulent wild-type parent only required two point 
mutations at positions 472 and 2034 of the genome (Westrop et al., 1989). 
 
The natural replication of all three PV serotypes can be followed easily due to rapid 
genome evolution, and this can be calculated with high precision. Nucleotide 
substitutions (of which > 80% are in the coding region) accumulate at an average rate 
of ~ 1% per year at each position, and this rate increases to ~ 3% per year when 
calculated for synonymous sites only (Kew et al., 1995; Martín et al., 2000). Rapid 
evolution of vaccine viruses, such as PV, also accounts for the adverse reactions 
associated with the use of live-attenuated vaccines. The level by which VDPVs differ 
from the vaccine Sabin strains can help determine when such viruses were originally 
transmitted. Isolated VDPVs can differ from OPV strains at 1% to 15% of VP1 nts 
when resequenced, which provides useful timelines for tracing origins of outbreaks 
(Shimizu et al., 2004).  
 
Over a decade ago, extensive sequence and phylogenetic analysis of enterovirus 
genomes revealed that evolutionary rates differed depending on the genomic region 
studied (Hyypiä et al., 1997). Different selection pressures are most likely applied to 
different regions; the capsid region is directly linked to host immune responses and 
over a significant amount of time, has diversified and evolved due to genetic drift, 
and this is clear from the wide range of receptors recognised for cell attachment. The 
5’ NCR shows the slowest rate of evolution (Hyypiä et al., 1997; McWilliam Leitch 
et al., 2009). Only two distinct phylogenetic groups exists for 5’ NCR in human 
enteroviruses, those belonging to species A and B, and the remaining serotypes in 
species C and D (Santti et al., 1999).   
 
Even though the RdRp of RNA viruses are usually cited as the reason for high 
sequence variability, the evolutionary rates observed in PV sequences are in fact 
higher than those attributed to RdRp fidelity alone (Freistadt et al., 2007). Genetic 
recombination may well provide the opportunity for evolutionary advancement that 
may be greater than that seen by the steady accumulation of point mutations. 
Coupled with the paucity of information of the molecular mechanisms and influences 
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on the process, the causes and outcomes of recombination were evaluated as part of 
this project. 
  
Evidence of virus recombination 
Recombination is a way for viruses to achieve dramatic alterations of a significant 
part of the genome. Evolution therefore occurs quicker than by the gradual 
acquisition and accumulation of natural mutations during replication (genetic drift). 
As a general rule, recombinants arise and evolve from either initial dual infections in 
the same cell, or as a result of superinfections. Superinfection is the process by which 
a cell that has previously been infected with a virus is subsequently co-infected by a 
different virus strain or type altogether.   
 
The phenomenon of recombination in non-segmented RNA viruses has been 
demonstrated previously and is an important evolutionary mechanism. Interspecies 
recombination in alphaviruses between an eastern equine encephalitis-like virus 
(EEEV) and a Sindbis-like virus gave rise to a related new virus – western equine 
encephalitis virus (WEEV) (Hahn et al., 1988). This virus combined the 
encephalogenic properties of EEEV but maintained the antigenic properties of 
Sindbis virus. 
 
In a further example, a recombination event between virus and host RNA enhanced 
the cytopathic properties of the virus, bovine viral diarrhoea virus (BVDV). 
Cytopathic and non-cytopathic forms of BVDV are classified by culture through 
cells, and it was determined that the cytopathic form contained host-cellular RNA 
encoding ubiquitin (Meyers et al., 1989). It was suggested that in persistently 
infected cattle, non-cytopathic BVDV evolved to the cytopathic form, triggered by 
recombination events that inserted cellular RNA into the virus genome. 
Recombination events (not involving host-cellular RNA) have enhanced virus 
pathogenicity in other animal viruses infecting cats, including feline infectious 
peritonitis viruses (FIPVs) (Vennema et al., 1998) and feline coronavirus (FCoV) 
type II (Herrewegh et al., 1995).   
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Recombination in enteroviruses 
Recombination in RNA viruses was first described in PV in the early 1960s (Hirst, 
1962; Ledinko, 1963) and it has been identified since then in many enteroviruses, 
and studied extensively in PV (Agol et al., 1985; Minor et al., 1986; Romanova et 
al., 1980; Savolainen-Kopra et al., 2009b). In the early PV experiments, both groups 
were able to characterise recombinants generated in vitro by mapping different 
selection markers passed onto recombinant progeny virus. Since then, recombination 
between PV serotypes has been  shown to occur as soon as 2.5 hrs post co-infection 
in replication complexes within HeLa cells (Egger & Bienz, 2002). Once cells were 
co-infected with PV1 (Mahoney strain) and PV2 (Sabin strain), type-specific 
fluorescent riboprobes were used to visualise the genome regions within replication 
complexes by fluorescent in situ hybridisation (FISH). Recombination was 
subsequently demonstrated by RT-PCR and sequencing.  
 
Multiple levels of recombination have been identified in natural PVs outside the 
laboratory: intraserotypic recombinants (within each PV serotype) and interserotypic 
recombinants (combining PV1, PV2, or PV3) have been isolated from OPV 
vaccinees (Cammack et al., 1988; Cuervo et al., 2001; Furione et al., 1993; Yang et 
al., 2005); wild-type PV serotypes 1, 2, and 3 have been shown to recombine with 
each other (Dahourou et al., 2002); wild-type and OPV strains have recombined 
(Georgescu et al., 1995; Guillot et al., 2000), and lastly, vaccine-derived PVs have 
recombined with unknown HEV-C strains (Kew et al., 2002; Rakoto-Andrianarivelo 
et al., 2007; Shimizu et al., 2004). As yet, there have been no reported cases of 
interspecies recombinants involving PV and other HEV species. Interspecies 
recombination is rare (Simmonds & Welch, 2006), and so far only one event has 
been suggested between HEV-B and HEV-C viruses (Bolanaki et al., 2007). 
 
The trivalent nature of the live attenuated OPV has, as a consequence, provided the 
best opportunity for interserotypic recombination to occur. High titres of all three PV 
serotypes are introduced into the one host at the same time, and target the same 
tissues. Recombination events between the PV serotypes of OPV recipients have 
been documented with higher frequencies between serotypes 2 and 3, which are 
considered to be less genetically stable than serotype 1 (Cammack et al., 1988; 
Furione et al., 1993; Paximadi et al., 2006). Better molecular methods have also 
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resulted in more cases of intraspecies recombinants being identified from PV 
outbreaks. For example, phylogenetic analysis revealed that the source of the 2000-
2001 outbreak of poliomyelitis in Hispaniola was due to recombinants formed 
between OPV derived PVs and the non-structural regions derived from an unknown 
enterovirus strain (species C) (Kew et al., 2002). Two other reports of cVDPV in 
Madagascar and the Philippines, implicated vaccine/non-polio recombinants 
(Rousset et al., 2003; Shimizu et al., 2004). These and other reports have confirmed 
that live attenuated strains of PV originating from vaccinees are able to recombine 
with circulating non-polio species C enteroviruses creating neurovirulent 
recombinant viruses capable of causing serious disease. Outbreaks attributed to PV 
or recombinant forms of PV are more likely to occur in regions where vaccine 
coverage is sub-optimal and the circulation of other enteroviruses is high (Kew et al., 
2005).  
 
Certain enteroviruses are thought to have emerged as a result of early recombination 
events. This includes evidence of speciation of PV from a coxsackievirus A (species 
C) ancestor that occurred through mutation of the capsid region. This speciation 
event involved a cellular receptor switch in order to possibly escape selective 
pressure imposed by the host (Jiang et al., 2007). Extensive analysis of HEV B 
species has also indicated recombination events involving other unknown species B 
virus sequences and this has occurred within the HEV B species group many times to 
create a complex mosaic of RNA genomes in a short, eight year period (Simmonds & 
Welch, 2006). Surprisingly, recombination events were observed not only between 
VP1 and 3Dpol, but between VP1 and VP4 virus sequences. Frequencies of 
recombination (between VP1 and 3D regions) were also related to time periods 
(i.e. virus isolation dates). Approximately 40% of species B isolates from the same 
year were recombinant, and this rose to 70% for isolates collected two to three years 
apart. Almost all isolates were recombinant in nature when the collection period 
exceeded three years. It was also noted that enterovirus diversity occurred 
asymmetrically between structural and non-structural coding regions, particularly in 
echovirus (E30) strains (McWilliam Leitch et al., 2009). Phylogenetic analysis 
shows that while VP1 sequences diverged by natural genetic drift, 3Dpol sequences 
clustered in groups and interspersed with other species B serotypes, further 
demonstrating the ‘modular’ evolution of structural and non-structural genome 
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regions. This illustrates the dynamic nature of species B evolution, where fluctuating 
outbreaks of E30 activity have been associated with new genomic lineages that have 
replaced previously circulating genotypes (Oberste et al., 1999).  
 
The location of recombination sites in enteroviruses appear to occur throughout the 
genome with most crossover events occurring in the 5’ NCR and in the 2A, 2B, 2C, 
and 3D protein encoding regions (Savolainen-Kopra et al., 2009). Recombination 
sites in the capsid region predominantly occur between PV serotypes 2 and 3, and 
usually at the C-terminal end of the protein region (Blomqvist et al., 2010; Tao et al., 
2010). Interserotypic recombination in the capsid region is rare, possibly due to the 
sensitivity of structural constraints that are important in order to maintain the correct 
capsid shell.   
 
Although recombination has been responsible for diverging viruses from ancestral 
lineages, the role of recombination in allowing virus populations to respond to 
selective pressures is unclear. At a genetic level this would include recombination in 
the genome that is ‘selected for’ by specific events, such as immunological responses 
from the host, differing temperature ranges of host cells and the influence of 
environmental chemicals.   
 
Methods of RNA virus recombination 
As mentioned briefly, genetic recombination is also responsible for and drives RNA 
virus evolution and this has been well documented in enteroviruses. This phenomena 
generates novel genomes that may encourage a selective advantage over the original 
parental genomes (Nagy & Simon, 1997). Genetic recombination involves the 
exchange of sequences between two non-segmented genomes and this can occur via 
two distinct methods. Non-homologous recombination occurs in genetic material that 
does not share sequence homology and this is relatively infrequent in RNA viruses 
(Kirkegaard & Baltimore, 1986, Lai, 1992). This process is a replication-independent 
mechanism of breakage and rejoining of segments of genetic material and is more 
commonly seen in DNA viruses (Lai, 1992). Until recently, only a few studies had 
investigated replication-independent recombination, however reports have described 
this process in PVs (Gmyl et al., 1999; Gmyl et al., 2003), BVDV (Gallei et al., 
2004), and bacteriophage Qβ (Chetverin et al., 1997). It was suggested that 
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recombination in PV may occur as the joining of broken RNA molecules by 
transesterification (Gmyl et al., 1999), although this would occur less often. 
Homologous recombination by contrast, is the result of crossovers between two 
similar or closely related RNA molecules containing extensive sequence similarity. 
This form of recombination is known as ‘copy-choice’ and is the consequence of 
template switching by the RdRp during negative-strand synthesis as demonstrated by 
Kirkegaard and Baltimore (1986). ‘Copy choice’ was first proposed as the 
mechanism for recombination in PV (Copper et al., 1974), and to date, the majority 
of studies of recombination in RNA viruses have supported this model (reviewed in 
Agol, 1997).  
 
RdRp ‘copy choice’ by template switching 
Replication-dependent recombination in plant and animal viruses requires RNA 
templates and viral replicase for successful template switching to occur. The simplest 
model suggests that two RNA templates are necessary, including the primary RNA 
template (donor) which binds RdRp to initiate replication, and the acceptor RNA 
template that receives the RdRp mid-elongation (figure 1.5A). The crossover sites or 
‘breakpoints’ occur at positions similarly matched in sequence so that the resultant 
recombinant RNA templates retain the same sequence length and structural integrity 
as the parental RNA molecules (Lai, 1992). This is commonly referred to as precise 
recombination. Imprecise recombination, on the other hand, results in changes 
including nucleotide mismatches, deletions, or insertions at the junction site, or close 
to it (figure 1.5B) (Lai, 1992; Nagy & Simon, 1997). Depending on the modifications 
that have occurred, a viable virus may still result from this form of genetic exchange. 
‘Copy choice’ template switching may not always occur between homologous RNA 
strands, but crossover sites in coding regions are somewhat constrained by reading 
frame, recognition sequences for proteolytic processing, and protein function, which 
could conceal such events (Wimmer et al., 1993). 
 
Template switching during replication is also thought to be responsible for the 
generation of naturally occurring deletion mutants, or DI particles (Lazzarini et al., 
1981). They can be generated naturally by multiple passage at high multiplicity of 
infection (MOI ), (i.e. 16 to 18 passages for PV1 Mahoney strain), and deletions in 
PV genomes are located in the capsid encoding region (Cole et al., 1971; Kajigaya et  
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Figure 1.5 Current replication-dependent template switching models for RNA 
recombination. (A) Template switching during replication. The RdRp exchanges 
one template (donor) for another (acceptor) at corresponding positions in the 
genome. There are several possibilities as to why the RdRp is removed from the 
donor template (see text). (B) Diagrams depicting precise and imprecise 
recombination events during replication. Non-homologous recombination is also 
demonstrated, although this may not be dependent on replication. (Source: Lai, 
1992). 
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al., 1985;(Cole et al., 1971; Kajigaya et al., 1985; Kuge et al., 1986; Wimmer et al., 
1993). It was observed that all deletions in isolated DI particles of PV occurred in 
frame (Kuge et al., 1986), suggesting that some viral proteins were required to be 
encoded in cis for genome replication. Poliovirus DI particles can therefore initiate 
their own replication but cannot produce progeny virions as they do not synthesise 
capsid proteins – these must be provided by a homologous helper virus. 
 
Since the same mechanisms for RNA recombination are thought to be responsible for 
the generation of DI particles, Kuge and colleagues performed comparative sequence 
analysis of PV1 DI particles to determine the underlying genetic mechanisms behind 
their generation (Kuge et al., 1986). Selection pressures may have influenced the 
location of deletions, as these were limited to between nucleotide positions 1226 and 
2705 of the capsid coding region. There was no evidence of sequence homology 
between immediate donor and acceptor template sites, and it was proposed that 
deleted regions were ‘looped out’ by secondary RNA structures, meaning that the 
RdRp skipped these regions during replication. As PV DI particles are rarely formed 
or identified, further study of the mechanisms behind their formation are limited.  
 
What mechanisms influence recombination? 
At the genomic level, intrinsic signals present on the donor or acceptor RNA 
templates may influence switching of the RdRp between templates. At present, it is 
suggested that RNA signals either pause or terminate the RdRp, both of which cause 
the release of RdRp from the RNA template (King, 1988; Nagy & Simon, 1997). 
Possible signals include: A/U-rich and U-rich sequences that promote RdRp 
slippage, local strong hairpin structures present on either template, the formation of 
stable heteroduplexes between templates, and mis-incorporations (Carpenter et al., 
1995; Makino et al., 1986; Pilipenko et al., 1995; Tolskaya et al., 1987). If local 
RNA signals are essential for template switching of the RdRp, then it is unclear why 
there is no consistency of crossover sites for the same PV strains reported in the 
literature. 
 
Researchers have succeeded in achieving genetic recombination of enteroviruses in 
vitro (in particular in PV) in an attempt to define the preferred region/s (but not 
specifically the RNA signals) for recombination. Duggal and Wimmer (1999) 
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demonstrated that selective pressure (e.g. temperature) influenced the regions at 
which crossover occurred between two PV RNA strands (Duggal & Wimmer, 1999). 
Recombinants produced at 34°C showed crossover sites predominantly in the capsid 
region while an increase in assay temperature (37°C - 40°C) shifted the crossover 
sites towards the non-structural genes. Sequence similarity also appears to be 
important for successful recombination and is detectable as a viable recombinant 
observed using in vitro methods. Kirkegaard & Baltimore, (1986) demonstrated that 
interserotypic recombination was 100 times less likely to occur than intraserotypic 
recombination in PV. This was measured using serotypes containing genetic markers 
(one was guanidine dependent and the other temperature sensitive) which were 
separated by 190 nts in the genome. Recombination frequencies (intra- and 
interserotypic crosses) were given as the yield of recombinant virus divided by the 
sum of yields of parental viruses. Although very few events have involved exchanges 
of sequences encoding regions of the capsid, the majority of studies have found that 
recombination producing viable virus occurs more frequently in the non-structural 
region of the genome, particularly in the 2A-2C region of enteroviruses although the 
precise regions of recombination or necessary requirements for high titre resultant 
progeny are not presently known (Chen et al., 2007; Kew et al., 2002; Oberste et al., 
2004b). Many constraints can be imposed on a virus population at several stages of 
viral infection and replication in the host, although the knowledge of their roles in 
causing recombination is undefined.  
 
Identifying virus recombination 
Sequence analysis coupled with phylogenetic techniques has proven to be effective 
in identifying and characterising several recombination events among RNA viruses 
from field isolates (Gao et al., 1998; Revers et al., 1996). Although these methods 
offer precise locations of putative crossover regions, these studies require full-length 
genome recombinant and non-recombinant reference sequence information, which is 
expensive and time consuming to acquire (Oberste et al., 2004b; Simmonds & 
Welch, 2006; (Zoll et al., 2009). Recombinant viruses are also identified by 
sequencing regions at either end of isolated genomes and identifying incongruent 
regions by phylogenetic analysis (Oberste et al., 2004c; Simmonds & Welch, 2006). 
Although now considered an outdated technique, groups used ribonuclease T1 
oligonucleotide fingerprinting to detect structurally unique patterns once viral 
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genomes were cleaved and separated in two dimensions (Agol et al., 1985; Kew & 
Nottay, 1984). Likewise, the use of genetic markers and Random Fragment Length 
Polymorphism (RFLP) have proven successful in identifying recombinant genomes 
in viral populations (Paximadi et al., 2006).  
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 1.4 Aims 
From this brief review of the literature, it is clear that the occurrence of 
recombination is well established in enteroviruses and other RNA viruses. 
Recombination acts to progress the evolution of viruses, and must provide 
advantages to viruses since these recombinants are associated with current disease 
outbreaks. Although groups have attempted to determine the molecular triggers for 
template switching in PVs, it is striking that there is no consensus between “hot 
spots” in these genomes and little agreement as to the intrinsic RNA signals 
responsible. The overall aim of this study was to investigate the mechanism of 
recombination and to characterise recombinant viruses obtained during the process. 
 
Specific Aims   
• To develop an experimental method for generating a population of natural 
interserotypic PV recombinants with little or no remaining parental virus in 
cell culture. 
• To facilitate the identification of early recombinant genomes without 
extensive selection/passage. 
• To determine the underlying mechanisms of template switching at the 
nucleotide and protein level, by characterising recombinants generated by the 
above method. 
• To investigate whether viruses generated by this method acquired growth 
advantages as a result of recombination. 
• To determine if recombination between enterovirus species is possible in an 
artificial in vitro setting.  
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CHAPTER TWO: Materials and Methods 
2.1 Cell Culture and Virological Methods 
 
Cell maintenance 
Human cervical (HeLa), human embryonic rhabdomyosarcoma (RD), murine 
fibroblast (L929), human embryonic lung (MRC-5), and African green monkey 
kidney (Vero) cells were grown as monolayers in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 100 µg/ml of streptomycin, 100 U/ml of 
penicillin, 2 mM L-glutamine, and 10% heat inactivated (HI)-foetal bovine serum 
(FBS). Baby hamster kidney cells stably transfected with a T7 RNA polymerase 
expression plasmid (BsrT7) were maintained in Glasgow Minimum Essential 
Medium (GMEM) supplemented with 100 µg/ml of streptomycin, 100 U/ml of 
penicillin, 2 mM L-glutamine, and 10% HI-FBS. Antibiotic G418 was also added to 
BsrT7 cell medium to select cells containing the T7 RNA polymerase gene under 
control of the cytomegalovirus (CMV) promoter and the neomycin resistance gene 
(Buchholz et al., 1999). Intracellular adhesion molecule-1 expressing RD (RD-
ICAM-1) cells were maintained in DMEM supplemented with 100 µg/ml of 
streptomycin, 100 U/ml of penicillin, 2 mM L-glutamine, and 10% HI-FBS (Shafren 
et al., 1997). All cells were passaged in the presence of trypsin-
ethylenediaminetetracetic acid (EDTA). 
 
Plasmid DNA and RNA transfection of mammalian cell lines  
Purified DNA or RNA (amounts as specified elsewhere) in H2O was made up to 
250 µl in serum and antibiotic free medium and mixed with an equal volume solution 
of Lipofectamine 2000 (3:1 Lipofectamine 2000 to µg DNA), (Invitrogen) in similar 
medium. The mixture was incubated according to the manufacturer’s instructions and 
added to cell monolayers in 6-well tissue culture plates.  
 
Short interfering RNA transfection of mammalian cell lines 
Transfections were performed in triplicate in 24-well format according to the 
manufacturer’s instructions (Invitrogen). Briefly, 0.5 µl Lipofectamine 2000 was 
diluted in 50 µl serum- and antibiotic-free medium and incubated at room 
temperature (RT) for 5 minutes (mins), during which 25 picomoles (pmol) of a short 
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interfering (si)RNA oligomer (Invitrogen) in H2O was made up to 50 µl in similar 
medium. Both mixtures were combined and after 20 mins incubation at RT, the 
solution was added to each well preincubated with 0.4 ml of fresh medium 
containing 10% HI-FBS.  
 
siRNA transfection of mammalian cells by electroporation 
HeLa cells from two T175 flasks were pelleted at 2000 revolutions per minute (rpm) 
for 5 mins and resuspended in serum-free DMEM twice before quantitating by 
haemocytometer. Cells were pelleted again and resuspended in sterile phosphate 
buffered saline (PBS). A Gene Pulser Xcell Electroporation System (Bio-Rad) was 
utilised for electroporations. 1.5 x 106 cells were transferred to a chilled 4 millimetre 
(mm) cuvette (Molecular BioProducts) together with 200 pmol siRNA and incubated 
on ice for 5 mins. Cells were electroporated using the following settings: voltage 
160 volts (V), resistance ∞Ω, capacitance 500 microfarads (µF), and transferred to a 
6-well plate containing 2 ml/well fresh medium with 10% HI-FBS.  
 
Virus infections 
Cell monolayers were infected with virus at the stated MOI 24 to 48 hr post-
transfection, after removal of transfection media. Virus was absorbed onto 
monolayers for 30 mins at 37ºC/5% carbon dioxide CO2/air. Virus supernatant was 
removed and replaced with medium supplemented with or without 10% HI-FBS. 
Virus supernatant was removed 24 to 48 hours post-infection, upon completion of 
full cytopathic effect (CPE; appearance of cell rounding or detached cells).  
 
Luciferase assay 
Supernatant was removed from transfected cell monolayers, cells were rinsed with 
PBS and lysed using 200µl or 500µl 1 x Glo Lysis Buffer (Promega®) per well in a 
12- or 6- well plate respectively. The oxidation reaction was catalysed by the 
addition of 100 µl cell lysate (luciferase enzyme) to 100 µl RT Bright-Glo™ 
Luciferase Assay System (Promega®) substrate and shielded from the light for 
5 mins. Luciferase activity was measured using a luminometer (Turner Biosystems) 
with values expressed in relative light units (RLU).  
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 Tissue culture infectious dose50 (TCID50) 
Virus from RNAi infections were titred by TCID50 which measures the quantity of 
virus required to infect 50% of inoculated microplate wells per sample (Minor, 
1985). Each well of 96-well plates was seeded with 3.75 x 104 HeLa cells, allowing 
for four replicates of titration per sample. In a separate 96-well round-bottomed 
plate, a serial 10-fold dilution of sample with DMEM/10% FBS/penicillin-
streptomycin (PS) from 10-1 to 10-12 was performed. Media was removed from 
confluent cells, 100 µl of the appropriate virus dilution was added to each well, 
(including 100 µl DMEM/10% FBS/PS to control wells) and incubated for 1 hour at 
37ºC/5% CO2. An extra 100 µl DMEM/10% FBS/PS was added per well and plates 
were incubated for four days. Plates were stained with crystal violet for one hour and 
rinsed with tap water before drying upside down on paper towel. Virus titre was 
expressed as log10 TCID50/ml (Reed & Muench, 1938).  
 
Plaque assay 
Cells were seeded in 6-well plates (5 x 105 cells per well) and grown to 90% 
confluency. Ten-fold dilutions of virus stock were made in medium/10% FBS/PS. 
Once medium was removed from seeded wells, cells were inoculated with 500 μl of 
prepared virus and incubated for 30 mins at 37°C in the presence of 5% CO2/air to 
allow absorption to occur. Plaque overlay media (refer to section 2.3 for contents) 
was added to each well and plates were incubated for two to three days at 37°C in the 
presence of 5% CO2/air. Cells were stained with crystal violet solution and re-stained 
post-removal of the plaque overlay media. Plaques were counted and the virus titre 
expressed as plaque forming units per millilitre (PFU/ml).  
  
Immunofluorescence assay 
Sterile 15 mm glass coverslips were placed in tissue culture plate wells before cell 
seeding. Coverslips were gently washed twice with PBS in wells before cells were 
fixed to coverslips with 4% paraformaldehyde for 10 mins. Coverslips were removed 
from wells and mounted upside down on glass slides (Menzel-Glaser) with mounting 
medium for fluorescence containing 4',6-diamidino-2-phenylindole (DAPI) 
(Vectashield). 4',6-diamidino-2-phenylindole is a fluorescent stain that binds to DNA 
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in fixed cells (Kapuscinski, 1995). Coverslips were attached to slides by nail polish 
and the presence of green fluorescent protein (GFP) was detected using a Leica SP2 
upright confocal microscope with an ultraviolet (UV) filter. 
 
Replication kinetics assay 
Replication kinetics of wild-type and recombinant viruses was compared in single-
step growth experiments performed in 12-well plates to determine the kinetics of 
virus growth (PFU over time) as a measure of viral fitness. HeLa cells were infected 
at an MOI of 10 for 30 mins before cells were washed twice with sterile PBS and 
incubated with fresh DMEM/10% FBS/PS. Plates were incubated at 
37ºC/5% CO2/air and supernatant harvested at various time points over 24 hrs. Virus 
concentrations were determined by plaque assay.  
 
Plaque purification by limiting dilution 
Recombinant virus from RNA transfections was biologically cloned by limiting 
dilution in 96-well microtitre plates. Virus dilutions were performed using a 
multichannel pipette in a round bottomed 96-well microtitre plate (Sterilin) prior to 
transfer onto fresh cell monolayers. Fifty-five microlitres of serum-free media was 
added to each well prior to addition of diluted virus. Approximately 55 µl diluted 
virus supernatant was added to each well in the top row. After mixing by pipetting, 
55 µl of solution was transferred to the next row (already containing 55 µl serum-
free media). Pipette tips were discarded after the mixture was mixed in each row and 
these two-fold dilutions continued down the plate. Fifty microlitres was transferred 
from each well onto a fresh cell monolayer in flat bottomed 96-well plates seeded 
with 2.6 x 104 HeLa cells/well. The plates were left to allow for virus absorption for 
30 mins at 37°C in the presence of 5% CO2/air. An extra 200 µl serum-free media 
was added to each well and plates were incubated at 37ºC/5% CO2/air. After 4 days, 
the supernatant was transferred to a new microtitre plate and cell monolayers were 
stained by crystal violet for the presence of complete CPE. RNA was extracted from 
the highest dilution of virus supernatant per column and RT-PCR was carried out to 
amplify the crossover region of the recombinant virus. 
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Statistical analysis (chapter three) 
All statistical analysis used SPSS for Windows, Rel. 17.0.0, 2008, Chicago: SPSS 
Inc with a two sided, non-directional test of the hypothesis with significance set 
at 5%. Homogeneity of the variance and a normal distribution was not assumed due 
to the relatively small number of data points in some of the experiments. Individual 
experiments were not prospectively powered to show statistical significance and 
therefore treatment differences are considered exploratory. The non-parametric, 
Kruskal Wallis test was used to test each micro (mi)RNA or siRNA experiment as 
per the following hypothesis: H0 = median of the PV serotype 1 or 3 wells = median 
of the siRNA/siRNA test wells. Ha = median of the PV serotype 1 or 3 
wells ≠ median of the miRNA/siRNA test wells. If the Kruskall Wallis test indicated 
a significant difference between treatments at 5% significance, individual miRNA or 
siRNA were compared to the PV serotype 1 or 3 virus controls by the non-parametric 
Mann-Whitney U test. Descriptive summaries are presented with graphs including 
the geometric mean ± standard error from assays performed in triplicate unless 
otherwise specified. A significance value of P < 0.05 is marked with an asterisks 
symbol.  
 
Statistical analysis (chapter five) 
A parametric, one way analysis of variance (ANOVA) (Dytham, 2003) was used to 
test whether there was significant difference between the mean point accepted 
mutation (PAM) values at the crossover sites and the mean PAM values for the entire 
region. H0 = mean PAM values at the cross over regions = mean PAM values for the 
entire sequence. Ha = mean PAM values at the cross over regions ≠ mean PAM 
values for the entire sequence. The analysis included a two sided, non directional test 
of the hypothesis with significance set at 5%. A normal distribution was assumed and 
the homogeneity of variance tested by Levene’s statistic (P = 0.87). 
2.2 Molecular Genetic Techniques 
Plasmid DNA extractions from Escherichia coli using commercial kits 
Overnight cultures (5 ml and 100 ml) of transformed E. coli in Luria-Bertaini (LB) 
broth with the appropriate antibiotic for selection were pelleted in preparation for 
minipreps and midipreps respectively. Small scale isolations were carried out using 
GeneJET™ Plasmid Miniprep Kit (Fermentas) according to the protocol provided. 
 -52-
Plasmid DNA was eluted in 40 µl distilled (d)H2O. Medium scale isolations were 
performed according the instructions supplied with the QIAfilter™ Plasmid Midi Kit 
(Qiagen) and DNA was resuspended in 500 µl dH2O. A list of plasmids/replicons 
used during this project is outlined in table 2.1 at the end of this chapter. 
 
Plasmid DNA extractions from Escherichia coli using alkaline lysis 
Constituents for Solutions I, II, and III are detailed in Section 2.3 Stock Solutions 
and Buffers. Single colonies were picked from agar plates and used to inoculate 
500 µl LB broth with appropriate antibiotic selection in 1.5 ml microcentrifuge tubes. 
Tubes were placed in a tube rack which was then wrapped with cling film, and 
allowed to shake at 250 rpm overnight at 37°C. Fifty microlitres of culture was 
removed the following day for storage and the remaining culture was centrifuged in 
the same tube for 2 min at maximum speed. The pellet was resuspended in 100 µl 
ice-cold cleared lysate buffer (Solution I). Following resuspension, 200 µl lysis mix 
(Solution II) was added and the tubes gently inverted 4 to 6 times to disrupt the 
bacterial membranes and release cell contents, at which time 150 µl of potassium 
acetate (Solution III) was added to neutralise NaOH from the previous step and 
precipitate genomic DNA and sodium dodecyl sulphate (SDS). The tube contents 
were mixed gently by inversion and centrifuged at 13 000 rpm in a bench top 
microcentrifuge for 5 min. Once the supernatant was removed carefully to a new 
microcentrifuge tube, the contents was combined with 500 µl 100% ethanol and 
inverted 3 to 4 times. Following incubation at RT for 2 mins, the tubes were 
centrifuged for 10 min at 13 000 rpm in order to pellet the precipitated DNA. The 
supernatant was carefully removed and the pellet washed with 200 µl 100% ethanol 
and centrifuged again for 1 min. The ethanol supernatant was removed and the pellet 
left to air dry at RT. The pellet was resuspended in 25 µl H2O and allowed to stand at 
RT for 10 min. 
  
Virus RNA extractions from cell culture supernatant  
RNAeasy Mini Kit (Qiagen) was used for RNA extraction from supernatant 
recovered from virus infections or transfections according to the manufacturer’s 
instructions. RNA was stored at -80°C and when required, was thawed in an ice bath. 
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PCR product clean up through column 
High Pure PCR Cleanup Micro Kit (Roche Applied Science) was used for DNA 
purification from PCR product according to the manufacturer’s instructions. Sterile 
dH2O was used in place of supplied elution buffer. DNA was stored at -20°C until 
required.  
 
Extraction of DNA from agarose gel 
Deoxyribonucleic acid fragments were extracted from agarose gel using the DNA 
Extraction Kit (Fermentas) according to the manufacturer’s instructions. The DNA 
was eluted in 10 to 30 µl dH2O and quantitated by spectrophotometry.  
 
Transformation of E. coli with plasmid DNA  
Between 1-3 µl ligation mixture was added to 50 µl ice-thawed α-Select Chemically 
Competent Escherichia coli (Bioline) and stored in an ice bath for 20 mins. The mix 
was placed in a 42°C waterbath for 30 secs before being returned to ice for 30 secs. 
Five hundred microlitres of SOC medium (Sambrook et al., 2000) was added before 
incubating the tube in a 37°C shaker (225 rpm) for 1 hour. One hundred fifty 
microlitres of cells were plated onto LB agar plates supplemented with appropriate 
antibiotic selection and incubated overnight at 37°C. 
 
A-tail reaction before ligation into blunt/T vectors 
Single deoxyadenosine (A) overhangs were attached to the 3’ end of amplified 
fragments by a shorter PCR cycle including deoxyribonucleotide adenosine 
trisphosphate (dATP) only and Taq DNA Polymerase (Fermentas) according to 
“Amplification of DNA fragments (up to 3kb) - Polymerase Chain Reaction (PCR)” 
later in the chapter. Briefly, 7 µl of column purified PCR product was added to a 
standard PCR mixture (with only dATP) in a 10µl reaction. The mixture was 
incubated at 70°C for 30 mins and purified again through a column as previously 
stated.  
 
Ligation of DNA fragments  
Amplicon or digested DNA fragments were ligated into vectors at a molar ratio of 
3:1 (insert:vector) in a 10 µl reaction containing 1 x Ligation Buffer (400 mM Tris-
HCl, 100 mM MgCl2, 100 mM dithiothreitol (DTT), 5 mM adenosine trisphosphate 
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(ATP) (pH 7.8 at 25°C)) and 5 U T4 DNA Ligase (Fermentas). Reactions were 
incubated at 4°C overnight and used directly without further purification for bacterial 
transformations. 
 
DNA sequencing 
Four hundred nanograms (ng) plasmid DNA or 70 ng amplicon was added to 
5.5 pmol sequencing oligonucleotide in a total reaction volume of 10 µl. DNA was 
sequenced by Molecular Biology Services at University of Warwick using an ABI 
PRISM 3130xl Genetic Analyser. Sequences were analysed using the Lasergene® 
v6.0 sequence analysis package by DNA*®. 
 
Restriction enzyme digestion 
Digestion of DNA was carried out using 1 U or 10 U of restriction enzyme in a 
solution containing 1 x the specific reaction buffer supplemented, and if required, 
with 100 μg/ml bovine serum albumin (BSA). Incubation temperature and 
subsequent thermal inactivation were carried out according to the manufacturer’s 
instructions. The digestion reaction was incubated from 1 to 4 hrs before being run 
on a 1% weight per volume total (w/v) agarose gel for size/banding pattern analysis. 
The restriction sites used to linearise plasmids during this project are outlined in table 
2.2 at the end of this chapter. 
 
In vitro reverse transcription (cDNA synthesis) 
Reverse transcription reactions were carried out using Superscript II Reverse 
Transcriptase (Invitrogen). Ten microlitres of purified RNA (at unknown 
concentration) was incubated in a mixture containing 100 pmol oligo dT 
(Invitrogen), 10 mM dNTP mix and 1.5 µl H2O for 5 min at 65ºC. Following a 2 min 
cool on an ice bath, 0.2 μmoles DTT, 1 x Superscript Buffer (250 mM Tris-HCl, 
pH 8.3 at RT, 375 mM KCl, 15 mM MgCl2), and 20 U RiboLock RNase Inhibitor 
(Fermentas) was added and incubated for 2 mins at 46ºC. Two hundred units of 
Superscript II was added to the reaction before a final 50 min incubation at 46ºC and 
reaction termination at 70ºC for 15 mins. The cDNA mixture was stored at -20ºC 
while not in use. 
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Amplification of DNA fragments (up to 3kb) - PCR 
A master mix was prepared containing 1 x Taq Buffer with (NH4)2SO4 (750 mM 
Tris-HCl (pH 8.8 at 25.5°C), 200 mM (NH4)2SO4, 0.1% Tween-20), 2.5 mM each 
deoxyribonucelotide triphosphate (dNTP), 30 pmoles of the relevant forward and 
reverse oligonucleotide, and 2.5 U Taq DNA Polymerase (Fermentas) in a 50 μl 
reaction volume. 
 
Thermal cycling comprised 25-30 cycles as follows: one cycle of denaturation for 
2 mins at 95°C, 24-29 cycles of denaturation for 1 min at 95°C, annealing for 30 sec 
at 55°C (or different according to oligonucleotide conditions) and elongation for 
1 min/kilo base pairs (kps) at 72°C, and a last cycle of 5 min at 72°C. A list of 
oligonucleotides is recorded in table 2.3 at the end of this chapter. 
 
Amplification of DNA fragments (full genome) - PCR 
This method was applicable for amplification of full-length genomes. A master mix 
was prepared containing 1 x PCR Buffer for KOD XL DNA Polymerase (contents 
proprietary), 0.2 mM of each dNTP, 50 pmoles of the relevant forward and reverse 
oligonucleotide, and 2.5 U KOD XL DNA Polymerase (Novagen) in a 50 μL 
reaction volume. Three µl of template was added following first strand synthesis of 
cDNA from virus RNA extracted from tissue culture supernatant.  
 
Thermal cycling comprised the following: 30 cycles of denaturation for 30 seconds 
(secs) at 94°C, annealing for 10 secs at 61°C and elongation for 6 mins at 72°C, and 
a final cycle of 10 mins at 74°C.  
 
Amplification of DNA fragments –PCR gradient 
Gradient PCR was used in instances where the annealing temperature of 
oligonucleotides was undetermined. The PCR mixture was set up according to 
protocols outlined in this chapter. Thermal cycling conditions replaced one annealing 
temperature with a range of temperatures (usually in increments ranging from 40 - 
60ºC across the heating block) to assess the hybridisation ability of oligonucleotides. 
Products from different cycling conditions were analysed on an agarose gel and 
optimal annealing temperature determined. 
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Site-directed mutagenesis 
Point mutations were introduced into virus encoding plasmids using QuikChange® 
Site-directed Mutagenesis Kit, or QuikChange® II XL Site-directed Mutagenesis Kit 
(Stratagene). Briefly, 20 to 40-mer oligonucleotides were designed for opposite 
strands of the plasmid and incorporated nucleotide mutations necessary for the 
project. The plasmids were amplified by PCR (using the mutagenic oligonucleotides) 
according to the provided protocol. Competent E. coli cells provided with the kit 
were transformed with amplified plasmid and individual clones sequenced to confirm 
the presense of specifically introduced mutations.  
 
Overlap extension PCR 
This method was applied to incorporate multiple point mutations when required. 
Polymerase chain reaction oligonucleotides complementary to both DNA strands 
were designed so that incorporated mutations were at least 8 base pairs (bps) from 
the 5’ and 3’ ends of the oligonucleotide. Two DNA fragments, overlapping in the 
region defined by the mutagenic oligonucleotides were amplified using appropriate 
external oligonucleotides. The gel purified fragments underwent linear amplification 
(in the absence of oligonucleotides) in order to obtain a complete double stranded 
(ds) amplicon using the following reaction mix and cycling conditions. 
Approximately 120 ng of each amplicon was mixed with 1 x PCR Buffer for KOD 
XL DNA Polymerase, 0.2 mM of each dNTP, and 2.5 U KOD XL DNA Polymerase 
(Novagen) in a 25 μl reaction volume. Thermal cycling comprised the following:  
95°C  2 min 
95°C  1 min 
45°C*  30 sec 
72°C  1 min/kbp 
5 cycles (* + 5°C per cycle) 
95°C  1 min 
72°C 2 min 
4°C  soak 
Both smaller PCR fragments with approximately 40 bases overlap were subject to 
final assembly amplification using the original external oligonucleotides used to 
amplify the smaller fragments. Polymerase chain reaction conditions are stated in 
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“Amplification of DNA fragments (up to 3kb) - PCR” using Taq DNA Polymerase 
(Fermentas). 
 
In vitro transcription 
Linearised plasmid for RNA transcription was first prepared by ethanol precipitation. 
Briefly, 2 x volume of 100% ice cold ethanol was mixed with the digestion reaction 
and incubated at -20°C for 30 mins. The cDNA was pelleted for 15 mins at 
13000 rpm before being air dried at RT and resuspended in 10 µl 
diethylpyrocarbonate (DEPC) treated H2O.  
 
Between 1 - 2 μg of linearised plasmid DNA suspended in DEPC H2O was incubated 
in a reaction mixture containing 1 x T7 transcription buffer (Fermentas), 20 nmoles 
of each ribonucleotide triphosphate (rNTP), 20 U RiboLock RNase Inhibitor 
(Fermentas), 0.2 μmoles DTT, and 20 U T7 RNA polymerase (Fermentas), to a total 
volume of 26.5 μl. The reaction was incubated in a 37°C waterbath for 4 hrs. 
Residual DNA template was digested with 2 U DNase Turbo (Ambion) at 37°C for 
15 mins. Between 1.5 and 2 μL of RNA was confirmed on a 1% agarose gel before 
column purification using RNeasy Mini Kit (Qiagen) and quantification on a 
spectrophotometer. 
 
2.3 Stock Solutions and Buffers 
Crystal violet 
0.5 g crystal violet powder in 20 ml 100% ethanol, 880 ml dH2O containing 0.9 g 
NaCl and 100 ml 40% formaldehyde.  
Mini-prep solutions  
Solution I: 50 mM glucose, 10 mM EDTA, 25 mM Tris-HCl pH 8.0 (store at 4°C) 
Solution II: 0.2 M NaOH, 1% SDS w/v 
Solution III: 5 M postassium acetate pH 4.8 (store at 4°C) 
DEPC-treated water 
0.1% DEPC to dH2O, store overnight at RT with a loose lid in a fume hood, 
autoclave and aliquot into single use volumes. 
 -58-
6 x DNA agarose gel loading buffer 
25 mg bromophenol blue to 3 ml 100% glycerol. Make up to 10 ml with dH2O. Store 
at RT.  
Guanidine hydrochloride 
Guanidine hydrochloride powder dissolved in H2O at 200mM. 
Plaque overlay medium 
10% v/v Minimum Essential Medium (EMEM) with Earle’s salts (10x), 1% v/v L-
glutamine, 3% v/v 7.5% sodium bicarbonate, 2% v/v FCS, 1% v/v PS, and 30% v/v 
2% agar. 
Agar for plaque overlay medium 
2% w/v bacto-agar (Dibco) in distilled water. Microwaved to dissolve powder and 
stored at RT.  
Penicillin/streptomycin 
Filter sterilised 10000 U/ml of penicillin and 10000 µg/ml in distilled water. 
DMEM, GMEM/G418, 10 x EMEM, trypsin/EDTA, and sterile PBS 
Supplied by the Media Preparation facility in School of Life Sciences, University of 
Warwick. 
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2.4 List of DNA plasmids 
Table 2.1 List of subgenomic replicon and full-length clones used in this study  
Plasmid Name Description Reference 
pE7Luc E7 replicon with virus capsid replaced 
by luciferase, derived from pT7 E7 
Chris Bull and 
Minghui Ao  
(in house) 
pEV70Luc EV70 luciferase-encoding subgenomic 
replicon with ribozyme and T7 
promotor 
Sheila Waugh’s 
thesis (in house)  
pRibo-CAV21-
NaeIDel-backbone 
(pRiboCAV21ΔP1) 
CVA21 backbone vector lacking 
complete capsid region with AgeI 
deletion  
Claire Blanchard’s 
thesis (in house) 
pRLucWTa PV1 replicon with virus capsid 
replaced by luciferase 
Andino et al., 1993 
pT7Rep3-L PV3 replicon with virus capsid 
replaced by luciferase derived from 
pT7FLC 
Barclay et al., 1998 
pT7FLC Full-length PV3 Leon P3/Leon/37 
infectious clone 
Goodfellow et al., 
2000 
pT7FLC/SL3 pT7FLC with mutated CRE, unable to 
synthesise positive-sense RNA 
Goodfellow et al, 
2000 
pT7 E7 Full-length E7 infectious clone Lindberg et al, 
1997 
PV3BKCVA21P1b Recombinant full-length PV3 
backbone with PV3 P1 replaced by 
CVA21 Coe P1  
Claire Blanchard’s 
thesis (in house) 
CVA21BKPV3P1b Recombinant full-length CVA21 
backbone with CVA21 P1 replaced by 
PV3 Leon P1 
Claire Blanchard’s 
thesis (in house) 
CVA21BKSabin1P1b Recombinant full-length CVA21 
backbone with CVA21 P1 replaced by 
PV1 Sabin strain P1 
Claire Blanchard’s 
thesis (in house) 
pT7CB4A/rep1 Replicon based on CBV4 infectious 
clone, capsid replaced by CAT gene 
Barclay et al., 1998 
pRibo-CVA21 Full-length CVA21 Coe strain in 
vector containing ribozyme, derived 
from pCVA21 
(Hughes et al., 
1989) 
pT7E30GB37 Full-length E30 strain GB37 in 
pGEMT-Easy vector, T7 promoter, 
amp resistant 
This project 
pT7E7ΔCRE pT7E7 with mutated CRE, unable to 
synthesis positive-sense RNA 
This project 
a Kind gift from Ian Goodfellow 
b Plasmids constructed by Claire Blanchard, University of Reading (unpublished). 
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2.5 Restriction Enzymes to Linearise Plasmids 
Table 2.2 Restriction sites used to linearise plasmids for RNA transcriptions  
Plasmid Restriction 
Enzyme 
Linearised Size (bp) 
pE7Luc XhoI 9726 
pEV70Luc SalI 10396 
pRibo-CAV21-NaeIDel-backbone XhoI 10429 
pRLucWT ApaI ~10500 
pT7Rep3-L SalI 10231 
pT7FLC SalI 11128 
pT7FLC/SL3 SalI 11128 
pT7 E7 NotI 10328 
pT7 EV70+Ribo SalI 11155 
PV3BKCVA21P1 SalI 11131 
CVA21BKPV3P1 SalI 10426 
CVA21BKSabin1P1 SalI 10435 
pT7CB4A/rep1 MluI 8473 
pT7FLC3GFP SalI 9304 
pT7E30 GB37 SalI 10493 
pT7E7ΔCRE NotI 10328 
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2.6 List of Oligonucleotides 
 Table 2.3 Oligonucleotides used throughout this study 
Name Database Sequence Target Identical 
location 
MJREV O-AH-7C ATAAGAATGTCGAC(TX29)CCGCACCGAATGCGGAGAATTTACCC E30 Last 26 nt 3’ end 
E30-1FClaI O-AH-6C ACGCCTCGAGATCGATTTAATTAAAACAGCCTGTGGGTTGWWCCCAC E30 1-27 
E7FcreMUT O-AH-5B GTAACTATATCCAATTTAAATCCAAGTGCCGTATCGAACCC E7 4390-4451 
E7RcreMUT O-AH-6B GGGTTCGATACGGCACTTGGATTTAAATTGGATATAGTTAC E7 4451-4390 
E7-3782F O-AH-3E GACTATGTCGAACAACTCGG E7 3782-3801 
M13R O-AH-5D CAGGAAACAGCTATGAC pUC19 - 
PV1/3-3280F O-AI-4G AACACRTMMGWGTCTGGTGC PV1, PV3 3280-3299 
GEN-4615R O-AG-6B RTADCCRTCRAAGTGWKMYGG PV1, PV3, CVA21 ~4615R 
PV3-2995F O-AG-5F GCAAACATCTTCCAACCCGTCC PV3 2995-3016 
PV3-5191R O-AG-1G GGAGTCAACTGCTTGAAGCAGA PV3 5191-5170 
PV1-3004F O-AG-6F GCAAACCTCATCAAATCCATCA PV1 3004-3025 
PV1-5200R O-AG-9F GGAGTCAACTGCTTGGAGCAAG PV1 5200-5179 
Oligo dT - TTTTTTTTTTTTTTT Poly(A)-tail - 
E7-6F O-AB-8C CAGATCATGTACATACC E7 2873-2889 
E7-5247R O-AH-2F GACACGAATGTGGTTAGTGC E7 5274-5255 
RiboSmaIE30F O-AI-3A CTCGTACCCGGGTTCTTAAAACAGCCTGTGGGTTG E30 - 
E305UTRSacIR O-AI-4A ATGTTTTTGGCCAGAGCTCCCATTTTGTTGTGTTGAG E30 - 
SacILucF O-AI-2A TGATGGGAGCTCTGGCCAAAAACATAAAGAAAG Luciferase - 
BstZ17ISmaILucR O-AI-6A CTCGTACCCGGGGTTCGTATACGGCACGGCGATCTTTCCG Luciferase - 
E30-2551F O-AH-2H AGTGGAGACAGGGCACAC E30 2551-2568 
 CHAPTER THREE: RNA-mediated Interference to Enrich Recombinants 
3.1 Introduction 
Although virus recombination is well documented, isolating recombinants from 
picornavirus populations is relatively difficult due to the high titre of progeny 
(Romanova et al., 1980). Recombination between PV serotypes was reported to 
occur at a frequency of 7.6 x 10-6, which is 100-fold lower than recombination within 
serotypes (Kirkegaard & Baltimore, 1986). The majority of literature identifies and 
characterises recombinant RNA viruses that have been the attributing cause of 
disease outbreaks and individual cases of pathogenesis. Unfortunately, less analysis 
has concentrated on studying the mechanisms behind RNA recombination, 
particularly in positive-strand RNA viruses. As described in detail in the 
introduction, researchers have succeeded in recapitulating genetic recombination of 
enteroviruses in vitro (in particular PV) in order to try and define the preferred 
region/s of recombination. Simply co-infecting cells with two strains/serotypes 
creates recombinants naturally, although this method is inefficient in that a progeny 
may only contain 1 to 10 recombinant viruses in a population of 106 to 107 virus 
particles. The parental viruses will always dominate during a co-infection and make 
it difficult to characterise replication competent recombinants that are present at low 
levels. In another method, recombinant crosses are performed involving partners 
with genetically defined selection markers (e.g. temperature and guanidine 
sensitivity/resistance) that limit growth ordinarily. Although the latter method is 
successful in generating small ranges of recombinant viruses for further study, these 
methods of selection are only applicable to viruses where such genetic markers are 
known. In most cases, the reversion rate of such genetic markers would exceed the 
rate of recombination. It is time consuming to select natural virus mutants that escape 
applied inhibitors followed by full genome sequencing to identify the location of 
associated mutations. These types of studies are therefore limited to well-
characterised RNA viruses such as PV, and to those viruses with extensive sequence 
information and phenotypic analysis.  
 
In order to study recombination in any number of enteroviruses available, regardless 
of extensive analysis on virus phenotypes etc, an alternative generic approach was 
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investigated. It was decided to attempt to select recombinants by the application of 
an RNA-mediated interference (RNAi) selection strategy. This method did not 
require extensive information about input virus partners beforehand, only that full 
genome sequences were available. Numerous enteroviruses have been sequenced in 
their entirety, with most sequences available in GenBank (National Center for 
Biotechnology Information, [NCBI]).  
 
The native cellular mechanism of RNAi has emerged to become a successful gene-
silencing technique for controlling sequence-specific degradation of homologous 
RNA in cultured cells (Fire et al., 1998). Ribonucleic acid-mediated interference is 
widespread and is a phenomenon found in plants, animals, and fungi. It also plays an 
important role in defending cells against viruses and other invading genes (van Rij, 
2008). Briefly, small non-coding RNA molecules mediate post-transcriptional gene 
silencing (PTGS) and can exist in several forms. MicroRNA are small double 
stranded (ds)RNA derived from endogenous RNA-coding genes in the genome that, 
once processed and exported to the cytoplasm, bind specifically to mRNA in a 
sequence dependent manner to regulate the expression of cellular proteins. 
MicroRNA either induce degradation of the target mRNA or inhibit translation from 
the mRNA template. Similarly, siRNA are small interfering RNAs derived from long 
exogenous dsRNA (such as invading viruses) and target the cleavage of foreign RNA 
by an endonuclease in a sequence dependent manner (Elbashir et al., 2001a; 
Hutvágner & Zamore, 2002). Although the primary transcripts and processing of 
miRNA and siRNA differ, both culminate in the cytoplasm to converge at the RNA-
inducing silencing complex (RISC) to target RNA degradation via the same process. 
 
Genome-encoded miRNA originate as large stemloop structures (primary miRNA) in 
the nucleus and are processed into shorter fragments by an RNase III enzyme Drosha 
and double stranded RNA-binding domain (dsRBD) (reviewed in Bushati & Cohen, 
2007). The ~ 70 nt precursor miRNAs (pre-miRNAs) are transported to the 
cytoplasm by Exportin-5 (Yi et al., 2003) where they are cleaved by the same 
process as precursors to siRNA. Briefly, pre-miRNAs or synthesised dsRNA 
molecules comprising > 26 nt RNA duplexes are processed by the ribonuclease 
(RNase) III-like enzyme Dicer into miRNA or siRNA respectively, both 
approximately 22 nt in length (Hutvágner et al., 2001). One strand in the duplex 
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(usually the strand with the least stable 5’ end, labelled the guide strand) is 
incorporated into the RISC (Schwarz et al., 2003) which contains Argonaute proteins 
capable of endonucleolytic cleavage (Liu et al., 2004). The miRNA/siRNA guides 
RISC to its target by bp interactions, which ultimately recognises and degrades 
sequence-specific mRNA or foreign nucleic acids.  
 
Several methods exist for performing RNAi in vitro and these are summarised in 
table 3.1. Chemically synthesised siRNA can be generated by the same methods as 
DNA oligonucleotides by commercial companies and introduced directly into cells. 
Expression plasmids and viral vectors (including adenoviral, retroviral, and 
lentiviral) can express siRNA or short-hairpin RNA (shRNA) off RNA polymerase II 
or III promoters that are later processed in cells. RNAi is a valuable research tool and 
is has been used for large-scale screens of gene function with miRNA libraries 
readily available for many host systems that target all known genes.  
 
Thousands of human miRNAs have been discovered, with the best known probably 
being miR-122. This miRNA is a liver-specific miRNA that regulates cholesterol and 
fatty-acid metabolism in mice (Esau et al., 2006). Hepatitis C virus is known to 
recruit miR-122, which enhances virus replication as a result (Jopling et al., 2005). It 
is not surprising therefore, that miR-122 has become an ideal therapeutic target for 
HCV infection. This is an unusual example of a non-viral miRNA benefitting virus 
replication. In contrast, several laboratories have demonstrated the effectiveness of 
partially inhibiting picornavirus propagation by specific siRNA (Liu et al., 2005; 
Saleh et al., 2004; Schubert et al., 2005; Sim et al., 2005) with some groups 
observing a reduction of up to two log10 of virus titre as a result of RNA sequence 
targeted degradation. In an elegant experiment, Gitlin and colleagues inserted 
another prominently studied miRNA, let-7, into PV cDNA prior to transfections with 
transcribed RNA (Gitlin et al., 2005). Transfected HeLa cells express high levels of 
let-7 naturally which controls developmental pathways (regulating cell proliferation 
and differentiation) (Hutvágner et al., 2001). Not only was virus replication reduced 
as a direct result of expression of let-7 miRNA in cells (down approximately 4 log10), 
but it was also concluded that only positive-stranded PV RNA was targeted by anti-
PV siRNA.  
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Table 3.1 Summary of RNAi and delivery methods 
RNAi Source Delivery Methods Expression 
chemically synthesised siRNA lipid-mediated transfection Transient 
(non-replicating) electroporation   
plasmid-expressing miRNA, shRNA lipid-mediated transfection Transient 
(self-replicating) electroporation   
viral vectors containing siRNA, shRNA:   
Adenovirus infection (dividing and non-dividing cells) transient (does not integrate) 
Lentivirus infection (dividing and non-dividing cells) transient and stable (can integrate*) 
Mouse stem cell virus (retrovirus) infection (dividing cells) transient and stable (can integrate) 
Baculovirus infection (dividing and non-dividing cells) transient and table (can integrate) 
PCR-generated siRNA or shRNA  lipid-mediated transfection Transient 
Expression Cassettes (in vitro transcribed electroporation  
siRNA or shRNA transcripts are later    
processed in the cell      
* Integrate into chromosomal DNA for long-term, consistent expression  
Sources: Ambion website (www.ambion.com/techlib/presentations/siRNA.pdf) and 
SuperArray Bioscience Corporation (http://www.sabiosciences.com/newsletter/rnai.html) 
Antiviral siRNAs can interfere with virus replication by targeting sequence 
dependent RNA degradation to reduce virus yields in cells, and this process was 
investigated in this project as a way to study virus recombination further. Figure 3.1 
provides schematic representations of siRNA action within the cell cytoplasm, as 
well as potential sites of siRNA targeting during the virus multiplication life cycle 
within cells. There are several methods by which short RNA-molecules can be 
introduced into cells, and the remainder of the study will focus on miRNA and 
siRNA. 
 
The overall aim was to investigate the sequence determinants and genome locations 
of recombination between two serotypes (and potentially two species) of 
enteroviruses by employing RNAi to select and enrich recombinant viruses from a 
mixed virus infection. The application of RNAi would be practical because of its 
ability to reduce virus titres in cells protected by anti-viral siRNA. It has been 
demonstrated in the studies mentioned above, that virus replication is inhibited to 
certain degrees by short RNA molecules that are designed specifically to target 
infecting and newly synthesised virus RNA. In the first stage of this project, several 
anti-PV miRNA expression plasmids and chemically synthesised anti-PV siRNA 
duplexes were tested for their ability to reduce virus titres during a single PV 
infection. It was known that a two log10 reduction in virus yield was the minimum 
level acceptable as this is the greatest reduction reported for antiviral siRNA so far 
(Gitlin et al., 2002; Lee et al., 2007). It was also considered the minimum level that 
might impact on the overall yield of progeny to facilitate identification of 
recombinants. If the indicated minimum level of virus reduction was achieved for a 
single PV serotype infection, then the ultimate purpose of the project was tested. The 
aim was to reduce parental virus titres during a dual infection by using short RNA 
molecules that targeted opposing ends of each infecting parent virus genome. At the 
same time, newly synthesised recombinant viruses would escape these specific anti-
viral measures due to the recombinant nature of their genomes – effectively 
enriching recombinants in the population. A diagrammatic representation of this is 
provided in figure 3.2. It was expected that reducing the high numbers of parent 
viruses in the progeny would effectively moderate competition between both parents 
and the resulting recombinants. This would aid in the retention of a diverse range of 
natural recombinants that could exhibit various levels of fitness.  
 -67-
  
 
Figure 3.1 RNAi silencing of mRNA in cells. Schematic representation of mRNA 
silencing by siRNA and potential sites of virus RNA targeting by siRNA during the 
virus cycle within the cell cytoplasm during infection. (A) Synthetic siRNAs are 
phosphorylated once transfected into cells, are unwound by a helicase, and the 
antisense strand of siRNA guides RISC to target mRNA. The target mRNA is 
cleaved by an endo-ribonuclease in the RISC, resulting in mRNA degradation. (B) 
Multiplication of virus in the cell upon infection. There are several instances during 
the life cycle with potential siRNA targets to degrade virus RNA. (Source: Colbere-
Garapin et al., 2005).  
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Figure 3.2 RNAi regimes to enrich recombinants in a virus population. (A) A 
simplified representation of an expected mixed virus population after a dual infection 
with two similar viruses coloured red and blue. (B) Diagrammatic representation of 
RNAi strategy to target mRNA degradation of infecting parental viruses and 
specifically orientated recombinant genomes.  
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It is only very recently that the first report into the use of RNAi to study RNA virus 
recombination was published (Gao et al., 2011). This study involved the use of 
HIV-1 subtype-specific siRNAs to enrich inter-subtype HIV-1 recombinants and 
inhibit parental HIV-1 replication during a dual infection. This group was successful 
in generating replication-competent recombinants and identifying a range of 
recombination breakpoints, some of which were similar to those found in natural 
isolates from HIV-1 patients.  
 
Aims 
The specific aim of this part of the project was to investigate the antiviral activity of 
specifically designed miRNA/siRNA against PV1 and PV3 replication in vitro, using 
different delivery methods. Antiviral activity was measured by determining the virus 
yield with and without the presence of miRNA/siRNA in infected cells. If RNAi 
successfully reduced virus production in HeLa cells during single virus infections, 
then this method would be expanded to incorporate dual infections to generate 
recombinant virus.  
_____________________________________________________________ 
 
3.2 Construction of anti-PV miRNA Expressing Plasmid 
Initially, a method involving the use of plasmid-derived/encoded miRNA sequences 
was tested. This method mimics the presence of endogenous miRNA produced 
naturally in cells and processes the short stem loops in the same way for 
incorporation into RISC. MicroRNA molecules were designed with high 
complementarity to virus sequences of interest and miRNA duplex-expressing 
plasmids were transfected into cells prior to virus challenge. Inhibition of virus 
replication was calculated by comparing virus titres in miRNA treated cells versus 
cells left untreated (mock transfected). A “scrambled miRNA” was also included in 
the studies. This scrambled miRNA was designed as an oligonucleotide control with 
no specificity to virus or cellular mRNA. This was to determine whether the 
transfection of cells with miRNA expressing plasmids affected normal cell function.  
 
James Taylor designed miRNA against VP1, VP3, 3C, and 3D in PV type 1 
(Mahoney) and 3 (Leon) miR 2 to miR 12 (table 3.2). These sequences were targeted 
Table 3.2 Synthesised miRNA oligonucleotides (DNA) and corresponding nucleotide positions in PV1 and PV3 genome  
Name Target Nucleotide (nt) sequence 
Nt 
locationa Region 
     
Cntrl-
scr(F)* - 5'TGCTGGGTTATCATAACCTCACAGCCGTTTTGGCCACTGACTGACGGCTGTGATTATGATAACC - - 
Cntrl-
scr(R)* - 5'CCTGGGTTATCATAATCACAGCCGTCAGTCAGTGGCCAAAACGGCTGTGAGGTTATGATAACCC - - 
miR 2(F) PV1 5'TGCTGTGTACAACATGTCTGGTTTGCGTTTTGGCCACTGACTGACGCAAACCACATGTTGTACA 2632 VP1 
miR 2(R)  5'CCTGTGTACAACATGTGGTTTGCGTCAGTCAGTGGCCAAAACGCAAACCAGACATGTTGTACAC   
miR 3(F) PV1 5'TGCTGTAGACTCTGACCTTGACCTATGTTTTGGCCACTGACTGACATAGGTCAGTCAGAGTCTA 2677 VP1 
miR 3(R)  5'CCTGTAGACTCTGACTGACCTATGTCAGTCAGTGGCCAAAACATAGGTCAAGGTCAGAGTCTAC   
miR 4(F) PV3 5'TGCTGATCAGAACTCCATCATTCGTCGTTTTGGCCACTGACTGACGACGAATGGGAGTTCTGAT 5716 3C 
miR 4(R)  5'CCTGATCAGAACTCCCATTCGTCGTCAGTCAGTGGCCAAAACGACGAATGATGGAGTTCTGATC   
miR 6(F) PV3 5'TGCTGAATAGGTCTGGATCGCATCCAGTTTTGGCCACTGACTGACTGGTGCGCCAGACCTATT 6607 3D 
miR 6(R)  5'CCTGAATAGGTCTGGCGCATCCAGTCAGTCAGTGGCCAAAACTGGATGCGATCCAGACCTATTC   
miR 7(F) PV3 5'TGCTGTTCACAATCAGAACTCCATCAGTTTTGGCCACTGACTGACTGATGGAGCTGATTGTGAA 5722 3C 
miR 7(R)  5'CCTGTTCACAATCAGCTCCATCAGTCAGTCAGTGGCCAAAACTGATGGAGTTCTGATTGTGAAC   
miR 8(F) PV1 5'TGCTGATCAAATTCAGGCAGCGCACAGTTTTGGCCACTGACTGACTGTGCGCTCTGAATTTGAT 1832 VP3 
miR 8(R)  5'CCTGATCAAATTCAGAGCGCACAGTCAGTCAGTGGCCAAAACTGTGCGCTGCCTGAATTTGATC   
miR 9(F) PV1 5'TGCTGAACCGAACCCTATACATATTTCCGTTTTGGCCACTGACTGACGGAAATGTAGGGTTCGGTT 1960 VP3 
miR 9(R)  5'CCTGAACCGAACCCTACATTTCCGTCAGTCAGTGGCCAAAACGGAAATATGTATAGGGTTCGGTTC   
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Name Target Nucleotide (nt) sequence 
Nt 
locationa Region 
     
miR 10(F) PV1 5'TGCTGATCCATGGCACTACCATAGTAGTTTTGGCCACTGACTGACTACTATGGGTGCCATGGAT 2257 VP3 
miR 10(R)  5'CCTGATCCATGGCACCCATAGTACGTCAGTCAGTGGCCAAAACTACTATGGTAGTGCCATGGATC   
miR 11(F) PV1 5'TGCTGTATGGTTTGCCGATACGTGGTGTTTTGGCCACTGACTGACACCACGTAGGCAAACCATA 2285 VP3 
miR 11(R)  5'CCTGTATGGTTTGCCTACGTGGTCGTCAGTCAGTGGCCAAAACACCACGTATCGGCAAACCATAC   
miR 12(F) PV1 5'TGCTGAAAGAGGGACGACTATTCTAGGTTTTGGCCACTGACTGACCTAGAATACGTCCCTCTTT 2354 VP3 
miR 12(R)  5'CCTGAAAGAGGGACGTATTCTAGGTCAGTCAGTGGCCAAAACCTAGAATAGTCGTCCCTCTTTC   
          
* Designed and constructed by Kym Lowry    
aNumbering according to PV1 Mahoney or PV3 Leon, 5’ end of the target sequence    
Underlined nucleotides - inserted linker and loop sequences (by Invitrogen) to generate secondary stem loop structure.   
 
 
as they flanked the recombination region found naturally in virus isolates, i.e. 2A to 
2C region near the middle of the genome (as shown in figure 3.2B). As part of this 
study, all miRNAs were sequenced and concentrations verified. The majority of 
miRNA inserts were designed using the web-based tool provided by Invitrogen1. The 
poliovirus sequence of interest was submitted in an online form; in this case, regions 
VP1 and 3C of both PV1 and PV3, and the website automatically calculated 10 
potential miRNA target sequences with high probability of target binding to the 
submitted sequence. Although the exact algorithms for calculating preferred binding 
sites for miRNA to RNA template was not available to the user, several guidelines 
have been established mainly by Tom Tuschl’s group (Elbashir et al., 2001a; 
Elbashir et al., 2002; Elbashir et al., 2001b). Suggested guidelines for choosing 
siRNA target sites are as follows: the targeted region is usually 21 nt in length, 
avoids intronic regions, targets beginning with AA are ideal as 3’ overhanging uracil 
dinucleotides are effective, siRNA/miRNA oligonucleotides to target mRNA should 
be selected outside regions of secondary structure, avoid sequences outside the 30-
50% GC content range, and avoid stretches of > 4 nucleotide repeats. The 
oligonucleotides designed using the Invitrogen website conformed to these 
parameters. Basic local alignment search tool (BLAST) was also performed later to 
avoid off-target binding to other sequences (virus and host genome). It was also 
confirmed by BLAST2 that each set of PV target sites differed between both 
serotypes, in order to eliminate cross-reactivity of miRNA to the heterologous virus.  
 
In total, 11 pairs of miRNA oligonucleotides targeting PV1 and PV3 were separately 
cloned into pcDNA6.2™-GW+EmGFP-miR expression vector provided in the kit 
according to the manufacturer’s instructions. Each pair of oligonucleotides consisted 
of a forward and reverse complementing miRNA sequence that was annealed prior to 
ligation into the vector. The top and bottom strand oligonucleotides annealed to 
generate a ds fragment with 4 nt overhangs necessary for directional cloning into the 
commercial vector. A plasmid containing a scrambled control was also constructed, 
having used the scrambling miRNA/siRNA design tool provided by the Promega 
website3. In short, a miRNA was submitted online and the program scrambled the 
                                                 
1 (https://rnaidesigner.invitrogen.com/rnaiexpress/) 
2 (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
3 (http://www.promega.com/siRNADesigner/) 
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sequence in such a way that no potential ‘off targets’ to mammalian genomes 
existed. Basic local alignment search tool results also identified no potential ‘off 
targeting’ sites in PV. This acted as a control to indicate whether the presence of 
random miRNA effected virus production and cellular function. 
 
A commercial expression vector system was employed to deliver virus specific 
miRNA to cells by lipid-mediated transfection. In the first instance, the BLOCK-
iT™ Lentiviral Pol II miR RNAi Expression System Kit was used to achieve this. 
Specific miRNAs are designed by the researcher and cloned into the vector backbone 
provided in the kit. This kit allows for the eventual construction of a replication-
incompetent lentivirus that distributes miRNA sequence of interest to both dividing 
and non-dividing mammalian cells. This initial expression clone contains the ds oligo 
encoding the pre-miRNA sequence (designed specifically by the user), which is 
expressed in cells using an RNA polymerase II promoter, specifically the human 
CMV immediate early promoter (figure 3.3A). The vector allows for co-cistronic 
expression of Emerald GFP to measure the efficiency of DNA transfection in cells by 
fluorescent cell imaging. Figure 3.3B illustrates the role of miRNA processing into 
RISC and its potential to target RNA degradation of virus RNA in cells.  
 
The first step was to determine if transient expression of antiviral miRNA in cells 
was capable of reducing virus production after virus infection in the same cells. If a 
reproducible reduction in virus yield by specific miRNA oligos was observed, the 
miRNA would be incorporated into a lentiviral vector in order to establish a stable 
transfectant in which antiviral miRNA are constitutively expressed in cells. Stably 
transfected cells would have integrated the nucleic acid into their genome and once 
expanded these cells could permanently express the miRNA of interest, making it 
ideal to perform RNAi experiments over the longer term. During virus infections, 
low levels of virus RNA will escape RNAi, and recombinants in a certain orientation 
(figure 3.2B) will be enriched. Mammalian cells that constitutively express antiviral 
miRNAs can be utilised for further recombinant experiments – for example, the 
presence/absence of external stimuli (temperature, virus concentrations, and 
mutagens) may alter recombination events.  
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 Figure 3.3 The expression vector kit used to deliver virus specific miRNA to 
cells. (A) The vector incorporates the coding sequence of Emerald GFP to allow for 
tracking of plasmid transfection efficiency. Double stranded miRNA 
oligonucleotides are cloned into the vector according to the manufacturer’s 
instructions. (B) Cellular or virus pre-miRNA processing in the nucleus, followed by 
RNA degradation once miRNA are incorporated into the RISC. 
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Statistical analysis using both Kruskal Wallis and Mann-Whitney U tests were 
performed to determine whether reductions in virus titre due to treatment with 
miRNA were stastically significant (see Materials and Methods for full details). 
  
3.3 Transient Expression of miRNA to Reduce Virus Replication 
miRNA plasmids express EmGFP in transfected HeLa cells 
HeLa cells were transfected separately with three miRNA expression clones to 
confirm the efficiency of transfection by Lipofectamine 2000 (Invitrogen) in this 
highly transfectable cell line. Approximately 3.5 x 105 cells cultured on sterile glass 
coverslips in 6-well plates were transfected with 2 µg plasmid DNA. Instructions 
supplied with Lipofectamine 2000 were followed regarding concentrations of 
plasmid DNA required for all transfections. After 48 hrs, the coverslips were 
removed, washed, fixed, and mounted using medium for fluorescence with DAPI 
(see Materials and Methods). Transfection efficiency was shown by direct 
fluorescence of GFP in the cytoplasm of cells, and this was interpreted to indicate the 
co-expression of anti-viral miRNA in the same cells. Untreated, control scrambled 
(cntrl-scr), and miRNA 7 plasmid transfected cells are shown in figure 3.4. Between 
40-50% of cells were transfected and levels of fluorescence varied between cells. 
Similar fluorescence results were seen for the remaining miRNA (data not shown).  
 
Anti-PV1 and PV3 miRNA targeted RNA degradation of PV1 and PV3 
Initially, the anti-PV miRNA encoded by these plasmids was analysed for the ability 
to inhibit virus replication by specifically targeting virus RNA degradation. By 
following the protocol outlined for transfections in 24-well plates, 500 ng of plasmid 
DNA was transiently transfected into HeLa cells in triplicate using 
Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). The 
following individual plasmids containing ds miR pairs were transfected into cells: 
cntrl-scr, miR 2, miR 3, miR 4, miR 6, miR 7, miR 8, miR 9, miR 10, miR 11, and 
miR 12. A mock transfection was performed each time containing Lipofectamine 
2000 alone in the absence of plasmid. Twenty-four hrs post-transfection, the medium 
was removed and cells were infected with an MOI of 0.1 with either PV1 (Mahoney) 
or PV3 (Leon) for 30 mins. Once virus was removed, medium was replaced and  
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 Figure 3.4 Immunofluorescence of GFP/ miRNA expressing plasmids in cells. 
Immunofluorescence of untreated/cntrl-scr/miRNA 7 HeLa cells at 24 hrs post-
transfection. The nuclei were stained with DAPI and the presence of GFP in the cell 
cytoplasm was examined under UV light.  
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plates were incubated at 37°C/5% CO2/air. Supernatant containing virus was 
harvested from cells 24 hrs post-infection and titred by TCID50. 
 
The plasmid expressing cntrl-scr miRNA displayed minimal disruption to PV1 and 
PV3 production (figure 3.5). This was expected since this was designed to have no 
sequence specificity to virus. This also suggested that miRNA expression plasmids 
used in the study did not affect normal cell function, as transfected cells appeared 
healthy (as seen by fluorescence microscopy) and produced similar titres of virus 
output. Transient expression of specific miRNAs, on the other hand, showed highly 
variable inhibition of virus production and results indicated no sequence specific 
effect of antiviral miRNAs on its targeted virus.  
 
All anti-PV1 and anti-PV3 miRNAs affected PV1 titres to varying levels, with 
reductions in virus titres ranging from 0.75 to 0.25 log10 TCID50 (miRNA 9 and 
miRNA 3 respectively) (figure 3.5A). Unexpectedly, the PV1 titre increased 
by > 0.5 log10 in the presence of miRNA 12, a result which remains unexplained. 
Anti-PV3 miRNA 4 exhibited subtle cross-reactive antiviral activity with just less 
than 0.5 log10 TCID50 reduction in titre compared to the PV1 control titre. A wide 
range of readings within replicates was noted, in particular for cells treated with 
miRNA 9 and 10. The excessive standard deviation (see error bars) meant that the 
difference in average virus titre may not have been significant.  
 
By referring to figure 3.5B, both anti-PV1 and anti-PV3 miRNA affected the titre of 
PV3 in HeLa cells to varying degrees, from approximately 0.75 log10 (anti-PV 
miRNA 3) to 0.1 log10 TCID50 (anti-PV1 miRNA 8). Although statistical analysis 
showed that virus titres were reduced significantly compared to the control, these 
reductions were still less than one log10. There was no evidence of serotype specific 
reduction due to miRNA, as was demonstrated by cross-reactivity between PV1 and 
PV3 miRNA.  
 
Intra-precision assays with miRNA expression plasmids  
To demonstrate intra-assay variability in miRNA transfection/virus titre, each well of 
the triplicate in the aforementioned experiment (miRNA 9 and 10 with PV1  
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 Figure 3.5 Effects of miRNA on PV replication. Representative results showing 
the effects of transient expression of miRNA expressing plasmids on (A) PV1 and 
(B) PV3 virus replication. Twenty-four hrs post-transfection, HeLa cells were 
infected with MOI 0.1 of either PV1 or PV3 for a further 24 hrs before virus was 
harvested and titrated. The graphed data are the geometric mean from triplicates, 
error bars indicate standard deviation. The blue bars indicate anti-PV1 miRNA, the 
red bars represent anti-PV3 miRNA. miRNA 10 has a SD of 0, depicted by the lack 
of error bar at three significant figures. Asterisk; P < 0.05 by Mann-Whitney U test 
with the test miRNA compared to the PV1 or PV3 alone, respectively. 
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challenge) was graphed separately (figure 3.6). This showed very wide transfection 
and infection variability between each well on the same plate performed 
simultaneously in one experiment. The virus titre from each well was determined 
once by TCID50. Intra-assay variation had a maximum value of two TCID log10 
difference in virus titre within cells transfected with the miRNA 10 expression 
plasmid. Given that two log10 was set as the minimum target for significant 
knockdown, an intra-assay variation of up to two TCID log10 was considered too 
large.  
 
To conclude, in those that were reduced, the log10 reduction was not considered 
extensive enough for use in recombination experiments. If a one log10 TCID50 
reduction from 105 was achieved using miRNA, the progeny would still contain 
104 TCID50 parent virus able to escape RNAi and re-infect surrounding cells. Also, 
cross-reactivity was observed between both sets of anti-viral miRNAs to PV1 and 
PV3 production, indicating a lack of specificity in the assay. Even if stable 
transfectants were constructed using the miRNAs, it was believed that intracellular 
virus RNA would still escape targeted degradation with cross-reactivity remaining an 
issue. Lastly, intra-assay variation was high as indicated by a large standard 
deviation for some results performed in triplicate. As an alternative approach, it was 
decided to investigate the direct transfection of siRNA to determine if this 
suppressed viral yield sufficiently for the planned recombination experiments.  
 
3.4 Transient Expression of siRNA to Reduce Virus Replication 
Antiviral activity of chemically synthesised siRNA duplexes 
An alternative RNAi delivery system was therefore employed whereby chemically 
synthesised ds siRNA molecules were directly transfected into cells. These were 
designed to provide anti-PV siRNA in cells. The synthetic siRNA oligonucleotides 
were designed to target regions within the VP1 and 3Dpol of PV1 and PV3 and were 
also designed using the web-based tool provided by Invitrogen (table 3.3). Of note, 
only one siRNA target overlapped with a miRNA target in the same virus region 
between both experiments. The BLOCK-iT™ RNAi Designer for siRNA used the 
same proprietary algorithms with 100% homology to their target, so that upon 
processing, their activity would result in cleavage of that mRNA target. The  
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 Figure 3.6 Intra-assay variation using miRNA. Representative results indicating 
intra-assay variation within a triplicate dataset. HeLa cells were transfected in 
triplicate with anti-PV1 miRNA expressing plasmid and infected with MOI 0.1 PV1 
24 hrs later. Virus supernatant was harvested and serially diluted 24 hrs post-
infection. Column (PV1) in graph was mock transfected, and infected with PV1 in 
the same manner as those with anti-PV1 miRNA.  
 
 
 
 
 
 
 
 -81-
Well‐to‐well Varation miRNA Plasmid Transfections
2.5
3
3.5
4
4.5
5
5.5
6
PV NA
V
ir
us
 T
it
re
 L
og
 T
CI
D
50
1 miRNA 9 miR  10
Each well of triplicate
 
 -82-
Table 3.3 Synthesised siRNA oligonucleotides (RNA) and corresponding nucleotide positions in PV1 and PV3 genome 
Name Target Nucleotide sequence Nucleotide locationa Region 
Cont-
scrambled - 5' UUAUCAUAACCUCACAGCCgg - - 
MET-2Cb PV1/3 5' AGAGCAAACACCGUAUUGAgc ~4460-4480 CRE/2C 
si-2599PV1 PV1 5' CCCUUCUGAUACAGUGCAAac 2599-2619 VP1 
si-3146PV1 PV1 5' GCACUAGGUGACUCCCUUUau 3146-3166 VP1 
si-6336PV1 PV1 5' GCUACCCUUAUGUAGCAAUgg 6336-6356 3Dpol 
si-6439PV1 PV1 5' CCUCCCACUGGUGACUUAUgu 6439-6459 3Dpol 
si-PV13D* PV1 5' GUGCGAUCCAGAUUUGUUUug 6619-6639 3Dpol 
si-7055PV1 PV1 5' GCUGACAAAUCAGCUACAUuu 7055-7075 3Dpol 
si-2769PV3 PV3 5' CCGGGCACAGAAACUAUUUgc 2769-2789 VP1 
si-2962PV3 PV3 5' GCACCCACACCAAAGUCAUgg 2962-2982 VP1 
si-6211PV3 PV3 5' GGACCAUUAUGCUGGACAAcu 6211-6231 3Dpol 
si-6243PV3 PV3 5' GGAUAUCAGCACAGAGCAAau 6243-6263 3Dpol 
si-PV33D* PV3 5' AUGCGAUCCAGACCUAUUCug 6610-6630 3Dpol 
si-6681PV3 PV3 5' CAGGAUACGACGCAUCACUua 6681-6701 3Dpol 
          
aNumbering according to PV1 strain Mahoney or PV3 strain Leon 
b Adapted from Lee et al., 2007 
* Adapted from Gitlin et al., 2005 
difference between miRNA and siRNA was that the output products for miRNA 
incorporated a small sequence to form a stem loop between the target sequence and 
appropriate nucleotide overhangs so that correct miRNA structure was achieved. 
Output siRNA duplex targets consisted of 21-mer target sequences without 
additional inserted sequences. Similar parameters were required for siRNA design 
(GC content, outside regions of secondary structure, etc.) as for miRNA which were 
discussed in detail earlier. Poliovirus type 1 siRNAs were further checked by BLAST 
to ensure that they did not contain high sequence identity to untargeted PV3 
sequence and vice versa. An siRNA targeting the highly conserved enterovirus CRE 
was also included in these experiments and was named MET-2C (Lee et al., 2007). 
All 21-mer oligonucleotide duplexes contained two 3’ nt overhangs matching the 
target sequence. To assess the antiviral effects of these siRNA individually, HeLa 
cells were transfected with individual siRNAs using Lipofectamine 2000 reagent and 
infected with either PV1 or PV3 at an MOI of 0.1 to determine if single siRNAs 
could inhibit virus production in cells and to determine whether there was a virus 
serotype specific response. Transfection and infections of HeLa cells were performed 
in triplicate, and each triplicate titred once by TCID50 assay. 
 
The effects of anti-PV1 and anti-PV3 siRNA on virus replication were quantified by 
comparing virus titre in the presence or absence of 25 pmol/well siRNA at 24 hrs 
post-infection. This was the recommended dose for siRNA according to the number 
of target cells using Lipofectamine 2000. The effect of single siRNAs transfected 
into cells prior to virus infection was calculated by comparing virus titres to those of 
untreated cells to give a log10 TCID50 virus yield. The geometric mean for each 
triplicate was graphed, together with the standard deviation (as error bars) and 
statistical significance marked with an asterisks symbol where appropriate.  
 
As expected, prior transfection with the scrambled control siRNA (cont-scrambled) 
had little or no effect on both PV1 and PV3 replication (figure 3.7). This proved that 
the scrambled siRNA sequence had little homology to an untargeted virus sequence, 
and also did not affect normal cell function since resulting virus titres were similar to 
mock transfected cells. With regards to antiviral PV1 siRNA (blue bars in 
figure 3.7), all but one was able to reduce PV1 yield in transfected cells, with the 
highest and statistically significant reduction caused by si-3146PV1 (> one log10),  
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 Figure 3.7 Effects of siRNA on PV replication. Representative results showing the 
effects of transient siRNA expression in HeLa cells on PV1 and PV3 replication. 
Twenty-four hrs post-transfection, HeLa cells were infected with MOI 0.1 of either 
PV1 or PV3 for a further 24 hrs before virus was harvested and titrated. The graphed 
data are the geometric mean from triplicates, error bars indicate standard deviation. 
Blue bars indicate anti-PV1 siRNA, red bars represent anti-PV3 siRNA. These 
experiments were performed on separate days, as indicated by the gap in the x-axis. 
The siRNA si-PV13D has a SD of 0, depicted by the lack of error bar at three 
significant figures. Asterisk; P < 0.05 by Mann-Whitney U test with the test miRNA 
compared to either the PV1 or PV3 control, respectively. The statistical analysis did 
not include siRNA si-PV13D. 
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followed closely by si-2599PV1 (one log10). In contrast, an increase in virus yield 
was seen in cells transfected with si-6439PV1 (0.25 log10). Two anti-PV3 siRNA (si-
6243PV3 and si-6681PV3) had a subtle effect on PV1 replication, reducing average 
virus yield by no more than 0.25 log10. 
  
All anti-PV3 siRNA reduced PV3 titres (red bars in figure 3.7), with the highest 
reduction caused by si-6243PV3 (1.5 log10). MET-2C (conserved CRE sequence for 
PV1 and PV3) also reduced PV3 by 1 log10. Although si-6439PV1 was calculated to 
reduce the PV3 titre significantly, the range of error bars suggested that this result 
required further testing of replicates. In fact, variation within several triplicates was 
high again as indicated by the standard deviation, but this did not affect the statistical 
significance of some average virus yield reductions (calculated on the median by 
non-parametric methods).  
 
The MET-2C siRNA was able to reduce both PV1 and PV3 titres when transfected 
into HeLa cells prior to virus challenge, indicating that this small siRNA 
oligonucleotide was able to interact with the stem loop structure of the CRE. This 
was expected as the siRNA targeted the conserved 2C-CRE region of enteroviruses 
essential for positive-strand synthesis and was able to inhibit virus replication, even 
if only in a limited capacity. 
 
 Unfortunately, antiviral siRNA were not able to protect HeLa cells from virus 
challenge to the levels first expected. Yield reductions of ≤ 1.5 log10 did not satisfy 
previous targets of 2 log10 reductions to begin recombination experiments involving 
dual virus infections. Modifications to experimental conditions were therefore 
employed in an attempt to improve the level of virus inhibition achieved.  
 
Dose-responses of siRNA duplexes 
After demonstrating the inhibition of PV1 and PV3 replication by certain specifically 
targeted siRNAs, it was necessary to determine the effectiveness of different 
concentrations of siRNA on virus replication. The expectation was that it should be 
possible to optimise the siRNA concentration to maximise the reduction in virus 
yield. A dose-response experiment was also performed to ascertain whether 
increased concentrations of siRNA would induce a non-specific cytotoxic effect in 
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HeLa cells when combinations of siRNA were used to inhibit virus replication 
during co-infection experiments. In the first instance, MET-2C was used as it was 
originally designed to cross-react with the conserved PV1 and PV3 CRE target and 
published data supported this (Lee et al., 2007). HeLa cells were transfected with 
3 to 100 pmol per well of MET-2C 24 hrs prior to PV1 and PV3 challenge at an MOI 
of 0.1. Mock and control (with cont-scrambled) transfections were also performed in 
the same assay. All transfections/infections were performed in triplicate and virus 
titres assayed once by TCID50 assay. Figure 3.8 shows virus titres of MET-2C 
transfected cells after PV1 and PV3 challenge. Although the virus titre was only 
reduced by approximately 1 log10 at best (12.5 pmol MET-2C against PV3), both 
PV1 and PV3 results showed a dose-response curve for virus titres across the range 
of MET-2C concentrations. The highest and lowest concentrations of siRNA had a 
smaller influence on virus production, whereas the highest reduction to virus yield 
was caused by the 12.5 pmol MET-2C siRNA, roughly a midway concentration. 
High siRNA concentrations may have had a reduced affect due to lower transfection 
efficiencies if more siRNAs aggregated with cationic lipid prior to introduction into 
cells. High siRNA concentrations may also have disrupted cell processes that limited 
defences.  
 
To determine whether this result was reproducible with another siRNA, cells were 
transfected with increasing concentrations of si-6243PV3 prior to PV3 challenge at  
an MOI of 0.1. Previously this siRNA was shown to exhibit significant antiviral 
activity against PV3 (figure 3.7). Results with varying concentrations of si-6243PV3 
showed that although the mean inhibition showed a subtle dose-response effect, the 
overlap of the standard deviation values (by error bar) indicated that there was no 
substantial difference between the effect of the concentrations (figure 3.9). This was 
despite the fact that 100 pmol of si-6243PV3 reduced PV3 replication significantly 
(by non-parametric methods using median values). Overall, the reduction was still 
less than one log10. Results indicated that an increase in siRNA concentration would 
not greatly improve anti-viral activity with a plateau effect evident. As no 
statistically significant difference was seen with the range tested, further studies 
continued with the use of 25 pmol siRNA, the recommended concentration according 
to the Lipofectamine 2000 protocol.  
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 Figure 3.8 Effects of MET-2C siRNA dose-response on PV replication. Antiviral 
activity of different concentrations of anti-CRE MET-2C (conserved for both PV1 
and PV3) on PV replication. Twenty-four hrs post-transfection with 3 to 100 pmol 
MET-2C per well in triplicate, HeLa cells were infected with MOI 0.1 PV1 or PV3 
for a further 24 hours before virus was harvested and titrated. The graphed data are 
the geometric mean from triplicates, error bars indicate standard deviation. The cont-
scrmb in the top graph had an SD value = 0, explaining the lack of error bar. 
Asterisk; P < 0.05 by Mann-Whitney U test with the test siRNA compared to the 
PV1 or PV3 alone, respectively. 
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Figure 3.9 Effects of si-6243PV3 siRNA dose-response on PV3 replication. 
Antiviral activity of different concentrations of si-6243PV3 on PV3 replication. 
Twenty-four hrs post-transfection, HeLa cells were infected with MOI 0.1 PV3 for a 
further 24 hrs before virus was harvested and titrated. The graphed data are the 
geometric mean from triplicates, error bars indicate standard deviation. Asterisk; P < 
0.05 by Mann-Whitney U test with the test siRNA compared to the PV1 or PV3 
alone, respectively. 
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Accessing the anti-viral activity of combinations of siRNA duplexes 
Although single anti-virus siRNAs were able to reduce the yield of virus production 
by as much as one log10, greater reduction (> 2 log10) was both expected and 
desirable for the selection of recombinant virus populations. The delivery of siRNA 
to all cells is important for efficient virus silencing, and it was likely that virus was 
escaping targeted degradation in cells that missed siRNA delivery. If only 40-50% of 
HeLa cells were transfected with siRNA (an assumption based on the transfection 
efficiencies seen with miRNA expressing plasmids), then this left half the number of 
cells unprotected against virus challenge. And although only an average of 9.5% of 
cells were infected initially at an MOI 0.1, this number increased with subsequent 
rounds of re-infection over a 24 hr period. Based upon the expected siRNA 
transfection level, approximately 50% of infected cells would be untransfected and 
therefore not able to display any suppression of parent viruses. This was evident by 
the scale of the reduction achieved with a single siRNA suggesting untreated cells 
were replicating parental virus to 5 to 6 TCID log10 (figure 3.7). Combinations of 
siRNA could improve virus inhibition both by potentially leaving more cells 
transfected (hence protected) and by the cumulative effect of multiple inhibitory 
siRNAs. This could also limit the ability of virus to escape RNA degradation by the 
introduction of spontaneous nucleotide mutations in siRNA target regions. It was 
expected that the use of two or more siRNAs in co-transfections could increase the 
effectiveness of virus inhibition by producing an additive or even synergistic effect. 
For example, two siRNA molecules co-transfected together would be expected to 
reduce virus progeny more than by a single siRNA molecule alone. An even greater 
reduction in virus titre (i.e. more than reduction of two single siRNA molecules 
added together) would indicate a synergistic result.  
 
Combinations of siRNA were transfected into HeLa cells simultaneously to 
determine if there was an additive, synergistic, or no antiviral effect. Each 
transfection contained 25 pmol of single siRNAs, so that a co-transfection with four 
siRNA contained a total of 100 pmol per reaction. Assays were performed in 
triplicate in 24-well plates and each triplicate was assayed once by TCID50 assay. As 
shown in figure 3.10, the virus titre was reduced up to one log10 (compared to virus 
alone) when cells were co-transfected with more than one virus-specific siRNA 
molecule which mirrored results from individual siRNA transfections (figure 3.7). 
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Figure 3.10 Effects of combinations of siRNA on PV replication. The inhibitory 
effect of mixed-siRNAs on PV1 and PV3 replication (top and bottom respectively). 
Two, three, or four siRNAs were transfected simultaneously into HeLa cells. 
Twenty-four hrs post-transfection cells were infected with PV1 or PV3 (MOI 0.1) for 
a further 24 hrs before virus was harvested and titrated. The plotted data are the 
geometric mean from triplicates, error bars indicate standard deviation. The blue bars 
indicate anti-PV1 siRNA, the red bars represent anti-PV3 siRNA. Asterisk; P < 0.05 
by Mann-Whitney U test with the test siRNA compared to the PV1 or PV3 alone, 
respectively. 
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However, there was no evidence of an additive or synergistic effect when cells were 
pre-treated with more than one siRNA. This will be discussed further at the end of 
the chapter.  
Optimising transfection methods for improved induction of RNAi 
It is not clear how long siRNA duplexes are able to induce RNAi and protect cells 
from virus infection. Since siRNA are unable to replicate within a cell, the 
concentration of siRNA is effectively diluted as the cells divide and therefore 
become less effective at inducing RNAi as a consequence. It was therefore necessary 
to perform a series of preliminary experiments in which the incubation period of 
either the siRNA transfection or virus infection was varied in order to optimise the 
reduction in virus titre by anti-viral siRNAs. The si-3146PV1 siRNA was selected, as 
this siRNA was shown to inhibit PV1 replication in previous experiments 
(figure 3.7). Briefly, HeLa cells were transfected with 25 pmol si-3146PV1 siRNA 
per well, together with 0.5 µL Lipofectamine 2000. The assay was performed in 
duplicate, in 24-well plates and included the control scrambled siRNA and negative 
‘mock’ transfection. Cells were infected with PV1 at an MOI of 0.1 at 6, 12, 24, or 
48 hrs post-transfection. Virus was harvested from all wells after a further 24 hrs and 
titred by TCID50 assay. Alternatively, HeLa cells were transfected as described above 
for 24 hrs only and infected with PV1 in the same manner, although virus was 
harvested after 8, 12, 24, or 48 hrs and subsequently titred by TCID50 assay. 
Figure 3.11 (both A and B) showed that anti-PV1 siRNA si-3146PV1 provided little 
or no protection to HeLa cells from PV1 infection. This experiment demonstrated 
variability between assays performed at different times, and although this has not 
been addressed in the results thus far, it indicated the lack of consistency with siRNA 
experiments (i.e. low reproducibility). No virus titre reduction was observed after 
48 hrs infection, indicating that virus was able to replicate uninhibited in cells with 
little or no siRNA protection. This suggested transfection efficiency and perhaps 
stability of siRNA in cells was not optimal or the siRNA was diluted as cells 
replicated over this time period. The greatest reduction in virus titre (i.e. best 
protection) was detected after a 12 hr virus harvest, which equated to one complete 
virus cycle. The non-specific scrambled control however, provided better protection 
than the virus specific siRNA.  
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 Figure 3.11 Optimisation of siRNA transfection and infection time points. (A) 
This graphs shows the changes in virus titre when HeLa cells are transfected with si-
3146PV1 from 6 to 48 hrs prior to PV1 challenge for 24 hrs. (B) The graphed data 
depicts virus titre after variable infection times after HeLa cells were transfected with 
si-3146PV1 for 24 hrs. Geometric means of duplicates shown. 
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Ultimately, this experiment did not show that any particular transfection/infection 
regime significantly influenced the inhibitory effect of the siRNA.  
 
Increasing MOI of virus infection post-siRNA transfection 
For further evaluation of the effectiveness of siRNA targeted degradation of 
propagating viruses, a selection of siRNA were tested against virus challenge at a 
higher MOI. This was essential as cells require successful co-infection to encourage 
recombination between the viruses, and this would only be achieved using higher 
MOI of parental viruses for future recombination experiments. To this end, two 
siRNAs that were shown to work individually against PV1 (si-3146PV1 and si-
PV13D) and PV3 (si-2962PV3 and si-6243PV3) were selected and transfected into 
HeLa cells with controls used as previously described. Transfections were performed 
in triplicate in 24-well plates with 25 pmol of each siRNA. After 24 hrs, cells were 
infected with either PV1 or PV3 at MOI 5 or 10 and incubated for 24 hrs. Virus was 
harvested and titred once by TCID50. The overall virus titres were generally 
comparable regardless of initial MOI suggesting that the infectious cycle had peaked 
at 24 hrs (figure 3.12). The scrambled control siRNA had little or no effect on virus 
titre which was expected and transfection with si-3146PV1 protected HeLa cells 
from PV1 challenge at both MOIs, but only by approximately 0.5 log10 which was 
calculated to be statistically significant using non-parametric methods. Likewise, si-
2962PV3 reduced PV3 titres in both experiments significantly, although progeny was 
only reduced by approximately one log10. The experiments suggested that anti-virus 
siRNA were unable to reduce the titre of propagating viruses to any useful degree 
(> two log10), especially when higher quantities of virus was used to challenge 
transfected cells. This was not a surprising result, considering that an average of 99% 
of cells would initially become infected by at least one virus particle when cells were 
infected at an MOI 5 or 10.  
 
3.5 Discussion 
Since its discovery in C. elegans, RNAi has become an efficient and commonly used 
tool to regulate gene expression and study cell processes in detail (Fire et al., 1998). 
Virologists have adopted this system as an antiviral tool with mixed results. The  
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Figure 3.12 Challenging siRNA transfected HeLa cells at higher MOIs of PV. 
(A) Representative results showing the effects of transient siRNA in HeLa cells on 
PV1 replication. Cells were transfected with 25 pmol virus specific siRNA and 
subsequently infected with PV1 at an MOI of either 5 or 10. Virus was harvested 
after 24 hrs and titrated by TCID50. Geometric mean and standard deviation of 
triplicates are shown. (B) Repeated with anti-PV3 siRNA and challenge with PV3. In 
graph B, the bars without error bars have a SD = 0. Asterisk; P < 0.05 by Mann-
Whitney U test with the test siRNA compared to PV1 or PV3 alone, respectively. 
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majority of groups directly challenged infectious virus with anti-viral siRNA and 
when presented as plaque forming units, demonstrated reductions in virus titre by 
1 to 2 log10 (Gitlin et al., 2002; Lee et al., 2007). Although reductions in virus load 
may be statistically significant, there still remains in excess of 105 to 107 PFU/ml 
virus in the progeny. This excess of parental viruses was not considered acceptable 
when attempting to identify recombinant progeny viruses. 
  
The present work suggested that transient expression of miRNAs provided 
unpredictable inhibition of virus replication and results demonstrated little sequence-
specificity of the plasmid generated miRNA to its targeted virus. This included the 
antiviral activity of scrambled controls and empty vectors, which has been observed 
in other studies (Wang et al., 2004) but was not presented in this chapter. Intra- and 
inter-assay variation was found to be excessive (data not shown) indicating that this 
method was not reproducible and appropriate given the desired target knock down of 
> 2 log10. Collectively, results suggested that RNAi using plasmid expression 
systems may be unreliable in that (1) transfection efficiency of plasmids was lower 
than necessary for complete cell protection against virus infection, (2) specific 
miRNAs cross-reacted with heterologous virus, therefore no virus specificity could 
be gained in the assay; (3) an interferon response may have been indirectly triggered 
by the presence of 60-70 base pair dsRNA duplexes made by the miRNA plasmids, 
even though there was no overall reduction in viral yield; (4) although reductions in 
virus yield were sometimes statistically significant compared to the controls, the 
amount of reduction did not warrant subsequent recombination experiments. 
 
It has been suggested that nonspecific interferon responses could be activated by 
plasmid-mediated miRNA expression, as longer ds RNA molecules are generated in 
cells by plasmids including those used in this study, and this was briefly investigated 
but without success (Elbashir et al., 2001a; Gitlin et al., 2002; Watanabe et al., 
2007). This was probably not an issue with these experiments, as some anti-viral 
miRNA had no effect on virus titre regardless. The project moved to using shorter 
siRNA duplexes to overcome potential complications involving interferon pathways. 
 
The second approach relied on introducing chemically synthesised siRNA duplexes 
designed against regions encoding VP1 (capsid), CRE and 3Dpol (RdRp) of PV1 and 
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PV3, into mammalian cells. Individual siRNAs reduced virus yield by up to one log10 
and showed specificity to the targeted virus. Similar outcomes were noted when pre-
treated cells were challenged with higher concentrations (MOI 5 and 10) of virus.  
 
There was no evidence of additive or synergistic antiviral activity when 
combinations of siRNAs were used as would be expected from this type of 
experiment. The lack of an effect was similar to recent results with other 
picornaviruses (Ahn et al., 2005; Wu et al., 2008). One possibility was that 
transfection reagent/siRNA complexes that formed were unevenly distributed to cells 
during the transfection process. Subsequently, a proportion of cells in the population 
lacked the protective action of siRNA, allowing for full replication of infecting virus. 
Alternatively, only a small proportion of virus RNA may have been accessible 
intracellularly in the first place. 
 
Binding of an individual siRNA molecule may also change the secondary structure 
of RNA, making the genome more or less accessible for local binding of another 
siRNA. Experimentally this could be verified by various RNA secondary structure 
studies including selective 2’ hydroxyl acylation analysed by primer extension 
SHAPE (Merino et al., 2005) but these additional investigations were not feasible 
given the scope of this project.  
 
Depending on the transfection efficiency of siRNA into mammalian cells (not 
tested), it has been postulated that a proportion of cells in the population lacked the 
protective action of siRNA, therefore allowing full replication of infecting virus 
effectively “by-passing” the siRNA in the experimental system (Ong et al., 2006; 
Pijlman et al., 2008). The transfection efficiency of siRNA in HeLa cells was not 
determined in these experiments, but could be calculated using a commercial 
fluorescently labelled siRNA.  
 
Electroporation provided an alternative method of delivering siRNA into cells, which 
could enhance the distribution of siRNA to a greater proportion of cells. An 
experiment was performed in which HeLa cells were electroporated with 
combinations of siRNA, using conditions outlined in materials and methods on the 
Gene Pulser Xcell Electroporation System (Bio-Rad), before PV challenge. There 
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was no observable difference in virus titre between the mock transformed controls 
and in the presence of anti-PV siRNA (data not shown). However, to be confident 
with these results, the assay would need to be repeated and possibly optimised 
further. 
 
RNAi may not have been an effective antiviral method from the start if it is accepted 
that mRNA degradation triggered by RNAi occurs away from areas in the cell 
involved in virus replication. It has been postulated that key components of RISC are 
somehow linked with processing bodies (P bodies) within cells, and disruption of P 
bodies can affect the efficiency of RNAi as a result (Jakymiw et al., 2005; Sen et al., 
2005). Dougherty et al have recently shown that P bodies are disrupted during PV 
infection and this correlates with the build up of viral proteinases in cells (Dougherty 
et al., 2011). According to earlier papers, it was not clear whether infecting viruses 
were associated with P bodies, but evidence suggested that infection of cells with PV 
could disrupt the formation of stress granules which are often docked to P bodies 
(Beckham & Parker, 2008; White et al., 2007). The association between RNAi and 
virus replication in cells remains to be determined, as virus replication occurs on 
rosette-like membranous vesicles (induced by virus and cellular proteins) which are 
shown to be ‘closed’ entities whereby no exchange of virus protein, RNA, or 
membranes is evident (Bienz et al., 1980; Egger et al., 2000; Teterina et al., 1997). It 
would be unlikely that the RISC/siRNA complex could interact with this replication 
complex in order to associate with target virus RNA. Taken together, this suggests 
that P bodies and virus replication complexes are separate entities within cells and 
may not associate with each other, meaning that induction of RNAi in vitro may not 
have reduced virus replication in cells. This is yet to be proven and was not included 
in the scope of this project.  
 
In conclusion, exogenously introduced RNAi was not an effective method for 
reducing virus replication in vitro (in this case, parental viruses upon co-infection). 
As demonstrated, virus titre reduction was not altered sufficiently (i.e. a minimum of 
> two log10) by the use of different siRNA delivery methods into cells. Thus, the 
relatively inefficient reduction in virus replication can be explained by a lower than 
expected transfection efficiency. Detectable recombination events are rare (frequency 
of 10-5 to 10-6 in vitro) and recombinants would be extremely difficult to isolate from 
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assays that only had a one log10 reduction in parental viruses in the final virus 
progeny.  
 
This study could be altered to limit the concentration of virus progeny. Infectious 
virus RNA (and not virus particles) could be co-transfected simultaneously with 
sequence-specific siRNA into a permissive cell line, e.g. L929 or BsrT7 cells. As the 
cell lines lack the necessary receptors for enteroviruses, they would not be able to 
reamplify viruses that have escaped RNAi in neighbouring cells. Low levels of virus 
RNA will always escape RNA degradation and form wild-type virus, but the process 
should allow for a higher proportion of recombinants to be selected using virus 
specific siRNA when following the original RNAi design (figure 3.2B). 
 
Ultimately, this approach to studying virus recombination was abandoned and an 
alternative strategy involving the use of parental genomes bearing defined lesions 
was investigated.  
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CHAPTER FOUR: In vitro Recombination  
4.1 Introduction 
The result of many separate recombination events have been observed and 
characterised predominantly from isolates obtained after virus outbreaks and natural 
infections (Furione et al., 1993; Kew et al., 2002; Oberste et al., 2004a; Simmonds & 
Welch, 2006). However, little is actually known about the mechanisms (viral and 
host) that establish the location of recombination breakpoints across the virus 
genome. Early in vitro and in vivo studies have investigated minor molecular 
mechanisms that influence or correspond to recombination events but there is scope 
for more exploratory analysis (Pilipenko et al., 1995; Romanova et al., 1986; 
Tolskaya et al., 1987). The primary challenge in studying recombinant viruses is 
their isolation from progeny, particularly when parental strains dominate the 
population and can out-compete the few functional recombinant viruses present. As 
an example, recombinant viruses have been shown to represent a fraction of the total 
virus population, with interserotypic recombinants estimated to have frequencies of 
1 x 10-6 (Jiang et al., 2007, Kirkegaard & Baltimore, 1986). The development of a 
method that increases recombinant viruses in a population, and allows for easier 
isolation of such viruses, will aid in understanding the underlying molecular 
mechanisms of recombination.  
 
An attempt to enrich recombinants from a virus population using RNAi proved 
unsuccessful (see chapter three) due to high titres of parental virus that could not be 
reduced by RNAi methods. Extremely high yields of parental virus would make 
identification of recombinant viruses difficult in this system, especially following a 
dual infection requiring high MOIs. A model that only produced recombinant virus 
in the absence of any background parental virus would be ideal. 
 
Recombination has been demonstrated from crosses in the presence of selection, 
using parent viruses that contain easily tractable point mutations that allow them to 
escape (or perish under) a single selection pressure (reviewed in chapter one). As a 
result, recombinants detected to date have ‘inherited’ the genetic mutations allowing 
them to survive under conditions that restrict growth of the parents. Although such 
 -99-
studies have been successful in generating recombinants, these recombinants would 
have had to arise more frequently than revertants in the original parent strains. If 
viruses originally evolve point mutations to escape selective pressure (e.g. guanidine 
resistance, temperature sensitivity, etc.), then it is probable that reversions of the 
point mutation can restore normal function to viruses. If point mutations occur 
slightly less than one per genome replication cycle, e.g. 2.1 x 10-4 to 5.9 x 10-4 for 
picornavirus RdRp, then this is more likely to occur than generating one 
interserotypic recombinant (10-6) during a dual infection (Crotty et al., 2001; 
Kirkegaard & Baltimore, 1986). If indeed rates of reversions are higher than 
recombination events, then this type of recombination experiment may have low 
levels of non-recombinants. Therefore, it would be ideal to incorporate two defective 
partners that are absolutely incapable of reverting to original infectivity without the 
help of recombination. For example, using virus RNA molecules with large deletions 
so that only portions of the genome are added, or destroying replication elements 
within the genome. This would create a tightly regulated process with no background 
from breakthrough parents.  
 
Therefore, a new in vitro method for generating chimeric viruses was formulated to 
simplify recovery of recombinant viruses in the absence of selection altogether. This 
system used two defective virus RNA molecules (herein described as “parents”) that 
were mutated so that neither parent RNA, when introduced into a cell alone, could 
generate a progeny virus. A subgenomic replicon was the obvious choice of a 
replicating RNA containing a large irreversible deletion (i.e. the virus parent 
encoding the capsid had been replaced by a reporter gene). When transfected into 
cells, this RNA would be unable to encode capsid proteins required to form virus 
particles, but would provide the non-structural region of the genome for potential 
crosses. A second partner would therefore be required to produce the capsid 
encoding region necessary, but contain irreversible defects in the non-structural 
region so that virus could not be generated from this partner alone. A good candidate 
for the second partner was a full-length virus RNA with mutations introduced in the 
CRE that disrupts positive-strand RNA synthesis (Goodfellow et al., 2000). This was 
deemed a semi-replication competent RNA partner, as only negative RNA strands 
are synthesised upon transfection into cells.  
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The system relied on introducing both parent virus RNAs to a single cell where 
subsequent recombination (donation of a full capsid and functional CRE by either 
parent) created functional, recombinant progeny which could be cloned and studied. 
As RNA was used for both parents, and not infectious virus, the method did not 
require cells susceptible to infection. It only required that cells were permissive to 
virus replication. Both RNA molecules retained the ability to replicate (although only 
partially for one partner), and for this reason, the aim was to investigate replication-
dependent recombination in enteroviruses.  
 
The proposed system allowed recombination with any enterovirus partner to be 
investigated, as long as virus sequence was available in plasmid form (cDNA). With 
the aid of reverse genetics, any enterovirus cDNA could be modified to incorporate 
mutations or large deletions that inhibited the production of infectious virus.  
As this approach relied on cell culture, recombinants were generated and 
characterised before they were subjected to significant selection pressures (i.e. 
immune system and selective pressures that would result from infecting multiple host 
cell types). 
 
This system was therefore used to determine whether recombination was possible 
within the cell between two RNA partners belonging to different species. This was 
possible by by-passing such restrictions as virus attachment to cells and infection 
process. The intention was to emphasise whether restrictions on recombination were 
imposed by virus factors, host factors, or both. This method was used to characterise 
recombinants and compare them to those naturally selected recombinants from 
patients and environmental samples, and possibly analyse mechanisms that influence 
the RdRp template switching process. 
 
Aim 
The aim was to develop a method to generate live, recombinant PV in vitro in the 
absence of infectious output parental viruses. If such an approach yielded infectious 
PV in the first instance, then the intention was to expand on input parental RNA 
sequences to include other non-poliovirus enteroviruses.  
_____________________________________________________________ 
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4.2 Proposed Methodology 
A replication-dependent method was developed to generate natural populations of 
recombinant viruses in vitro without the presence of parent virus in the progeny. To 
make this system free of non-recombinant background virus, two PV RNA 
molecules containing lesions rendering them unable to generate viable virus on their 
own were co-transfected into either mouse fibroblast (L929) or baby hamster kidney 
(BsrT7) cells. Both cell lines were permissive for virus RNA replication but lacked 
the necessary PV receptor necessary for infection, therefore any recombinant 
progeny virus generated was unable to re-infect neighbouring cells. In theory, the 
joining of a 5’ capsid encoding region with 3’ non-structural parts of the PV genome 
should result in the generation of a complete infectious PV genome that could be 
identified upon passage to a susceptible cell line. 
 
A diagrammatic representation of this method is provided in figure 4.1. The first 
virus genome was a full-length RNA molecule with introduced mutations (“lesions”) 
in the CRE. Mutations in the CRE were lethal to the generation of viable virus but 
still allowed for synthesis of negative RNA strands (Goodfellow et al., 2003), which 
complemented this process, since recombination has been shown to occur during 
negative RNA strand synthesis (Kirkegaard & Baltimore, 1986). The second RNA 
molecule was a subgenomic replicon that had the capsid region replaced with a 
reporter gene (e.g. luciferase). This was entirely replication competent but could not 
generate a viable virus without capsid proteins. As defects existed in each partner 
RNA molecule, only recombined RNA could generate virus, and recombination 
could only occur in the region between the virus capsid sequence and the CRE 
sequence (i.e. viral sequences 2A, 2B and part of 2C), which in the case of PVs is 
where the majority of recombination is reported to occur in natural isolates (refer to 
chapter one).  
 
Figure 4.2 provides a diagram showing the method used to generate and isolate 
viruses. As mentioned briefly, two parent RNAs were simultaneously transfected 
into either L929 or BsrT7 cells. As cells blocked reamplification of newly generated 
recombinant viruses, this removed competition between recovered viruses. As a 
consequence, a range of possible recombinant viruses could be recovered regardless 
of growth advantages as this assay essentially yielded viruses that had only  
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Figure 4.1 Generating recombinant virus in the absence of infectious parental 
virus. Two RNA molecules containing “lesions” rendering them unable to generate 
viable virus on their own were co-transfected into L929 mouse cells. Viable 
infectious virus was recovered only when both RNA molecules were present and 
able to recombine. Genome A encoded a full-length virus cDNA with mutated CRE 
that inhibited positive-strand synthesis during virus replication. Genome B contained 
a reporter gene (such as luciferase) in place of the capsid region in a subgenomic 
replicon. Crossover regions were targeted to 2A, 2B, and 2C before the CRE.  
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Figure 4.2 Method used to generate recombinant viruses by co-transfection. 
Two virus RNA partners were co-transfected into L929 or BsrT7 cells. Twenty-four 
to 48 hrs post-transfection, supernatant (s/n) was harvested and plated undiluted onto 
fresh HeLa cells and overlaid with overlay medium. Cells were stained with crystal 
violet after 48 hrs and supernatant positive for viable virus was diluted onto fresh 
HeLa cells in 96-well plates. Supernatant was harvested, cells stained again, and 
virus RNA was extracted and amplified by RT-PCR. 
 -104-
experienced a single round of replication. Viable viruses capable of causing CPE 
could be detected in co-transfection supernatant by plaque assay using mammalian 
cells (HeLa cells) susceptible to PV infection.  
 
The next step involved isolating individual viruses in the progeny to characterise the 
nature of infectious genomes recovered. It was necessary to limit the use of RT-PCR 
for identifying viruses in a mixed population as some DNA polymerases are known 
to switch from one template to another during the amplification process (Pääbo et al., 
1990). This could introduce false crossover sites into the sequences of recovered, 
recombinant viruses. Consequently, PVs were biologically cloned by limiting 
dilution in 96-well plates using a method adapted from TCID50 assays (refer to 
Materials and Methods). Virus genomes could be analysed by standard molecular 
methods thereafter.  
 
4.3 Recovery of Intraserotypic Recombinants 
Recovery of PV3/PV3 intraserotypic recombinants from co-transfections  
To test this experimental system, two homologous virus RNA partners were used to 
establish whether the model would generate viable recombinant viruses. If 
combining two PV3 RNA molecules sharing 100% sequence identity was 
unsuccessful, then this approach would require further modification. Both PV3 
subgenomic replicon pT7Rep3-L and full-length PV3 CRE mutant pT7FLC/SL3 
plasmids were linearised with SalI and RNA transcribed using T7 polymerase. Two 
micrograms RNA per well was singly or co-transfected into L929 cells in 6-well 
plates with Lipofectamine 2000. In the first instance, different ratios of partner RNA 
were transfected into cells, 1:1, 1:4, and 4:1 (replicon: full-length CRE mutant). As a 
control to demonstrate the dependence of replication on this recombination process, 
an additional co-transfection was performed in the presence of 4 mM guanidine 
hydrochloride, a potent inhibitor of PV replication (Caliguiri & Tamm, 1968). In 
addition, a luciferase expression control using the luciferase replicon with and 
without the addition of 4 mM guanidine hydrochloride was performed 
simultaneously to assess the effectiveness of transfections and replication in cells, 
and this was implemented for all subsequent replicon transfections. Since 
observations at 24 hrs showed no signs of CPE due to the lack of virus re-infection, 
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supernatant was left a further day and harvested 48 hrs post-transfection. As 
concentrations of potential virus were unknown, 500 µl of undiluted supernatant was 
used to inoculate 6-well HeLa plates for plaque assays. Plates were incubated for 
48 hrs, stained with crystal violet, and photographed. 
 
When either pT7Rep3-L or pT7FLC/SL3 RNA was transfected into L929 cells 
alone, supernatant harvested from L929 cells did not yield plaques in HeLa cell 
monolayers, although in some experiments drying artefacts were observed in some 
wells (both test and control) (figure 4.3A). When both RNA partners were 
transfected into L929 cells simultaneously, viable infectious virus was detected in 
harvested supernatant regardless of input RNA partner ratio (figure 4.3A). As 
undiluted co-transfection supernatant was used to inoculate HeLa cells for plaque 
assays, it was evident that the resulting virus titre was very limited. Although plaque 
numbers were difficult to count in 1:1 and 1:4 wells, plaque numbers at a 4:1 of RNA 
indicated the recovery of 84 PFU/ml of infectious virus.  
 
No virus was produced in the presence of guanidine hydrochloride which confirmed 
that RNA replication was required during the process of virus recovery. The 
guanidine hydrochloride control did not rule out the occurrence of RNA breakage 
and ligation as a form of recombination in cells but did suggest that RNA required 
continuous replication to produce enough RNA copies for continued virus 
propagation in the L929 cells.  
 
To determine the efficiency of this model for producing virus from two genome 
‘halves’, full-length infectious PV3 RNA (pT7FLC) was transfected into L929 cells 
using the same experimental conditions described above. Approximately 
1.05 x 105 PFU/µg wild-type RNA was generated. This was 2500-fold more than the 
concentration of virus recovered from pT7Rep3-L and pT7FLC/SL3 co-
transfections, which were two homologous RNA partners. Evidently, if this virus 
was in fact the result of genetic recombination in cells, then this illustrates the 
infrequent occurrence of RNA recombination.  
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Figure 4.3 Virus recovered from L929 cells co-transfected with PV3 RNA 
molecules. (A) Crystal violet stained HeLa cells infected with undiluted transfection 
supernatant and overlaid with plaque assay overlay medium. Control wells 
containing one RNA partner each and when both pT7Rep3-L and pT7FLC/SL3 RNA 
partners were cultured with and without guanidine hydrochloride. Plaques were 
visible after co-transfection with both partners at various RNA ratios. (B) Diagrams 
outlining imprecise intraserotypic recombinants PV3(1-3390)PV3(3313-7432) and 
PV3(1-3393)PV3(3367-7432) with insertions at the crossover junctions. 
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 Characterisation of intraserotypic PV3 recombinants 
The virus population generated from co-transfections above were further analysed to 
confirm that infectious virus was indeed PV3. Several PV3/PV3 viruses were 
biologically cloned by limiting dilution and sequenced in order to define genome 
sequence between capsid and mutated CRE in the 2C region. To enable the 
generation of viable virus, a recombination event would have occurred in this region 
of the virus sequence. The crossover region was amplified using oligonucleotides 
PV3-2995F and PV3-5191R (table 2.3). The majority (n=13) of the sequenced 
PV3/PV3 clones contained no changes to PV3 sequence between the capsid and 
CRE. However, two viruses contained imprecise junction sites with additional 
PV3 sequence identified (figure 4.3B). The first clone, PV3(1-3390)PV3(3313-7432) 
contained an extra 78 nt sequence in viral sequence 2A, while the second clone, 
PV3(1-3393)PV3(3367-7432), had 27 nts inserted also in the 2A region. Crossover 
positions were determined from full-length PV3 sequence strain Leon (GenBank 
accession number X00925). 
 
The identification of imprecise crossover sites was unexpected considering that two 
identical molecules of virus RNA were used, apart from differing by the ‘defects’ 
used in each to force recombination.  
 
4.4 Recovery of Interserotypic Recombinants 
Recovery of PV3/PV1 interserotypic recombinants from co-transfections 
As this model was able to produce viable virus from two RNA molecules encoding 
the same virus (PV3), the next step was to demonstrate in vitro recombination 
between two different serotypes that are known to recombine, e.g. PV serotypes 
1 and 3 (Cuervo et al., 2001; Paximadi et al., 2006). Poliovirus 
serotype 1 subgenomic replicon pRLucWT and full-length PV3 CRE mutant 
pT7FLC/SL3 plasmids were linearised with ApaI and SalI, respectively, and 
transcribed into RNA using T7 polymerase. The RNA partners were transfected into 
BsrT7 cells and again, different ratios of RNA were combined during co-
transfections to determine whether an excess of one viral partner affected the 
outcome of recombination. Ribonucleic acid concentrations 1:1 (1 µg:1 µg), 1:4 
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(0.4 µg:1.6 µg) and 4:1 (1.6 µg:0.4 µg) of replicon to full-length CRE mutant were 
used. The BsrT7 and L929 cells were used interchangeably throughout experiments 
and did not exhibit cell-specific recombination outputs (data not shown). 
 
As expected, BsrT7 cells transfected with either pRLucWT or pT7FLC/SL3 RNA 
alone did not generate infectious virus. No plaques were present in these control 
wells using HeLa cell monolayers (figure 4.4A).  
 
However, plaques were obtained in co-transfection supernatant when pRLucWT and 
pT7FLC/SL3 were introduced into cells simultaneously at 1:1 and 1:4 ratios. 
Figure 4.4A shows the plaques present in HeLa cells when undiluted co-transfection 
supernatant was inoculated onto cells. The absence of virus recovered from the 4:1 
RNA ratio (replicon: CRE mutant) was not surprising, since it has been shown that 
the frequency of recombination depends on an excess of acceptor template 
concentration (Jarvis & Kirkegaard, 1992). Previously, a lower titre of virus was 
recovered from 4:1 (pT7Rep3-L: pT7FLC/SL3) co-transfections (figure 4.3A).  
 
The method described here has been proven to generate interserotypic PV 
recombinants from two virus cDNA molecules, and this is discussed in chapter five. 
There was no evidence of background contaminants or virus using this method and 
populations of recombinants were recoverable as a result of a tight selection process 
(no revertant parent viruses). There was little or no host selection applied to 
recombinants once generated, as cells were not susceptible to re-infection. However, 
viruses were selected at the genome level, particularly for continued viability. 
Recombinant genomes had to remain in-frame for correct protein translation, and 
conserve cleavage regions for appropriate post-translational processing. The 
complete characterisation of 100 biologically cloned PV3/PV1 recombinants was 
performed and is discussed in detail in chapter five. 
4.5 Recovery of Intraspecies Recombinants 
Recovery of intraspecies C recombinants from co-transfections  
Both intra- and interserotypic PV recombinants have being reported, and a few 
intraspecies crosses between PV and species C viruses have been identified in  
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 Figure 4.4 Virus recovered from BsrT7 cells co-transfected with PV1 and PV3 
RNA partners. (A) Crystal violet stained HeLa cells infected with undiluted 
transfection supernatant and overlaid with plaque assay overlay medium. Control 
wells containing one RNA partner were clear; plaques were present at ratios 1:1 and 
1:4 of combined RNA partners. (B) Schematic of PV3/PV1 recombinants generated 
by co-transfection, with RdRp template switching occurring between luciferase and 
mutated CRE (within the shaded region).  
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clinical isolates (Kew et al., 2002; Rakoto-Andrianarivelo et al., 2007). However, 
widespread intraspecies recombination has been described for other members of 
enteroviruses, justifying the need to attempt similar experiments using the method 
developed in this study (Oberste et al., 2004a; Oprisan et al., 2002; Santti et al., 
1999; Simmonds & Welch, 2006). 
 
To examine whether this model could yield intraspecies recombinants, the available 
PV subgenomic replicons were co-transfected with artificially constructed 
recombinants containing coxsackievirus A (CVA)21 non-structural regions. A series 
of full-length, intraspecies recombinant clones containing CVA21 with PV1 or PV3 
segments were constructed by Dr. Claire Blanchard using basic molecular cloning 
techniques during her PhD (figure 4.5). The plasmids CVA21BKSabin1P1 and 
CVA21BKPV3P1 contained a PV1 and PV3 capsid respectively, in a pRiboCVA21 
backbone. Plasmid PV3BKCVA21P1 was constructed by introducing a CVA21 
encoded capsid into a PV3 backbone vector derived from pT7FLC/REP3 (Barclay et 
al., 1998). Exchanges of P1 sequence were performed whilst retaining 
phenylalanine/glycine (in the case of CVA21) and tyrosine/glycine (in the case of 
PV3 and PV Sabin-1) amino acid sequences at the VP1/2A junctions to maintain 
correct processing (Claire Blanchard’s thesis, University of Reading, 2004). 
Interestingly, the transfected chimeric T7 RNA transcripts did not cause CPE in 
HeLa or RD-ICAM cells meaning that they did not produce viable virus. VP1 protein 
expression was detected in cells transfected with RNA derived from recombinant 
cDNAs indicating correct translation and processing by heterologous proteases of 
RNA. Although all constructs translated and processed-proteins correctly (as shown 
by in vitro and in vivo transcription/translation assays), they were not capable of 
producing infectious virus, explained by possible defects in virus maturation, 
assembly, or possible lack of compatible packaging signals. The constructed 
recombinants appeared to be replication-competent, even though levels of newly 
synthesised RNA were not as high as those observed in positive control samples. As 
a CVA21 replicon and full-length CVA21 CRE mutant were not available during the 
current project, the aforementioned clones provided replication-competent CVA21 
RNA for co-transfection experiments with PV RNA using this model. Restriction 
sites used to linearise plasmids are outlined in table 2.2. The three constructs were  
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Figure 4.5 Intraspecies C recombinants constructed by Dr. Claire Blanchard. 
The genomic origin of recombinants constructed previously – the capsid sequence 
has been removed from the full-length infectious cDNA and replaced with another 
species C virus capsid sequence. 
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co-transfected with either pRLucWT (PV1) or pT7Rep3-L (PV3) subgenomic 
replicons. 
 
Using similar assay conditions to those employed previously, a total of 2 µg of 1:1 
RNA partners was co-transfected into L929 or BsrT7 cells. Likewise, individual 
partner RNA was also transfected into cells to confirm their inability to create viable 
virus alone. Supernatant was harvested 48 hrs post-transfection and inoculated 
undiluted onto HeLa cells or RD-ICAM cells in the case of reactions containing 
CVA21 coding capsid regions. RD-ICAM cells are modified RD cells expressing 
ICAM-1 receptor required by CVA21 for cell attachment and infection. 
Figure 4.6 illustrates results of plaque assays in HeLa cells only. Each RNA partner 
transfected into cells alone did not produce virus as indicated by clear HeLa 
monolayers – neither the replicons nor constructs were able to generate virus on their 
own.  
 
However, virus was recovered from the following co-transfections: pRLucWT + 
CVA21BKPV3P1, pRLucWT + CVA21BKSabin1P1, pT7Rep3-L + 
CVA21BKPV3P1, and pT7Rep3-L + CVA21BKSabin1P1 (figure 4.6). No CPE was 
evident with RD-ICAM cells when supernatant was harvested from cells co-
transfected with either replicon together with PV3BKCVA21P1 (data not shown). It 
was not surprising that virus was not recovered from these co-transfections, as it was 
shown previously that chimeras generated with CVA (species C) capsids and the 
replication proteins of PVs were either dead or weakened (Jiang et al., 2007). This 
phenomenon is discussed in more detail at the end of this chapter.  
 
Virus containing supernatants harvested from pRLucWT + CVA21BKSabin1P1 and 
pT7Rep3-L + CVA21BKPV3P1 co-transfections were retained for future 
investigation. Recovered viruses were confirmed as recombinants by sequencing and 
crossover junctions between RNA partners were characterised and are discussed in 
detail in chapter five. 
 
 
 -113-
 Figure 4.6 Virus recovered from intraspecies RNA co-transfections. These 
combined PV subgenomic replicons and Dr. Blanchard’s constructed intraspecies 
recombinants (CVA21BKSabin1P1, CVA21BKPV3P1, and PV3BKCVA21P1). 
Transfection supernatant was plated undiluted onto a HeLa monolayer and overlaid 
with plaque overlay medium. Cells were stained 48 hrs post-infection. All control 
wells with one RNA partner only were negative. Plaques are evident in co-
transfected wells (subgenomic replicon and full-length intraspecies recombinants). 
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4.6 Co-transfections with RNA Partners Belonging to Species B 
A method has been described that generated infectious virus from various defective 
PV and RNA partners containing the CVA21 non-structural region by co-
transfections. The final intention was to determine whether similar assays could be  
performed between RNA partners from different enterovirus species to yield 
interspecies recombinants.  
 
Before this was attempted, it was reasonable to repeat earlier co-transfection 
reactions with two homologous partners from an enterovirus species other than 
species C. Therefore, the aim was to validate the system by attempting the recovery 
of a species B recombinant. 
 
To test this, two echovirus (EV)7 RNA partners were used. Subgenomic replicon 
pT7E7luc (table 2.1) and full-length pT7E7ΔCRE (construction details in 
chapter six) were both used for the assay. A luciferase reporter gene replaced the 
capsid region in pT7E7luc and the CRE was mutated in a full-length E7 infectious 
clone. Although the replication ability of pT7E7ΔCRE was not tested, it was 
assumed that this behaved in the same manner as fully characterised pT7FLC/SL3. 
The CRE structure and location is conserved in both viruses and mutations 
introduced in pT7E7ΔCRE mimicked those in the PV3 virus equivalent. 
Transfections with pT7E7ΔCRE RNA alone did not yield infectious virus.  
 
Plasmids pT7E7luc and pT7E7ΔCRE were linearised with XhoI and BspEI 
respectively and RNA transcribed using T7 polymerase. A total of 2 µg of RNA 
(0.4 µg pT7E7luc + 1.6 µg pT7E7ΔCRE) was transfected into BsrT7 cells with 
Lipofectamine 2000 in 12-well plates. Each partner was transfected individually for 
controls; a practice used for all controls. Transfection supernatant was harvested after 
48 hrs and inoculated undiluted onto fresh RD cells in order to perform plaque 
assays.  
 
Echovirus 7 encoding RNA did not cause CPE in RD monolayers when transfected 
into cells alone, an expected result (figure 4.7). Virus was detected, however, when 
both RNA partners were co-transfected into cells simultaneously. Virus plaques were 
present in RD cell monolayers. To confirm that E7 was generated in this assay,  
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Figure 4.7 Virus recovered from pT7E7luc + pT7E7ΔCRE co-transfections. 
Crystal violet stained RD cells infected with undiluted supernatant and overlaid with 
plaque assay overlay medium. Control wells contained individual RNA partners; 
dual transfection reaction was positive for plaques.  
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individual viruses were cloned by limiting dilution in 96-well plates layered with RD 
cells and several virus samples were sequenced. Briefly, virus RNA was extracted 
from clonal populations of virus dilutions and used to generate cDNA with 
Superscript II Reverse Transcriptase (Invitrogen). Oligonucleotides E7-6F andE7-
5247R (table 2.3) were used to amplify the region between both “lesions” in the 
partners used by PCR using Taq DNA Polymerase (Fermentas). Eight biologically 
cloned viruses were confirmed as being E7 by sequencing a portion of the PCR 
product. Due to time constraints, the entire targeted region of recombination was not 
sequenced; therefore conclusions could not be drawn as to whether crossover sites 
were precise or imprecise. In conclusion, this method was deemed suitable for 
generating viable virus from both species B and species C RNA partners.  
 
Co-transfections with interspecies RNA partners  
To perform co-transfection assays between RNA partners from different enterovirus 
species, several plasmids available during the project were used. All RNA partners 
available, as well as the combinations used in co-transfections, are outlined in 
table 4.1.  
 
Details of plasmid features and references are summarised in table 2.1. The 
restriction enzymes used to linearise plasmids prior to RNA transcription are outlined 
in table 2.2. All co-transfections were performed in either L929 or BsrT7 cells and 
1 µg of each partner was introduced into cells by Lipofectamine 2000 in 12-well 
plates.  
 
After attempts in which the majority of possible RNA partners were co-transfected 
into cells, it was only possible to detect virus in supernatant harvested from one co-
transfection assay (figure 4.8). A limited number of plaques were observed when 
cells were co-transfected with pT7CB4A/rep1 and pT7FLC/SL3 RNA partners. This 
virus population was biologically cloned and several viruses were sequenced across 
the targeted region to determine whether they contained a combination of coxsackie 
virus species B (CVB)4 and PV3 sequence. However, only PV3 sequence was 
detected over the region, indicating contamination during this experiment. No 
plaques were observed in any other plaque assays. 
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Table 4.1 Combinations of interspecies co-transfections performed 
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Replicons        
pRLucWT  0 ++ 0 0 ++ ++ 
pT7Rep3-L  0 ++ 0 0 ++ ++ 
pE7Luc  0 0 ++ 0 0 0 
pEV70Luc  0 0 0 0 0 NT 
pRiboCAV21∆P1  0 0 0 0 0 0 
pT7CB4A/rep1  NT 0 0 NT NT NT 
    (0) no virus detected, (++) virus detected, (NT) not tested.  
  
Continued over the page. 
 -119-
 Figure 4.8 Plaque assays of interspecies co-transfection supernatant. Crystal 
violet stained cells infected with undiluted transfection supernatant and overlaid with 
plaque assay overlay medium. Control wells contain one RNA partner each, co-
transfections are labelled with ‘both’ or those labelled with the RNA ratio.  
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Recombination between RNA from different species was not observed using this 
method. Either interspecies recombination did occur but the presence of recombinant 
virus was below the level of assay detection, recombination occurred but the  
resulting recombinants were not viable, or it was indeed not biologically possible in 
the first place. If interserotypic recombination occurred at a frequency 100-fold 
lower than intraserotypic recombination, then it is not unexpected that recombination 
between species has an even lower frequency (King, 1988; Tolskaya et al., 1983). If 
this frequency was reduced 100-fold again, the frequency of interspecies 
recombination could be as low as 1 x 10-7, or one virus particle in the typical yield 
from a standard flask of cells. 
4.7 Discussion 
 
An in vitro approach for generating recombinants of PV and other enterovirus 
species in the absence of parental virus background was demonstrated. This robust 
approach was replication-dependent and captured what is believed to be the initial 
products of genome recombination. This effectively limited post-recombination 
amplification of viruses and removed potential additional mutations (i.e. insertions, 
deletions, further recombination) in chimeric viruses that would lead to 
misrepresentation of results.  
 
Initially, co-transfections using different ratios of parental RNA molecules was 
investigated and the majority of RNA ratios resulted in the generation of infectious 
virus. As mentioned already, the concentration of acceptor template (CRE mutants in  
this case) had a subtle effect on recombination efficiency: more plaques were evident 
when acceptor template was in excess. Jarvis and Kirkegaard observed this 
phenomenon previously and suggested that recombination was more likely to occur 
when RNA template was concentrated in replication complexes (Jarvis & 
Kirkegaard, 1992). A 1:1 ratio of replicon to full-length CRE mutant was applied 
thereafter (1 µg of each partner; molar ratio of ~ 1.16:1) because this ratio of RNA 
gave consistent results and spared RNA for further experiments. Approximately 
2.9 x 1011 molecules of replicon and 2.5 x 1011 molecules of full-length genome were 
co-transfected into approximately 9.5 x 105 BsrT7 or L929 cells to yield a range of 
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viable recombinant virus titres (from 6 to 160 PFU/ml), depending on the sequence 
identity of the RNA partners.  
 
A striking observation was the inability to recover intraspecies recombinant viruses 
containing a CVA21 capsid with PV replication proteins. This phenomenon of 
incompatibility was investigated using CVA20 and PV as models (Jiang et al., 2007; 
Liu et al., 2010). Both these studies implicated a role of protein 2CATPase in virus 
morphogenesis and found that a single mutation in either VP3 (capsid protein) or 
2CATPase could rescue virus production weakly, and mutations in both regions could 
restore virus to the wild-type phenotype. Therefore, incompatibilities between 
CVA21 VP3 and PV1/3 2CATPase could explain the lack of these chimeric viruses 
identified during these experiments.  
 
This model allowed expansion and incorporation of interspecies partners. A series of 
co-transfection experiments were performed incorporating interspecies partners and 
no viable virus was detected as a consequence. It seems that interspecies 
recombinants, with a junction site in the centre of the genome, have either remained 
undiscovered, or are not viable due to incompatibilities in RNA-RNA, RNA-protein, 
or protein-protein interactions during replication. This will be discussed further in 
chapter seven.  
 
The primary restriction to the use of this method is the availability of infectious 
cDNAs for the parental genomes. Virus partners can be mutated to inhibit production 
of live virus while maintaining partial or complete replicating ability (qualities 
required for RNA partners in this method). Moreover, changes to recombination 
types as well as frequencies can be examined further by introducing mutations into 
the RdRp of the RNA partners to alter replication fidelity, a concept that has been 
explored previously using PV and brome mosaic virus (Arnold et al., 2005; Arnold 
& Cameron, 1999; Figlerowicz et al., 1997).  
 
The next step would be to sequence a large population of recombinants to 
characterise crossover sites. Several questions remain including the suggested causes 
for RdRp pausing during elongation, (which may encourage template switching) and 
whether precise or imprecise template switching is sequence dependent. These 
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questions could be addressed by producing RNA partners with specific mutations 
introduced to the RdRp sequence and observing the frequency of recombinant 
changes when incremental changes to the viral sequence between the luciferase and 
CRE junctions was introduced. The possibility that RNA partner heterogenicity 
resulted in reduced recombination frequencies, as observed using PV1/PV1 and 
PV1/PV2 recombinants in the approach described by Kirkegaard, may suggest a 
hypothesis for why fewer intraspecies recombinants are observed in nature 
(Kirkegaard & Baltimore, 1986). However, this experiment should be initially 
expanded using an appropriate statistical method to compare the observed and 
expected frequencies (i.e. Chi square if normality is assumed) using a larger number 
of recombinants. In this instance, the null hypothesis would be that the observed 
frequency of recombinants in the PV3/PV3 experiments is equal to the observed 
frequency of recombinants in the PV3/PV1 experiments. 
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CHAPTER FIVE: Characterisation of Recombinants 
5.1 Introduction 
Chapter four described and demonstrated a new system for generating recombinant 
species C enteroviruses in the absence of parental viruses in the population. The 
results revealed that enteroviruses could be generated by RNA recombination 
between two genomic virus RNA molecules that were at least partially replication-
competent but unable to form virus on their own. The replication-dependent method 
yielded intraserotypic, interserotypic, and intraspecies C recombinant viruses, the 
identity of which were confirmed by sequencing.  
 
Many papers describe the occurrence of recombination and how such viruses shape 
enterovirus evolution, but few of these examine the underlying mechanisms of 
recombination in detail with the exploratory analysis of many crossover points 
(Pilipenko et al., 1995; Tolskaya et al., 1987). It is difficult to capture early 
recombination events when viruses are subjected to selection pressures involving 
significant passage or competition. In contrast, this experimental model allowed for 
the identification of what are believed to be early recombinants.  
 
The next step was to analyse junctions from a population of recombinants generated 
using this method. An analysis of the junctions would allow speculation on the 
mechanism by which these early recombinants were generated; for example, 
following RdRp pausing on the donor template strand. This could be investigated by 
looking at the following possible correlations, including: U-rich or AU-rich stretches, 
local secondary structures in RNA sequence such as hairpins, heteroduplexes, and 
mis-incorporations. Recombination could occur with or without the presence of such 
RNA features and the aim was to determine the molecular mechanisms that 
influenced these events.  
 
Aims 
The aim was to perform a large scale experiment by repeating the interserotypic 
recombination experiment outlined in chapter four with the intention of performing 
an exploratory analysis of crossover sites for an extensive population of chimeric 
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PV1 and PV3 recombinants (100 biological clones in total). This number was 
considered sufficient to allow a representative number of different recombinants to 
be identified with the intention of determining if there were specific patterns to 
recombination junctions observed. Intraspecies C recombinants first generated and 
discussed in chapter four were also characterised to determine the crossover positions 
between input RNA partners. By carrying out detailed RNA sequence analysis, the 
purpose was to determine whether the donor or acceptor virus sequence influenced 
RdRp template switching and to characterise the fitness of chimeric viruses before 
and after further selection. The final aim was to establish whether recombinants 
generated by this method reflected those found naturally and whether this method 
provided an accurate ‘snap shot’ of RNA recombination in mammalian cells. 
_____________________________________________________________ 
 
5.2 PV3/PV1 Recombinants 
Generation of PV3/PV1 recombinant viruses 
Briefly, two virus RNA molecules containing “lesions” rendering them unable to 
generate viable virus on their own were co-transfected into permissive cells. 
Poliovirus serotype-1 subgenomic replicon pRLucWT and full-length PV3 CRE 
mutant pT7FLC/SL3 plasmids were linearised with ApaI and SalI respectively, and 
transcribed into RNA using T7 polymerase (Fermentas). A 25 cm2 flask of L929 
mouse cells was prepared the day prior and co-transfected with 2600 ng of each 
RNA partner using Lipofectamine 2000. Almost equimolar ratios of both template 
were used (subgenomic replicon: full-length CRE mutant) and calculated to be 
approximately 1.16:1. The transfection supernatant was harvested after 48 hrs and 
500 µl of this supernatant was used undiluted to inoculate a single well of a 6-well 
plate containing HeLa cells in order to detect virus by plaque assay. Plates were 
stained after 48 hrs with crystal violet and recombinant virus identified by the 
presence of plaques in the HeLa monolayers. Although controls were not performed 
in this instance, the transfection of single RNA partners in L929 cells had not 
resulted in the recovery of infectious virus on several previous occasions.  
 
Stained HeLa cell monolayers demonstrated the presence of plaques, interpreted as 
viable virus (figure 5.1A). Supernatant containing virus at an initial titre of 
86 PFU/ml was subsequently biologically cloned by limiting dilution in 96-well  
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Figure 5.1 Identification and biological cloning of 100 PV3/PV1 recombinant 
viruses.  These were recovered from co-transfections in L929 mouse cells. (A) Co-
transfection supernatant was plated undiluted onto a fresh HeLa cell monolayer and 
overlaid with plaque overlay medium. Cells were stained 48 hrs post-infection with 
crystal violet. Viable virus is evident by the presence of plaques. (B) Biologically 
cloning recombinant viruses in transfection supernatant by limiting dilution. (C) Gel 
electrophoresis of RT-PCR product of recombination region. Ethidium bromide 
stained agarose gels showing a heterogeneous mixture of amplified virus sequences 
from cloned recombinants.  
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plates (see Materials and Methods). Briefly, 40 µl of transfection supernatant passage 
0 (p0) was mixed with 70 µl serum-free DMEM/PS in each well of row A across 96-
well plates. This seeded each well with approximately 3.44 PFU of recombinant 
virus before doubling dilutions were performed down the column with further 
medium so that 55 µl virus mix remained in each well. Fifty microlitres of each virus 
dilution was transferred to fresh 96-well plates containing monolayers of confluent 
HeLa cells. Post-infection, virus supernatant (now p1) was removed and stored and 
cells were stained for CPE using crystal violet (figure 5.1B). Cytopathic effect was 
evident by clear wells after staining, indicating that virus had infected cells and 
destroyed the HeLa monolayer. The highest dilution of supernatant to cause CPE was 
retained for further analysis.  
 
Genetic characteristics of PV3/PV1 recombinants 
The target was to analyse the crossover junctions of 100 PV3/PV1 biological clones 
(generated as described in chapter four, figure 4.2) in order to provide an exploratory 
investigation of recovered virus. The aim was to observe a range of variation in 
progeny, and considering the workload involved, this was a manageable number of 
viruses to study. Thus, a statistical power calculation or subsequent statistical 
analysis was not applied. The targeted region of recombination was sequenced for 
each biologically cloned virus. Virus RNA was extracted from p1 supernatant and 
cDNA was synthesised using Superscript II Reverse Transcriptase (Invitrogen) with 
an oligo dT oligonucleotide. The PCR was used to amplify the targeted 
recombination region, from the 3’ end of the VP1 region to the start of the CRE 
in the 2C region. Oligonucleotides PV3-2995F and PV1-5200R (table 2.3), were 
used to amplify PV3/PV1 recombinant cDNA using KOD XL DNA Polymerase 
(Novagen) as they were specific for each parental ‘donor’ part of the genome. A 
small portion of RT-PCR product was loaded into a 1% agarose gel for 
electrophoresis (figure 5.1C). Each band in the agarose gel represented the crossover 
region from a biologically cloned virus. The first observation was that the single 
amplified product was not of a uniform size, and that the vast majority were larger 
than the expected target of 2205 bps. The expected target was calculated as the 
distance between both oligonucleotide pairs when PV1 and PV3 sequences were 
aligned together. This suggested that recombination was imprecise in nature with 
extra sequence inserted at the junction site. The RT-PCR product was column 
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purified, sequenced and analysed to identify junction sites between the PV3 and PV1 
parental sequences. Identifying sequences belonging to either PV1 or PV3 manually 
without the aid of recombination software was straightforward. The sequence length 
between the 3’ end of the capsid coding region and start of the CRE (crossover 
target) was the same in both viruses (1058 nt) and shared 77% nt sequence identity.  
 
In total, 110 virus clones were sequenced. Of these, 10 were removed from further 
analysis as they did not contain a clonal population of virus as was evident from the 
sequence chromatogram (figure 5.2). This occurred despite such samples apparently 
generating a single sized PCR fragment. Low levels of contaminating virus may have 
been below levels of detection on an agarose gel.  
 
The recombinant viruses consisted of a PV3 structural and PV1 non-structural 
region, henceforth referred to as PV3/PV1. Therefore, the PV1 virus RdRp was able 
to switch templates during replication and combine both RNA partners to form 
viable virus with a PV3 capsid region replacing the luciferase gene (refer to chapter 
four, figure 4.4B, for a depiction of this process). Sequence analysis of 100 
recombinants identified 16 distinct crossover junctions within the ~1 kb separating 
the “lesions” used for selection. Table 5.1 lists the distinct groupings of crossover 
junctions in the recombinants recovered including the approximate genome positions 
at which point template switching occurred and the number of extra nucleotides 
incorporated at the crossover site where applicable. Only one group from 16 
contained a precise junction site, and this was situated in the 5’ terminus of the 2C 
region [PV3(1-4277)PV1(4278-A tail)]. All remaining recombination events were 
imprecise and incorporated extra sequence at the junction site. Figure 5.3 shows a 
sequence chromatogram for one virus clone (105B); PV3 sequence ended at position 
306 in the chromatogram sequence, the following 137 bps belonged to the 3’ 
terminus of the luciferase gene, and the remainder of the sequence was PV1 from 
position 444. This equated to a recombinant virus PV3(1-3491)Luc(137 
nt)PV1(3380-A tail) with an extra 249 nt sequence incorporated at the junction site. 
Correct numbering and crossover positions were determined from a Clustal 
alignment (Saitou & Nei, 1987) containing full-length PV1 strain Mahoney and PV3 
strain Leon (GenBank accession numbers V01149 and X00925 respectively). In 
every instance, the extra nucleotides inserted at the junction site were divisible
  
Figure 5.2 An example of a non-clonal recombinant virus mixture.  Virus RNA was extracted from p1 supernatant after biological cloning by 
limiting dilution in 96-well plates. The region of targeted recombination from 2A to start of the CRE in 2C was amplified by RT-PCR and 
sequenced. The chromatogram shows that dual peaks are present in sequence from position 308 (red star) indicating the presence of more than 
one template type in the reaction.  
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Table 5.1 Characterisation of PV3/PV1 recombinants by crossover region from single co-transfection 
  Clone
Position of crossover 
junctions Luciferase Total extra No. 
Name* Name PV3  PV1 sequence# nucleotides clones~ 
PV3(1-3431)luc(134)PV1(3380-A tail)  11A 3431 3380 134 186 12 
PV3(1-3449)luc(107)PV1(3380-A tail)  1C 3449 3380 107 177 45 
PV3(1-3454)luc(174)PV1(3380-A tail)  36B 3454 3380 174 249 2 
PV3(1-3465)luc(205)PV1(3380-A tail)  34D 3465 3380 205 291 1 
PV3(1-3491)luc(137)PV1(3380-A tail)  105B 3491 3380 137 249 2 
PV3(1-3505)luc(168)PV1(3380-A tail)  53A 3505 3380 168 294 2 
PV3(1-3612)PV1/3(447-462)PV1(3386-A tail)  25A 3612 3386 PV1/3 447-462 243 8 
PV3(1-3621)luc(79)PV1(3380-A tail)  67B 3621 3380 79 321 1 
PV3(1-3669)luc(1)PV1(3380-A tail)  16B 3669 3380 1 12 1 
PV3(1-3850)PV1(3848-A tail)  9C 3850 3848 - 3 1 
PV3(1-3851)PV1(3813-A tail)  33B 3851 3813 - 39 1 
PV3(1-3868)PV1(3797-A tail)  83B 3868 3797 - 72 6 
PV3(1-3894)PV1(3742-A tail)  51G 3894 3742 - 153 1 
PV3(1-3901)PV1(3782-A tail)  58A 3901 3782 - 120 2 
PV3(1-3917)PV1(3693-A tail)  14C 3917 3693 - 225 1 
PV3(1-4277)PV1(4278-A tail)  4E 4277 4278 - 0 14 
* Numbering according to Clustal alignment of poliovirus type 1 Mahoney and poliovirus type 3  
Leon strains (GenBank accession numbers V01149 and X00925 respectively) 
# No. of nts from the 3’ end luciferase fused into PV1 sequence at position 3380 of genome 
~ No. of clones per crossover in single co-transfection 
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Figure 5.3 Chromatogram of sequenced recombinant virus 105B. Red arrows indicate PV sequence, and black arrow highlights luciferase 
sequence incorporated at the crossover junction. Luciferase sequence is inserted between nts 306 and 444 according to chromatogram base pair 
numbering. The chromatogram demonstrates that a clonal population of virus has been sequenced. 
 
3’ end Luciferase 137nt 
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PV3 sequence to 3491nt 
PV1 sequence from 3380nt 
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by three and therefore maintained an in-frame translation product for all viruses, as 
would be expected.  
 
It was not appropriate to analyse the frequency by which the crossovers occurred in 
the entire set of 100 clones, as distinct recombinants may have arisen either from a 
single event in a single cell that replicated abundantly, or the same event may have 
occurred in several cells to produce the same frequencies.  
 
Figure 5.4 provides a diagrammatic view of all 16 crossover junctions identified in 
the PV3/PV1 recombinants. The recombinants grouped into those containing extra 
PV sequence, those containing extra PV and luciferase sequence, and the single virus 
with a precise junction in 2C. In every recombinant, the coding region for 2A and 2B 
was derived in its entirety from one or the other parental genomes, e.g. none of the 
recombinants relied exclusively on a chimeric 2A or 2B coding region. Recombinant 
4E, of which 14 clones were recovered from 100 sequences, was the only virus with 
a chimeric protein (2C) derived from the crossover event. The presence of a precise 
junction was an exception rather than the rule, indicating that this result could be a 
rare event during RNA recombination early in cell infection. It also remains to be 
determined whether this virus was advantaged as a result, as several virus clones 
were recovered in the set.  
 
Five recombinants (11A, 34D, 53A, 67B, and 4E) in the set contained a single 
nucleotide at the recombination junction which was identical for PV1 and PV3 
(figure 5.5). In other words, it was not possible to define whether the exact crossover 
occurred before or after the nucleotide or which parental genome the nucleotide was 
derived from. It was not clear whether one shared nucleotide provided evidence for a 
dependency of RNA sequences in determining regions of template switching, as this 
was found in 31% of junctions. If recombination occurred randomly, 25% of 
junctions would be predicted to show single shared nucleotides (Gallei et al., 2004), 
although this would rely on sequence that consisted of equal proportions of each 
nucleotide. It was later determined that the PV regions were slightly A-rich in 
composition. The potential role of donor and template sequences was investigated 
and is discussed in detail later in this chapter. 
Figure 5.4 Sixteen distinct crossover junctions identified from 100 cloned PV3/PV1 recombinants. The targeted region of recombination is 
shown in both pRLucWT and pT7FLC/SL3 RNA partners. PV1 RdRp initiated RNA synthesis from the 3’ end of the genome, and switched to 
the PV3 acceptor genome as indicated by the arrows. The RdRp continued to copy to the extreme 5’ end of the PV3 genome. The red arrow 
indicates clone PV3(1-3612)PV1/3(447-462)PV1(3386-A tail), which contained a 15 nt insertion derived from the 5’ NCR.
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 Figure 5.5 Sites of crossover junctions in recovered PV3/PV1 recombinants. 
Boxed regions indicate recombinant sequence; red boxes show nt identity at 
crossover junctions. Yellow box indicates inserted sequence from IRES. 
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One recombinant recovered from the set contained a 15 nt sequence insert at the 
crossover junction (25A). Interestingly, the inserted sequence originated from the 
5’ NCR, specifically the IRES, and was conserved between PV1 and PV3. The 
reason for this insertion remained unclear, and it was difficult to speculate on spatial 
locations of both regions of the genome during replication, particularly when the 
genome would have been unwound by the virus replicase during the recombination 
event. The inserted sequence originated from between stem loops IV and V of the 
IRES, with half the sequence base paired in stem loop V and the other half single 
stranded (figure 5.6) (Kafasla et al., 2010). As this figure provided a secondary 
structure for IRES folding only, it was not possible to predict the location of the 
sequence origin at a tertiary structure level.  
 
In another independent co-transfection experiment with pRLucWT and 
pT7FLC/SL3 RNA partners in L929 cells, four distinct groups with unique crossover 
sites were recovered from 31 biologically cloned viruses (table 5.2). The infectious 
recombinant viruses demonstrated different crossover junctions to those previously 
identified. Once again, the crossover sites were either precise, or imprecise with 
inserted sequence at the junction (figure 5.7). The precise recombination junction 
sites occurred at the 3’ terminus of 2A and the very start of the CRE in 2C and were 
located in conserved amino acid regions. Recombination at conserved sites probably 
accounted for the fact that chimeric proteins were obtained in this experiment, and it 
seems that these recombinants adhere to the same general rule observed with the 
previous recombinant set, in which a complete 2A and 2B region was obtained from 
one parent during template switching. The recombinant 2A protein was not chimeric 
by amino acid sequence. It also appeared that chimeric 2C proteins are tolerated by 
recombinants. From two independent experiments, it was becoming apparent that 
there were favoured ‘regions’ for template switching, but not necessarily specific 
sites from which the RdRp exchanged templates.  
 
To conclude, the unexpected nature of recombinants recovered from this assay, 
including ‘extraneous’ sequence insertions, warranted further investigation to 
determine whether these were rarely observed ‘early’ events of virus RNA 
recombination or simply the product of this artificial system. Examples of such
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Figure 5.6 Origin of the inserted 15 nt sequence in recombinant 25A at the 
crossover site. This fragment of sequence is conserved between PV1 and PV3. 
(Source: Balvay et al., 2009). 
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Table 5.2 Characterisation of PV3/PV1 recombinants by crossover region from an independent co-transfection in L929 cells. 
 
  Clone
Position of crossover 
junctions Luciferase Total extra No. 
Name* Name PV3  PV1 sequence# nucleotides clones~ 
PV3(1-3553)luc(120)PV1(3380-A tail)  28C 3553 3380 120 294 3 
PV3(1-3623)PV1(3383-A tail)  32A 3623 3383 - 240 1 
PV3(1-3824)PV1(3825-A tail)  35C 3824 3825 - 0 14 
PV3(1-4473)PV1(4474-A tail)  44B 4473 4474 - 0 13 
* Numbering according to Clustal alignment of PV serotype 1 Mahoney and PV serotype 3  
Leon strains (GenBank accession numbers V01149 and X00925 respectively) 
# No. of nts from the 3’ end luciferase fused into PV1 sequence at position 3380 of genome 
~ No. of clones per crossover in single co-transfection 
 -138-
Figure 5.7 Four distinct crossovers identified from 31 cloned PV3/PV1 recombinants in a repeated, independent experiment. The targeted 
region of recombination is shown in both pRLucWT and pT7FLC/SL3 RNA partners. Poliovirus serotype-1 RdRp initiated RNA synthesis from 
the 3’ end of the genome, and switched to the PV3 acceptor genome as indicated by the arrows. The RdRp continued to copy to the extreme 5’ 
end of the PV3 genome. Green arrows represent the four distinct crossover sites from this second experiment.  
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imprecise recombination events are not reported for natural isolates. The nature and 
size of inserts will be discussed later in this chapter.  
 
Growth kinetics in HeLa cells (single-step growth curves) 
The system allowed the recovery of viruses with minimum subsequent selection, so it 
may have been sensitive enough to capture initial events during the virus replication 
cycle. It was necessary to determine whether the viruses demonstrated similar growth 
characteristics compared to the parent viruses from which they were derived. Two 
PV3/PV1 viruses were selected for further analysis. Both were selected because of 
the substantial stretch of inserted sequence at the junction site and also because 
template switching occurred in either virus region 2Apro or 2B. The first, PV3(1-
3894)PV1(3742-A tail), henceforth referred to as 51G, acquired a 153 nt insert 
consisting of PV sequence at the crossover junction. The second, PV3(1-
3454)Luc(174)PV1(3380-A tail), referred to as 36B hereafter, gained an extra 249 
nts at the junction site, with 174 nt derived from the luciferase reporter gene in 
pRLucWT. Both viruses were subjected to five further passages (p3 to 7) through 
susceptible HeLa cells to determine whether changes would occur to these viruses 
over the short term that would affect the nature of the additional sequences retained 
within the genome. Briefly, HeLa cells were infected with the selected viruses (p2) at 
an MOI of 10 for 30 mins at 37°C. Virus was removed and cells were washed twice 
with sterile PBS to remove excess virus. New serum-free DMEM was added to cells 
and plates were incubated at 37°C. Supernatant was removed after 24 hrs and a 
quarter of this supernatant was used undiluted for each subsequent inoculum onto 
fresh HeLa cells. 
 
Single-step growth curves were performed in HeLa cells (figure 5.8). Cells were 
infected at an MOI of 10 with PV1, PV3 or the selected recombinants after two and 
seven passages (p2 to 7) through HeLa cells. Virus supernatant was harvested at 
various time points up to 24 hrs post-infection and titrated by plaque assay.  
 
Unpassaged 51G (p2) demonstrated reduced fitness (one log10 from 6 to 24 hrs) 
compared with wild-type viruses. The recombinant shared the same replication 
kinetics with both parent viruses after five further passages through HeLa cells,  
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 Figure 5.8 Single-step growth curves. These were performed by comparing PV 
parents with two PV3/PV1 recombinants generated from co-transfections with 
pT7FLC/SL3 and pRLucWT RNA partners. (A) Growth curve comparing PV3(1-
3894)PV1(3742-A tail) to PV1 and PV3 parents. (B) Growth curve comparing 
PV3(1-3454)Luc(174)PV1(3380) to both parents from which it was derived.  
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indicating that this growth characteristic of the passaged virus was indistinguishable 
from both wild-type parents (from which the original virus RNA was derived).  
This was not the case for recombinant 36B. The serially passaged virus seemed to 
decline in fitness over the short term, indicating that either the extra inserted 
sequence was a hindrance, or a mixed population of viruses was forming which 
confounded virus replication. These points were addressed by performing 
competition assays with parent viruses as well as characterising recombinant viruses 
after continuous passage. 
 
Plaque phenotypes were compared between parent viruses (PV1 and PV3) and 
PV3/PV1 recombinants at passages 2 and 7 (figure 5.9). The recombinants displayed 
small and irregular plaques at p2, whereas the plaque phenotypes started to reflect 
the same size and regularity of parents PV1 and PV3 following subsequent rounds of 
replication in HeLa cells (p7). Plaque size and morphology were altered following 
passage in cell culture, indicating that these recombinant viruses were 
changing/adapting through subsequent rounds of replication. These findings suggest 
that insertions in the centre of the virus genome modulate virus plaque size 
phenotype, and not the chimeric nature of the recombinant.  
 
In summary, there was a small yet noticeable difference between recombinant 
viruses before and after serial passage through cells. This suggested that passaged 
virus was changing as a result of further rounds of replication, and it was essential to 
investigate this further. 
 
Competition assays between recombinants and wild-type parents  
As briefly mentioned above, competition assays were also performed as a way of 
determining if ‘atypical’ recombinants would survive in a mixed infection if both 
parents were also present. Were the recombinant viruses fitter than parents as a result 
of the exchange of genetic material? This perhaps more accurately reflects the 
natural conditions under which recombinants arise. 
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 Figure 5.9 Plaque phenotypes of parent and two selected recombinant viruses. 
HeLa cells were infected with a 10-fold dilution series of virus and overlaid with 
plaque assay overlay medium. Cell monolayers were stained after 48 hrs with crystal 
violet. Wild-type parents PV1 and PV3, and recombinants 51G and 36B, after 2 and 
7 further passages through HeLa cells. Recombinant virus plaques change 
morphology after five subsequent rounds of replication, to more closely reflect those 
of PV1 and PV3.  
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HeLa cells were infected with a virus mix containing an MOI of 10 of each 
recombinant and both parents PV1 and PV3. The resulting supernatant was passaged 
through HeLa cells five times and the recombination target region was amplified 
again by RT-PCR. Generic PCR oligonucleotides PV1/3-3280F and GEN-4615R 
(table 2.3) were used to amplify both parents and recombinants and specific products 
were discernable by band size. As the expected band size for the parent target region 
was approximately 1335 bp, larger bands would originate from recombinant viruses 
with sequence inserted in the amplified region.  
 
Two DNA bands were evident at p2 belonging to either recombinant or wild-type 
viruses on 1% agarose gels (figure 5.10), with original virus mix used to inoculate 
cells labelled p2. Mixed virus populations were present in both p2 and p3 RT-PCR 
product, as dual bands existed in both lanes. After five passages (to p7), gel bands 
derived from recombinants were indistinguishable from the wild-type bands – 
suggesting that recombinant viruses had effectively disappeared. There might be two 
simple explanations for this: (1) recombinant virus was literally outcompeted by 
parent viruses and ceased to survive further rounds of infection, or (2) recombinants 
remained in the virus mix but were altered by the removal of additional sequence. If 
the latter occurred, the same pattern would emerge if the recombinants were 
passaged individually. As an aside, it is not clear why the ‘recombinant’ DNA band 
was less intense than the smaller ‘wild-type’ DNA band in p2 PCR product. Both 
virus populations were infected at an MOI of 10, and infectious virus titres were 
originally determined by plaque assay. Either PCR conditions were not optimal for 
amplifying recombinant cDNA, or there was a significantly lower particle-to-PFU 
ratio for the PV3/PV1 recombinants.  
 
Continuous passage of recombinants alters crossover junctions 
Above mentioned recombinant viruses only were serially passaged 10 times through 
HeLa cells and the amplification of the crossover region was repeated to determine if 
recombinants were altered. Cells were infected at an MOI of 10 with p2 recombinant 
virus. Virus RNA was extracted from inoculum (p2) and supernatant after 1, 5, and 
10 passages (p3, 7 and 12 respectively) and amplified by RT-PCR as described 
above.  
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Figure 5.10 Competition assays between recombinant and wild-type viruses in 
the same infection. HeLa cells were infected with a virus mix containing an MOI of 
10 of each recombinant and both parents PV1 and PV3. The resulting supernatant 
was passaged through HeLa cells five times and the recombination target region was 
amplified again by RT-PCR. Passage 2 was the initial virus mixture inoculated onto 
cells. ‘Neg’ refers to the template control (H20) in PCR. Both recombinant and parent 
viruses are present in p2 and p3 lanes, but the recombinant virus (indicated by larger 
band) disappears altogether in gel (A), while the majority of virus remaining in gel 
(B) is indistinguishable from the product generated from entire PV1 or PV3 
(1335 bp).  
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PCR product was resolved on a 1% agarose gel by electrophoresis and stained with 
ethidium bromide. The predominant amplified product changed in 51G virus 
preparations between 4 and 7 passages through cells, as indicated by the reduced 
band size from 1488 bp to 1335 bp (figure 5.11). By p7, the majority of amplified 
product from virus supernatant was the same size as the expected wild-type product, 
and this was the band present after a further 5 passages. The same was evident for 
recombinant 36B, although removal of extra sequence at the crossover junction 
progressed more slowly (from passage 7 onwards). After 10 passages, the 
predominant, amplified product from supernatant reflected the wild-type band size, 
although larger PCR product was still present. It is quite possible that a complete 
change in virus band size would occur with subsequent rounds of replication in HeLa 
cells but this was not tested. 
 
There were no intermediate DNA bands visible between ‘recombinant’ and ‘wild-
type’ PCR product on agarose gels, suggesting that these were either below the level 
of detection, perhaps not resolved well on an agarose gel, or did not exist. To 
conclude, it was clear that the nature of the recombination crossover site changed 
after further rounds of replication, and reflected the size expected for precise 
junctions. Removal of additional sequences presumably occurred by an additional 
recombination event, either intramolecularly or with a co-infecting genome – 
therefore in cis or trans. If the passaged recombinants had indeed changed as a result, 
it was of interest to ascertain the nature of these new crossover sites.  
 
Characterisation of junction sites of serially passaged PV3/PV1 recombinants 
The aim was to serially passage recombinants at high MOIs rapidly through HeLa 
cells to determine the effect on growth kinetics and plaque phenotype. After 
continuous passage of PV3/PV1 recombinants 51G and 36B through HeLa cells, it 
was clear that the distance between both PCR oligonucleotides became smaller, 
indicating that the crossover junction (originally containing inserted sequence) was 
visibly reduced. Virus recovered after 12 passages was biologically cloned again 
before repeating RT-PCR and sequencing of the crossover regions. This was to 
determine if changes had occurred at the recombination junctions and to establish the 
fate of these sizeable insertions.  
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Figure 5.11 Changes in crossover regions from passaged PV3/PV1 
recombinants. Following five subsequent passages through HeLa cells, RT-PCR 
product of amplified region in recombinant viruses was run on a 1% agarose gel and 
stained with ethidium bromide. (A) Recombinant 51G crossover region gradually 
reduced in size from 1488 bp (with insert) to 1335 bp. This was the length of the 
precise crossover region. (B) Likewise, 36B crossover regions contained two 
populations after 5 passages, with the majority of the original recombinant with 
insert still present. Following 10 subsequent passages, most virus in the population 
contained a precise junction site with 1335 bp.  
 -147-
Virus from p12 supernatant material was biologically cloned in 96-well plates and 
prepared for RT-PCR and sequencing as stated earlier. Oligonucleotides PV3-2995F 
and GEN-4615R were used to amplify the recombination region (table 2.3). RT-PCR 
product was run by electrophoresis on a 1% agarose gel (figure 5.12) and several 
clones were analysed for each original recombinant.  
 
Visibly, the once heterogeneous collection of virus clones for each recombinant 
(figure 5.1C) in the initial population appeared uniform in size and were the length of 
the calculated target region without inserted sequence (figure 5.12). The RT-PCR 
product recovered from all clones was sequenced to determine the nature of the 
altered crossover regions. Eight virus clones were analysed for the 51G recombinant 
and 15 clones for the 36B recombinant.  
 
By p12, recombinant virus clones contained precise junctions between PV3 and PV1 
sequence with no insertions or deletions (relative to the parental viruses) detected at 
these sites. New virus labelling and junction sites are outlined in table 5.3, and the nt 
sequences of PV3, PV1, and each clone were aligned and compared in figure 5.13A 
and B. 
 
Progeny virus derived from the 51G recombinant no longer contained extra PV 
sequence at crossover junctions, and interestingly, the eight clones analysed fell into 
four distinct groups with unique crossover sites between the PV3 and PV1 template. 
Therefore, mixed populations of recombinant viruses were recovered from originally 
cloned virus. It was not possible to pinpoint the exact crossover site in each virus, as 
this occurred within a small region of sequence conserved between donor and 
acceptor template, hence the approximate sites of the recombination junctions are 
shown in brackets, i.e. PV3(3820-4)PV1 in table 5.3.  
 
Similarly, the extra inserted sequence originating from luciferase and PV at the 
crossover junction was removed upon further passage of recombinant 36B. Five 
separate recombination junction sites were identified from virus clones and 
figure 5.14 depicts the original recombinants and subsequent passaged virus clone 
junction sites across the target region. Once more, exact crossover points were not  
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Figure 5.12 Crossover regions of PV3/PV1 recombinants after serial passage 
through HeLa cells. Gel electrophoresis of RT-PCR product of recombination 
region. Ethidium bromide stained 1% agarose gels showing the uniform size of 
amplified virus fragments from both biologically cloned recombinants. The expected 
band size of approximately 1620 bp was observed in all samples and these were 
sequenced to determine crossover junctions between PV3 and PV1 sequence. Both 
PCRs were performed simultaneously, with the single negative control (H2O) 
included on the 36B clone agarose gel. The PV3/PV1 recombinant plasmid controls 
were not available for inclusion in PCR assays. The forward oligonucleotide (PV3-
2995F) was specific for PV3 sequence only.
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Table 5.3 Characterisation of PV3/PV1 recombinants by crossover region after continuous passage through HeLa cells 
  
Position of crossover 
junctions Luciferase Total extra No. 
Name* PV3  PV1 sequence Nucleotides Clones
PV3(1-3894)PV1(3742-A tail)# 51G 3894 3742 0 153 - 
PV3(3757-8)PV1 3757-8 3757-8 0 0 1 
PV3(3784-5)PV1 3784-5 3784-5 0 0 2 
PV3(3796-7)PV1 3796-7 3796-7 0 0 2 
PV3(3820-4)PV1 3820-4 3820-4 0 0 3 
      
PV3(1-3454)luc(174)PV1(3380-A tail)# 36B 3454 3380 174 249 - 
PV3(3386-98)PV1 3386-98 3386-98 0 0 1 
PV3(3523-9)PV1 3523-9 3523-9 0 0 1 
PV3(3538-9)PV1 3538-9 3538-9 0 0 9 
PV3(3634-54)PV1 3634-54 3634-54 0 0 2 
PV3(3640-54)PV1 3640-54 3640-54 0 0 2 
* Numbering according to Clustal alignment of PV serotype 1 Mahoney and PV serotype 3  
Leon strains (GenBank accession numbers V01149 and X00925 respectively) 
# Original PV3/PV1 recombinant subsequently passaged through cells. Four recombinants beneath  
represent new recombination crossover sites from recovered virus 
 
  
Continued over page. 
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Figure 5.13 Sites of the recombination junctions in the passaged recombinants 
51G and 36B. Numbering according to Clustal alignment of PV serotype 1 Mahoney 
and PV serotype 3 Leon strains (GenBank accession numbers V01149 and X00925 
respectively). Dashes depict nt matches to PV3 sequence and red shading indicates 
the approximate region of template switching. (A) Four unique crossover sites 
identified from clones after recombinant 51G was passaged through HeLa cells. (B) 
Crossover sites of five unique recombinants after serial passage of 36B through 
HeLa cells. The red star highlights the nt mis-incorporation. 
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Figure 5.14 New crossover sites for serially passaged recombinants. Viruses are colour-coded as follows, 51G [PV3(1-3894)PV1(3742-A 
tail)] and 36B [PV3(1-3454)Luc(174)PV1(3380-A tail)]. Blue arrows represent precise junction sites for biologically cloned viruses derived from 
51G. Red arrows indicate the same for 36B clones. The latter viruses could not have evolved from the original PV3/PV1 recombinant because 
the new crossovers occurred outside available sequence, and this is discussed in the chapter further. 
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located for these clones as they occurred within a region of shared sequence identity. 
A mis-incorporation occurred at the site creating more ambiguity, as is shown in 
figure 5.13B in clone PV3(3634-3654)PV1. 
 
Unfortunately, in the case of the 36B parental virus, all but one newly acquired 
precise crossover regions did not fall within the available PV3 and PV1 sequences 
that were present in the primary recombinant. On this basis, it was impossible that 
the serially passaged recombinants evolved from the original selected recombinant. 
This was clear in figure 5.14, in which the solid red arrows, indicating new precise 
junctions, fell outside the junction sites for donor and template sequence. The 
passaged viruses must have arisen from another primary recombinant, not from the 
one originally selected. To confirm that the correct primary recombinant was utilised, 
material from the initial inoculum (p2) was reamplified and sequenced to validate the 
exact location of template switching. Indeed, the equivalent result was obtained. The 
RdRp left PV1 donor template 174 nt in from the 3’ luciferase gene and joined the 
PV3 acceptor template from position 3454 nt. A possible explanation was the 
presence of undetectable levels of contaminating recombinant/s with different 
crossover sites at early stages that survived through subsequent virus passages. This 
contaminating recombinant may have had either a growth or stability disadvantage 
(leading to more rapid evolution) compared to the predominant recombinant as well. 
This may have contributed to continuous recombination events providing unexpected 
crossover sites.  
 
For the nine new recombinants, it was not possible to pinpoint the exact nucleotide 
positions for recombination junctions. Between two to 15 nts at the sites were 
identical for both partners (refer to figure 5.13). The fact that 100% of the 
recombination junctions contained ambiguous nucleotides (compared to 31% of 
original recombinants recovered) demonstrated the role of the sequences in 
determining crossover sites. These extremely short regions of sequence identity may 
have guided RdRp during template switching, as previously reported (Tolskaya et 
al., 1987).  
 
All original PV3/PV1 recombinants contained a complete 2A and 2B sequence 
derived in its entirety from one or the other parent. The imprecise nature of junction 
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sites meant that parts of 2A and 2B were also incorporated into the infectious 
genome. After continuous passage of two recombinants with these attributes, it was 
shown that these viruses removed/deleted extraneous sequences at the junction site, 
and in the process, generated chimeric 2A protein and more significantly, restored 
the length of the genome. According to this data, it was suggested that precise 
recombination events that produced chimeric proteins within genomes was a rare 
event during early stages of virus replication. Only one precise crossover event 
occurred initially, represented by clone 4E, which contained a chimeric 2C encoding 
region.  
 
5.3 Intraspecies Recombinants 
Characterisation of intraspecies C recombinants recovered from co-transfections 
As discussed in chapter four, co-transfections were performed using different 
serotypes of RNA partners encoding the CVA21 non-structural region. As a CVA21 
subgenomic replicon was not available for co-transfections, non-infectious PV 
recombinants containing the CVA21 non-structural region were used instead. Virus 
was recovered from the following crosses: pRLucWT + CVA21BKPV3P1, 
pRLucWT + CVA21BKSabin1P1, pT7Rep3-L + CVA21BKPV3P1, and pT7Rep3-L 
+ CVA21BKSabin1P1 (figure 4.6). Supernatant containing virus was harvested from 
transfected cells and biologically cloned as previously described.  
 
Biologically cloned virus derived from partners pRLucWT + CVA21BKSabin1P1 
and pT7Rep3-L + CVA21BKPV3P1 co-transfections were examined further to 
confirm the existence of recombinant virus and to determine the location of 
crossover junctions.  
 
All amplified PCR products (figure 5.15) were sequenced for each group of viruses 
using oligonucleotides outlined in table 2.3. Recombinant virus resulting from 
partners pRLucWT + CVA21BKSabin1P1 contained the following fragments of 
virus cDNA across the whole genome when the composition of input RNA partners 
was taken into account; CVA21/PV1/CVA21/±Luc/PV1. Co-transfections with RNA 
partners pT7Rep3-L + CVA21BKPV3P1 resulted in recombinant virus with the 
following genome organisation, CVA21/PV3/CVA21/±Luc/PV3.  
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Figure 5.15 RT-PCR product of biologically cloned intraspecies C 
recombinants. These were recovered from co-transfections in L929 and BsrT7 cells. 
Gel electrophoresis of RT-PCR product of recombination region. Ethidium bromide 
stained agarose gels showing a heterogeneous mixture of amplified virus sequences 
from cloned recombinants. Controls in top gel (PV1 and PV3 plasmids) were 
performed to check specificity of virus specific oligonucleotides. Positive controls 
were not included in the bottom two PCR assays. 
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Crossover positions were determined from a cDNA Clustal alignment (Higgins & 
Sharp, 1988) with PV1 strain Mahoney, PV3 strain Leon, and CVA21 strain Coe 
(GenBank accession numbers V01149, X00925, and D00538 respectively). All virus 
clones sequenced, regardless of the RNA partner origin, contained imprecise junction 
sites and several distinct recombinants were recovered from each co-transfection 
performed. All recombinants contained extra sequence at the site of the crossover.  
 
Table 5.4 outlines the RNA partners involved in crosses and resulting recombinant 
viruses identified through sequencing. The unexpected result was the number and 
nature of extra nts that were incorporated into these infectious recombinants. As an 
example, CVA21/PV1/CVA21/±Luc/PV1 recombinants contained between 123 and 
513 nts of extra sequence at the junction sites and more importantly, sequence 
derived from the luciferase gene was incorporated. Nine unique recombinants were 
identified from 16 clones sequenced, with template switching sites occurring in the 
2A region of CVA21. Figure 5.16 illustrates the virus sequence fragments that 
formed recombinant CVA21(1-711)PV1(712-3403)CVA21(3404-
3413)Luc(318)PV1(3385 to A-tail). 
 
Six unique recombinants were identified from 15 CVA21/PV3/CVA21/±Luc/PV3 
clones recovered from co-transfections in L929 cells. Similarly, four unique 
recombinants emerged from five clones derived from BsrT7 cells. Again, crossover 
sites clustered in the 2A region of CVA21. All recombinants contained extra 
sequence at the crossover site, ranging from 18 to almost 300 nt, and this occurred 
irrespective of transfection cell type (L929 or BsrT7). Interestingly, the four unique 
recombinants recovered from BsrT7 cells did not contain luciferase, although 
conclusions could not be drawn from this due to the low number of clones examined. 
The majority of crossover sites were different between the cell lines indicating 
random RdRp movement between virus templates that differed with each 
experiment.  
 
Regardless of crossover site locations, recombinants recovered from both RNA 
partner crosses contained a complete set of 2A and 2B virus proteins from the 
subgenomic replicon (CVA21BKSabin1P1 + pRLucWT) and 
(CVA21BKPV3P1 + pT7Rep3-L) (figure 5.17). With reference to figure 5.17B, the 
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Table 5.4 Recombinant viruses recovered from three intraspecies co-transfections  
   Luciferase Total extra 
RNA Partners Recombinant Name* sequence nucleotides 
pRLucWT + CVA21(1-711)PV1(712-3403)CVA21(3404-3413)Luc(318)PV1(3385-7460) 318 345 
CVA21BKSabin1P1 CVA21(1-711)PV1(712-3403)CVA21(3404-3419)Luc(135)PV1(3385-7460) 135 168 
(BsrT7 cells) CVA21(1-711)PV1(712-3403)CVA21(3404-3423)Luc(227)PV1(3385-7460) 227 264 
 CVA21(1-711)PV1(712-3403)CVA21(3404-3425)Luc(84)PV1(3385-7460) 84 123 
 CVA21(1-711)PV1(712-3403)CVA21(3404-3456)Luc(443)PV1(3385-7460) 10G 443 513 
 CVA21(1-711)PV1(712-3403)CVA21(3404-3498)Luc(227)PV1(3385-7460) 227 339 
 CVA21(1-711)PV1(712-3403)CVA21(3404-3508)Luc(43)PV1(3385-7460) 43 165 
 CVA21(1-711)PV1(712-3403)CVA21(3404-3552)Luc(227)PV1(3385-7460) 227 393 
 CVA21(1-711)PV1(712-3403)CVA21(3404-3691)Luc(67)PV1(3385-7460) 12E 67 372 
    
pRep3-L + CVA21(1-711)PV3(712-3403)CVA21(3404-3420)Luc(84)PV3(3313-7460) 84 192 
CVA21BKPV3P1 CVA21(1-711)PV3(712-3403)CVA21(3404-3421)Luc(107)PV3(3313-7460) 2B 107 216 
(L929 cells) CVA21(1-711)PV3(712-3403)CVA21(3404-3428)Luc(183)PV3(3313-7460) 183 300 
 CVA21(1-711)PV3(712-3403)CVA21(3404-3516)PV3(3346-7460) - 171 
 CVA21(1-711)PV3(712-3403)CVA21(3404-3519)PV3(3307-7460) - 213 
 CVA21(1-71)PV3(712-3403)CVA21(3404-3554)PV3(3393-7460) - 162 
    
pT7Rep3-L + CVA21(1-711)PV3(712-3403)CVA21(3404-3420)PV3(3403-7460) - 18 
CVA21BKPV3P1 CVA21(1-711)PV3(712-3403)CVA21(3404-3469)PV3(3378-7460) - 93 
(BsrT7 cells) CVA21(1-711)PV3(712-3403)CVA21(3404-3505)PV3(3353-7460) - 153 
  CVA21(1-711)PV3(712-3403)CVA21(3404-3520)PV3(3338-7460) 19E  - 183 
* Numbering according to Clustal alignment of PV serotype 1 Mahoney, PV serotype 3 Leon, CVA21 Coe strains  
(GenBank accession numbers V001149, X00925, and D00538 respectively).  
Figure 5.16 Single intraspecies recombinant formed from RNA partners. RNA 
partners pRLucWT and CVA21BKSabin1P1 were co-transfected into BsrT7 cells. 
Supernatant was removed 48 hrs post-transfection and inoculated onto fresh HeLa 
cells to plaque. Virus in transfection supernatant was biologically cloned and 
individual viruses amplified by RT-PCR across the targeted region of recombination. 
Both constructed and natural recombination junction sites are represented with red 
numbering.
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Figure 5.17 Crossover junctions of intraspecies C recombinants formed from replicons and Dr. Blanchard’s constructed recombinants. 
Arrows indicate crossover sites that occurred between pRLucWT and CVA21BKSabin1P1 RNA partners. The RdRp left the donor template 
(pRLucWT) within the luciferase gene, and rejoined the acceptor template early in the CVA21 2A region. (B) Crossover sites between 
pT7Rep3-L and CVA21BKPV3P1. Red arrows indicate recombinants recovered in L929 cells, black arrows in BsrT7 cells.
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RdRp always switched from pT7Rep3-L in either the small remaining region of PV3 
VP1 (of which only 84 nts were present) or the 3’ terminus of luciferase, but never 
from the 2A region. These subgenomic replicons were constructed in such a way that 
a small portion of VP1 remained after the reporter gene and before the 2A region. 
This was to ensure that the appropriate virus protease cleavage site was retained. 
Even though the number of recombinant viruses studied was small, no clones were 
recovered which showed the RdRp leaving the replicon in the 5’ portion of the 2A 
coding region. Although template switching may have been random at the nucleotide 
level, it was possible that viruses with complete virus proteins and not those with 
chimeric CVA21/PV proteins were detected because of viable protein function. Once 
again, the recombination events adhered to some general rules already observed; the 
crossover sites were unlikely to be precise, the inserted sequence was no more than 
513 nts in length, and chimeric 2A or 2B coding regions were not observed. 
 
Genetic stability of the recombinants 
Chimeric viruses were recovered after a single round of replication, thus were not 
exposed to significant purifying selection that could further modify virus sequence. 
For this reason, four intraspecies recombinants with inserted sequence at the 
crossover junctions located in 2A were subjected to 10 further passages through 
HeLa cells to determine if the recombinants removed the additional inserted 
sequence over the passages. For brevity, the recombinants (2B, 10G, 12E, and 19E) 
were coded and identified in table 5.4. Briefly, HeLa cells were infected with the 
following viruses (p2) at an MOI of 10 for 30 mins at 37°C. Cells were washed twice 
with sterile PBS once virus was removed and replaced with serum-free DMEM. 
Supernatant was removed after 24 hrs and a quarter of this supernatant was used 
undiluted for each subsequent inoculum onto fresh HeLa cells. After selected 
passages, RNA was extracted directly from the harvested supernatant using 
RNAeasy Mini Kit (Qiagen) and RT-PCR performed using oligonucleotides 
bordering each junction site. The crossover regions were amplified using 
oligonucleotides PV3-2995F, PV1-3004F, GEN-4615R, or PV1-5200R (table 2.3) 
according to virus cDNA partners used and sequenced in order to locate the 
crossover junctions.  
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The different sized cDNA fragments in the targeted crossover region were 
discernable by gel electrophoresis using a 1% agarose gel and provided a semi-
quantitative measure as to whether the additional sequences was removed upon serial 
passaging. 
 
Visually, the length of crossover region altered over serial passages through HeLa 
cells (figure 5.18). The recombination region became smaller as indicated by the 
faster migration of bands and this became increasingly reflective of the expected 
product size (for precise junction sites). Interestingly, three bands representing the 
crossover site were present in the virus mix during passages on the gel for clone 10G. 
This mix of band sizes appearing after the first passage suggested that the extraneous 
sequence was removed in a stepwise fashion from the crossover region in at least two 
distinct fragments. In comparison, clone 12E removed the entire fragment abruptly 
within five passages with only a single phenotype emerging (figure 5.18 top right). 
Agarose gel results imply that the majority of recombinant viruses recovered were 
unstable due to extraneous sequence inserted at the junction crossover sites and these 
insertions self-corrected over time after subsequent passage through cells. However, 
recombinant 2B proved to be an exception. The crossover region remained the same 
length after 10 passages through HeLa cells, indicating neither an advantage nor 
disadvantage associated with the additional 216 nt sequence. It would be of interest 
to determine if this virus maintained its stability while in competition with its 
parental viruses. If the inserted sequence was retained and the recombinant grew as 
well as the wild-type parents, then the junction sites may be of interest for future 
research purposes.  
 
To conclude, recombinant species C viruses with CVA21 were serially passaged 
through HeLa cells at high MOIs in an attempt to apply small selective pressures on 
the viruses and determine whether the unexpected nature of crossover sites were 
eventually corrected. This indeed proved to be the case from three of the four clones 
tested. Although viruses were not sequenced again after 10 subsequent rounds of 
passage, semi-qualitative changes were observed in crossover lengths using gel 
electrophoresis. Due to time restraints, it was not possible to assess the chimeric 
nature of progeny virus. Ideally, the effect of complex selective pressures on these 
‘aberrant’ recombinant viruses would be assessed in vivo. 
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 Figure 5.18 Changes in crossover region of serially passaged intraspecies 
recombinants. HeLa cells were infected with p2 virus supernatant at an MOI of 10 
and serially passaged over 24 hr time points, 10 more times. Virus RNA was 
extracted from supernatant at these passages and amplified by RT-PCR. The target 
region of recombination was amplified across the passages and PCR product was run 
on ethidium bromide stained 1% agarose gels. Band shifts were evident in later 
passages of virus, indicating that the extra sequence at crossover junctions was being 
removed from viruses. The smaller band correlates in size to the expected target 
sequence (1056 bp). Full recombinant names/details are provided in table 5.4.  
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5.4 Comparative Bioinformatic Analysis of RNA Partner Sequences 
This method of generating recombinant PV was originally developed to study the 
fundamental features of early virus RNA recombination within the cell. It was 
speculated that the virus RdRp pauses during RNA synthesis (Wu et al., 1995), and 
removes the nascent RNA with it to another template before continuing with RNA 
synthesis. The primary objectives were to determine whether this occurred at the 
nucleotide level by studying RNA sequences at crossover junctions. From then on, it 
was necessary to gain insight into recombination at the protein level – to determine 
whether functional requirements directly influenced these events. Survival of most 
randomly constructed recombinants at RNA level may be restricted by stringent 
structural requirements of virus proteins so that chimeric proteins have a distinct 
disadvantage. This could explain why recombination events rarely occur in the 
enterovirus capsid region, as it requires strict protein-protein assembly for correct 
particle formation and virion encapsidation. 
  
Initially, comparative analysis was performed on the genomic RNA sequences of the 
two PV partners PV1 (pRLucWT) and PV3 (pT7Leon) as this large scale experiment 
provided exploratory data for study. All PV3/PV1 recombinants contained a 
crossover event within a region of 1058 nts encompassing the 2A and 2B encoding 
regions, as well as the first 319 nts of 2C before the CRE. Initial recovered 
recombinants’ crossover sites were found to be unevenly distributed across this 
region (on the donor template), with preferences towards luciferase (56.25%), the 2A 
region (31.25%), 2B region (6.25%), and 2C region (6.25%) (figure 5.4). However, 
after serial passages of recombinants in cell culture, the now precise crossover sites 
among the progeny viruses occurred exclusively in the 2A region. Passaged virus 
from the 51G recombinant contained new junction sites at the 3’ terminus of 2A 
(within a range of approximately 65 nt), while new viruses from passaged 36B had 
scattered junctions sites in the first half of 2A (over approximately 295 nts). The 
crossover sites occurred within small identical nucleotide regions of both parental 
genomes, sometimes only 2 nts in length.  
 
To analyse whether sites of RNA recombination correlated with RNA partners 
sharing high sequence identity, a pairwise comparison was performed using 
similarity scanning analysis run by bioinformatics software Simmonic 2005, version 
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1.75 between the targeted regions of pRLucWT and pT7Leon (Simmonds, 2006). 
Both imprecise and precise recombination sites (from initial recombinants and 
passaged progeny respectively) were superimposed along the regions of nucleotide 
identity (figure 5.19). Nucleotide similarity between PV1 and PV3 ranged from 62-
100% in these regions (the average being 78.9%), and no apparent link was evident 
between the occurrence of precise recombination junctions and regions of high 
sequence identity. In relation to local sequence identity – if recombination required 
sequence specificity, then it must be very short, particularly if between 1 and 15 nts 
are shared between both templates as determined by data from this study.  
 
Pausing or termination of RdRp has been implicated in the process of template 
switching, and this is thought to be mediated by sequence and/or local secondary 
structure (reviewed in Nagy & Simon, 1997). Short direct repeats (generally U-rich 
or AU- rich sequences) were strongly preferred for switches between donor and 
acceptor templates by RdRp (King, 1988, Pilipenko et al., 1995). It was postulated 
that the RdRp may ‘slip’ on AU-rich stretches that created low thermodynamic 
stability. Analysis of PV1 (donor) nucleotide composition indicated that the region of 
interest was slightly A-rich (33%) compared to a 24% composition of U nts. 
Similarly, A and U compositions were 31% and 27%, respectively across the PV3 
acceptor template. Junction sites were plotted together with mononucleotide 
frequencies across PV1 and PV3 target regions. Frequencies were calculated in 21 nt 
sliding windows and advanced by 1 nt, thereby generating thousands of values across 
the genome that could be graphed (figure 5.20). Less than 50% of crossovers were 
flanked by A-rich regions, and only one followed a U-rich region.  
 
To increase the resolution of sequence motifs adjacent to crossover sites, the 
presence of small sequences of identical nts, such as AAAA, GGG, or TTTTTT, 
called homopolymers was investigated. To determine whether small homopolymeric 
stretches were situated close to junction sites, all possible homopolymers of 3-10 nts 
were identified computationally (DJE, personal communication). Locations of all 
≥ 3 nt homopolymers in the PV1 and PV3 region of interest were plotted along the x-
axis. The different homopolymers were assigned arbitrary values to allow the 
separation and visualisation of the sequences across the region (figure 5.21). 
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 Figure 5.19 Imprecise and precise recombination junctions and correlation to 
sequence identity between RNA partners. Target regions of pRLucWT and 
pT7Leon were scanned for stretches of nucleotide sequence similarity. In this case 
the number of matches in a sliding window size of 21 nts was presented as a 
percentage. Junction sites were given an arbitrary value of 100% and are represented 
by columns at the genome position. (A) Both PV1 and PV3 junction sites identified 
from original pRLucWT and pT7Leon co-transfections were plotted along with 
nucleotide identity. (B) Precise junction sites identified from passaged recombinant 
progeny correspond to the exact genome position of PV1 and PV3. 
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Continued over page. 
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 Figure 5.20 Mononucleotide composition of RNA partners. (A) donor 
(pRLucWT) and (B) acceptor (pT7Leon) template regions of targeted recombination. 
Composition scans performed in Simmonic 2005 V1.75 across a 21 nt window 
advancing by 1 nt each time. Donor and acceptor template nt composition (average 
should be 5.25 per nt) with precise and imprecise junction sites superimposed onto 
graphs. 
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Figure 5.21 Comparison of junction sites and homopolymers located in 
recombination regions of PV1 and PV3. All features in the legend have been 
assigned an arbitrary number in order to graph locations on X- and Y- axes. Data 
generated by Prof. David Evans. (A) Location of all homopolymers (≥3 nts) and 
crossover sites in donor pRLucWT PV1 sequence. (B) Homopolymers and crossover 
sites were plotted along genome axis of acceptor template pT7Leon. Y-axis values 
were applied to each catergory to allow them to be readily visualised. 
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There was no apparent clustering of sequence motifs or repeated nucleotides close to 
crossover junctions, particularly along the donor template where RdRp would 
initially detach. Therefore, factors other than nucleotide identity or the existence of 
homopolymers were responsible for the occurrence of template switching. 
 
The targeted region of recombination is relatively unstructured with the CRE in the 
2C region the only identifiable conserved secondary structure (Goodfellow et al., 
2000; Simmonds et al., 2004). To determine if recombination occurred at locations 
within or flanked by sequences with the potential to form local secondary structures, 
programs were developed to identify small palindromic sequences with the potential 
to form perfectly matched hairpin structures in RNA during synthesis. Palindromic 
sequences with a minimum length of 11 nts were identified (a 4 bp duplex and 3 nt 
loop). The longest sequences potentially forming stem loops were located in 
pT7Leon (positions 4165 nt and 4229 nt) with 12-7 (6 bp duplex and 7 nt loop) and 
10-9 (5 bp duplex and 9 nt loop) configurations, and at genome position 2559 nt in 
pRLucWT (10-9). Graphs in figure 5.22 suggested that recombination between both 
templates was not affected by the presence of potential minor stem loop structures.  
 
Furthermore, Minimal Free Energy Differences (MFED) were calculated across the 
region. This method predicted native folding free energy of the native RNA 
secondary structure, and compared this to the free energies calculated from 
999 random scrambles of the same region (maintaining codon composition, codon 
order, and dinucleotide frequencies). This was performed within 101 nt sliding 
windows which advanced by 3 nt, and was expressed as the percentage difference 
between native and the mean value of the randomised scores (Zuker, 1989; Zuker, 
2003) (Simmonics 2005 Version 1.75). Since the accepted model suggests that 
recombination occurs during negative-strand synthesis, particular attention was paid 
to structures formed in positive-sense RNA strands. This was to determine whether 
RNA secondary structure in the template strand contributed to the polymerase 
pausing mid-elongation of negative-strand synthesis. Although minimum and 
maximum values were high, the average MFED values ranged from 1.48% to -2.75% 
for pRLucWT (donor) and pT7Leon (acceptor) sense strands respectively to denote 
unstructured RNA sequence (figure 5.23).  
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 Figure 5.22 Palindromic sequences identified within targeted recombination 
region of PV1 and PV3. These are represented by the blue bars at the nucleotide 
location. Palindrome combinations ranged from a minimum length of 11 nts (4 bp 
duplex with 3 nt loop) to 19 nt (6 bp with 7 nt loop) and were plotted along the 
region of recombination, together with precise and imprecise crossover locations 
from characterised recombinants (squares and triangles). (A) Crossover sites in 
pRLucWT PV1 (donor) superimposed onto axis showing locations of palindromic 
sequence. (B) Similar for pT7FLC/SL3 PV3 (acceptor) sequence. Y-axis values were 
applied to each catergory to allow them to be readily visualised. 
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Figure 5.23 Local secondary structures using MFED analysis for PV1 and PV3 
regions of recombination. (A) Minimal free energy difference readings throughout 
recombination region for donor pRLucWT RNA, both sense and antisense values (B) 
for acceptor pT7FLC/SL3 RNA. The precise and imprecise sites of template 
switching are added to the graphs as green and purple lines respectively. 
 
 
 
 
 
 
 
 
 
 
 -173-
Plotted crossover sites did not correlate visually with ‘all peaks’ or ‘all troughs’ in 
the graphs. The absence of stable local RNA secondary structure indicated that 
crossover sites did not correspond to structural elements during negative-strand 
synthesis. 
 
RNA sequence and structural analysis above did not explain the location of crossover 
sites identified in PV3/PV1 recombinants. Junction sites were not evenly distributed 
throughout the available sequence space as expected, and the original recombinants 
incorporated a complete set of non-structural regions (namely 2A and 2B) together 
with fragments of sequence caused by the imprecise nature of junction sites. As 
already mentioned, a general pattern started to emerge that governed recombination 
events; the imprecise nature of most crossover junctions, the length of inserted 
sequence (≤ 513 nts), the lack of sequence identity associated with the junction site, 
and the incorporation of a complete 2A or 2B coding regions from either parent. It 
was possible that these were the consequence of early selection, and any other 
recombination event deviating from these ‘rules’ would not generate a viable virus.  
 
The requirement for structural compatibility in chimeric proteins posed a reason for 
selective localisation of junctions after virus passage. Junction sites would be 
selected for those changes that did not interfere with normal virus protein function by 
disrupting structural integrity. Amino acid similarity scans were performed using a 
program in Simmonic 2005 Version 1.75 that scanned pairs of sequences using a 
Point Accepted Mutation (PAM) matrix developed by Margaret Dayhoff (Dayhoff et 
al., 1978). This compared closely related amino acid sequences and scored regular 
and rare substitutions according to chemically related amino acids. For example, 
amino acids that replaced each other regularly would score positively while amino 
acids that rarely replaced each other (from different groups) would score negatively. 
High scores were still given if conservative amino acids were interchanged (scores of 
10 indicated similarities of sequence approaching 100%). Amino acid sequences 
were highly conserved within the targeted regions of PV1 and PV3 (averaging 9.64, 
SD = 0.57), suggesting that chimeric proteins would not alter protein structure 
significantly (figure 5.24). The average PAM value for the nine crossover sites at the 
approximate positions 3410, 3524, 3539, 3635, 3641, 3758, 3785, 3785, 3797 and 
3821 was 9.61, SD = 0.47. There was no significant difference (P = 0.87) between  
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Figure 5.24 Amino acid similarity scan between PV1 and PV3. Analysis was 
performed using Simmonics 2005 Version 1.75. Comparisons of pairs of amino acid 
sequences were calculated within a sliding window size of 10 amino acids with a 3 nt 
overlap to generate data points across the recombination region. The precise 
crossover sites forming chimeric PV proteins were plotted according to the location 
within the region and were given arbitrary values to aid in visualisation. Amino acid 
similarity plots were calculated by PAM matrix, and this compared closely related 
amino acid sequences and scored regular and rare substitutions according to 
chemically related amino acids. Amino acids that replaced each other regularly 
scored positively while amino acids that rarely replaced each other (from different 
groups) scored negatively. High scores were still given if conservative amino acids 
were interchanged (scores of 10 indicated similarities of sequence in the window 
approaching 100%).
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the mean PAM values of the crossover sites (mean = 9.61, 95% confidence interval 
[CI] 9.25, 9.97) and the mean PAM value for the entire sequence (mean = 9.64, 95% 
CI 9.58, 9.70). Considering the high degree of conservation, it was surprising that 
such precise chimeric recombinants were not identified in the early events that were 
captured. 
 
To test whether precise crossover sites occurred away from sequences that encoded 
active regions of virus proteins, the positions of conserved domains of 2Apro (as 
determined by crystallography of CB4 2Apro) were superimposed onto recombinant 
junction sites of PV1 and PV3 (Baxter et al., 2006). Poliovirus 2Apro encodes a 
proteinase that cleaves virus proteins in cis and cellular proteins in trans, and 
similarly to CVB4 2Apro, consists of a catalytic triad (H20, D38, C109), a four-
stranded antiparallel β-sheet as the N-domain, a C-terminal domain containing a six-
stranded antiparallel β-barrel, helical loops, an interdomain loop, and a C-terminal 
domain essential for virus RNA replication (Baxter et al., 2006; Li et al., 2001; 
Petersen et al., 1999). The location of precise crossover junctions forming chimeric 
PV3/PV1 virus proteins was superimposed onto the crystal structure of HRV2-2Apro 
as well as onto PV3 sequence encoding purported motifs/domains (figure 5.25). The 
crystal structures in figure 5.25A demonstrate that recombination events did not 
occur at the ‘interacting’ faces of the 2A dimer, meaning the chimeric protein was 
either all PV3 or all PV1 in that region. Although 50% of crossovers occurred within 
β-strands, this would not significantly disrupt structures as PV1 and PV3 share high 
sequence identity in these regions. This must not have affected functionality of the 
virus protease as the resulting chimeric viruses remained infectious in cell culture. 
The potential cleavage sites of selected imprecise recombinants (14C, 16B, 25A, 
34D, and 67B) were mapped according to the new recombinant polyprotein structure 
(appendix 1). A complete 2Apro present in each construct should have been able to 
cleave excess protein from the polyprotein to retain normal viral characteristics.  
 
The recombinant nature of intraspecies recombinants was investigated briefly. 
Results reflected those observed with PV3/PV1 recombinants. Recombinants with a 
complete set of virus proteins, and not those with chimeric forms due to junction 
sites, were the initial products of recombination. According to all documented 
crossover events in figure 5.17, a complete PV 2A encoding protein was included in  
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Figure 5.25 Comparing 2Apro domain structures to precise junction sites. (A) 
Crystal structure of the dimer 2A proteinase from HRV2. The chimeric nature of the 
proteins (as derived from recombinants in this region), are colour-coded. Poliovirus 
serotype 3 portions are represented by gold tubes, while purple tubes highlight PV 
serotype 1 sequence. The catalytic triad is depicted by small black stars in structure 8 
(His-18, Asp-35, and Cys-106). (Source: NCBI/Cn3D 4.1). (B) Location of structural 
features of PV3 2Apro in relation to precise recombination junction sites of passaged 
recombinant progeny. The PV structural domains were extrapolated from the 
solution structure of CVB4 2Apro (Baxter et al., 2006) and mapped according to nt 
positions in the recombination region. The eight precise junction sites of 
recombinants are numbered 1 to 8 (also reflected in the individual dimers in part A). 
Y-axis values were applied to each category to allow separation of structural 
features. 
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the recombinant, to match the PV VP1 sequence, therefore the fragments of 
incorporating CVA21 2A were extraneous and served no purpose. 
Coxackievirus A21 genome shares approximately 80% amino acid sequence identity 
to PV, and the similarity scans in figure 5.26 emphasised divergence that would 
suggest issues of incompatibility within the protein (Xiao et al., 2001).  
 
Comparing natural isolate crossovers with those obtained during this project 
Recombination events with insertions at the junction site are rarely reported in 
natural enterovirus isolates, whether from patients or from samples collected during 
sewerage surveillance etc. This is not surprising, since human isolates have 
undergone extensive rounds of replication and selection while in the host. This 
magnitude of selection pressure could repair mutations (such as insertions or 
deletions) at the crossover site, as was demonstrated during this project. The location 
of precise junction sites in PV recombinants reported in the literature, and from those 
acquired from this study, were plotted together for comparison.  
 
Figure 5.27 depicts the approximate positions of several recombination junction sites 
derived from human isolates, and those recovered from two recombinants that were 
serially passaged through HeLa cells during this project. There is limited overlap of 
sites between both sets of recombinants, and sites appear to distribute evenly over the 
region. Recombination ‘hot spots’ have not been accentuated from this small 
exercise, and not all reported recombinants could be included if sequence data was 
not provided.  
 
Correlation between donor and acceptor sites, and the size of insertions 
A Spearman rank-order correlations coefficient analysis (Dytham, 2009) was 
performed on recovered populations of recombinants to determine whether the 
location of the junction site on the acceptor template was influenced by the location 
of the donor site for template switching. Locations of donor and acceptor sites were 
plotted along the targeted region of recombination only (being the same sized 
fragment for both templates) applied to the 16 distinct crossover junctions identified 
from one co-transfection with PV1 and PV3 partners (pRLucWT and pT7FLC/SL3) 
(table 5.1), and the three co-transfection experiments involving CVA21 containing 
RNA partners (table 5.3). The 2-tailed analysis of correlation (P < 0.05) assumed that 
 
 
Figure 5.26 Amino acid similarity scans comparing PV1, PV3, and CVA21 protein sequences across the recombination region. Scans 
were performed using bioinformatics software Simmonic 2005 Version 1.75. Amino acid similarity plots were calculated by PAM matrix, and 
this compared closely related amino acid sequences and scored regular and rare substitutions according to chemically related amino acids. Amino 
acids that replaced each other regularly scored positively while amino acids that rarely replaced each other (from different groups) scored 
negatively. High scores were still given if conservative amino acids were interchanged (scores of 10 indicated similarities of sequence in the 
window approaching 100%). 
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 Figure 5.27 Crossover sites in PV3 and PV1 recombinants from this study and from the literature. New crossover sites for serially 
passaged recombinants 51G and 36B are shown in red arrows. Sites from natural isolates reported in the literature are shown with grey arrows, 
those in red are sites from this study.  
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the recombination sites were on a continuous scale (range ~1400 nt between the 
luciferase and CRE sequences) and did not assume a normal distribution. The 
hypotheses tested a null-hypothesis (H0) = there was no significant relationship 
between donor and acceptor sites and an alternate hypothesis (Ha) = there was a 
significant relationship between donor and acceptor recombination sites. 
 
Figure 5.28 shows scatter graphs depicting the relationship between donor and 
acceptor sites for the recombinant virus populations analysed, as well as their 
r values.  
 
The results suggested a significant positive association between PV3 and PV1 
recombination sites (r = 0.815, d.f. = 14, P <0.01) (experiment 1). Although the 
recombination sites were imprecise (except one), they showed strong association, yet 
the biological mechanism behind this strong statistical association remains unclear. 
No significant associations were found between junction sites for co-transfections 
involving pRLucWT + CVA21BKSabin1P1 or pT7Rep3-L + CVA21BKPV3P1 
RNA partners in L929 cells (experiments 2 and 3). A perfectly negative association 
was found between PV3 and CVA21BKPV3P1 RNA partners in BsrT7 cells 
(r = -1.0, d.f. = 2, P < 0.01). These recombination sites were imprecise and were 
strongly negatively associated, meaning that the donor and template sites of 
recombination were linked by similar distances between both points. 
 
To conclude from this analysis, there could be an association between the donor and 
acceptor template sites, but this could only be confirmed and expanded at a later date 
with larger datasets.  
 
The regions of template switching were also of interest and warranted further 
investigation. It was observed that once the RdRp removed itself (and the nascent 
RNA strand) from the donor template, its ‘reattachment’ to the acceptor strand did 
not extend beyond a certain distance, particularly from the 3’ end of donor PV1 2A 
(figures 5.4 and 5.17). This suggested there were restrictions imposed on template 
switching distances between templates. In theory, the RdRp could switch from the 
3’ end of region 2A and reattach in region 2C, but this was not observed. One 
possible restriction would be that a packaging limit is almost certainly applied to an  
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Experiment 1: PV3/PV1 recombinants from pRLucWT and pT7FLC/SL3 (table 5.1). 
Spearman rank-order correlation indicated a significant positive association between 
PV3 and PV1 recombination sites. 
 
 
(r = 0.815, d.f. = 14, P < 0.01) 
Experiment 2: Recombinants from pRLucWT and CVA21BKSabin1P1 
cotransfections in BsrT7 cells (table 5.4). Spearman rank-order indicated no 
significant positive association between PV1 and CVA21 recombination sites. 
 
 
(r = 0.424, d.f. = 7, P = 0.256) 
Experiment 3: Recombinants from pT7Rep3-L and CVA21BKPV3P1 
cotransfections in L929 cells (table 5.4). Spearman rank-order indicated no 
significant positive association between PV3 and CVA21 recombination sites. 
 
 
(r = 0.714, d.f. = 4, P = 0.111) 
 
Continued over page. 
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Experiment 4: Recombinants from pT7Rep3-L and CVA21BKPV3P1 
cotransfections in BsrT7 cells (table 5.4). Spearman rank-order indicated a 
significant negative association between PV3 and CVA21 recombination sites.  
 
 
(r = -1.0, d.f. = 2, P <0.01) 
 
Figure 5.28 Correlation coefficients for locations of junction sites in 
recombinants recovered. Locations of donor and acceptor sites were plotted along 
the targeted region of recombination only (being the same sized fragment for both 
templates). The corresponding genome fragments for donor and template are plotted 
on the X- and Y- axis, but exact nt positions in the genome are not provided 
(fragment locations of recombination occur between ~ 3404 to 4465 nts in aligned 
PV1 and PVl3 sequences). This was applied to the 16 distinct crossover junctions 
identified from one co-transfection with PV1 and PV3 partners (pRLucWT and 
pT7FLC/SL3) (table 5.1), and the three co-transfection experiments involving 
CVA21 containing RNA partners (table 5.4). Spearman rank-order correlation 
indicates a significant positive (or negative) association between X and Y (r = value, 
degrees of freedom = number of pairs – 2, P <0.05). Values of -1 or 1 are perfectly 
negatively or positively correlated.  
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RNA genome with inserted sequence, and this could be approximately 513 nt (the 
largest insertion size observed in this study). This is discussed in chapter seven. 
Preliminary analysis was performed to determine whether the length of inserted 
sequence was related to the location of the RdRp switching from the donor template. 
Figure 5.29 includes graphs that plotted the nt difference from donor to acceptor 
template locations, versus the donor location in the recombination region where the 
RdRp removed itself.  
 
In mapping the distance the RdRp travelled from donor to acceptor templates, it was 
noted that the RdRp reattached on the acceptor template at indiscriminate distances 
from the luciferase sequence on the donor stand (clear in experiment 1, figure 5.29). 
Results from all other experiments suggested that as more donor strand was 
incorporated at the crossover site, this was offset by the addition of less acceptor 
template at the junction. In other words, the RdRp travelled a shorter distance 
(measured in nts) from donor to acceptor templates. 
5.5 Discussion 
All viruses recovered from the system that was developed during this project 
underwent recombination in the region targeted during the experimental design. In 
all cases, recombination occurred predominantly in the non-structural 2A region 
between replication competent virus RNA partners. Upon generating a population of 
natural PV3/PV1 recombinants in vitro, it remained to be determined if template 
switching correlated with specific events at the genome level. Substantial lengths of 
extra sequence were incorporated at junction sites, and preliminary analysis indicated 
that these additional sequences were lost from such recombinants during subsequent 
rounds of replication. This method showed that viable virus was generated by 
imprecise recombination between two complementary RNA sequences, indicating 
that close interactions across templates occurred, but not necessarily at corresponding 
sequences. 
 
The unanticipated nature of recombinants signified very early events in the virus life 
cycle which are rarely available for study because of experimental design. 
Recombinants identified from isolates associated with enterovirus outbreaks have 
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Experiment 1: PV3/PV1 recombinants from pRLucWT and pT7FLC/SL3 (table 5.1). 
 
 
 3’ end Luc 2A 2B 5’ end 2C 
 
Experiment 2: Recombinants from pRLucWT and CVA21BKSabin1P1 
cotransfections in BsrT7 cells (table 5.4). 
 
 
 3’ end Luc 2A 2B 5’ end 2C 
 
Continued over page. 
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Experiment 3: Recombinants from pT7Rep3-L and CVA21BKPV3P1cotransfections 
in L929 cells (table 5.4). 
 
 
 
3’ end Luc 3’ end VP1 2A 
 
Experiment 4: Recombinants from pT7Rep3-L and CVA21BKPV3P1cotransfections 
in BsrT7 cells (table 5.4). 
 
 2A 3’ end Luc 3’ end VP1  
 
Figure 5.29 Distance of template switching from original displacement from 
donor template. X-axis is the genome position where the RdRp left the donor 
template. The distance from donor to acceptor template was calculated from Clustal 
alignments containing full sequence data of each RNA template.  
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been exposed to numerous selective pressures in vivo (i.e. several levels/layers of 
complex host systems and host resistance mechanisms) and may therefore reflect 
highly adapted viruses. Although studying recombination using RNA fragments has 
been reported previously whether in picornaviruses or plant viruses, no results have 
shown the frequency and variability of insertions at crossover junctions on this scale 
(Cascone et al., 1990; Chetverin et al., 1997; Gmyl et al., 1999; Gmyl et al., 2003; 
Raju et al., 1995). One study does describe a deletion at the crossover site, and this 
phenomenon was reported in recombinants generated from Sindbis virus RNA 
transcripts, where in one instance, the crossover site contained a 76 nt deletion (Raju 
et al., 1995).  
 
The overall data suggests that recombination is at least a two stage process that 
initially produced random chimeras combining two RNA partners in frame before 
further rounds of replication. The nature of the recombinants recovered suggests that 
template switching occurred in a ‘promiscuous’ and unpredictable manner, 
particularly with the unexpected insertion of non-virus sequence in the final virus 
genome. Such recombinants were eventually corrected so that the junctions no longer 
contained any insertions – this was aided by rapid passages at high MOI and 
selection through susceptible cells. To demonstrate the rapid evolutionary properties 
of RNA viruses, further passages of original clonal virus populations produced new 
heterogeneous progeny of recombinants containing several variants (five different 
crossovers identified from one clone). The generation of quasispecies and continuous 
recombination served to stabilise genomes and remove unfavourable mutations while 
creating newly defined genomes. Ideally, it would have been beneficial to perform 
single-step growth curves to compare growth characteristics of passaged 
recombinants to their original seed and wild-type parents.  
 
Tolskaya et al had previously found that several non-random interserotypic PV 
recombination events took place within RNA secondary structure elements (Tolskaya 
et al., 1987). Crossover sites were mapped on a model of the secondary structure of a 
793 nt RNA region of PV1 (between 3823 and 4616 nts) which corresponded to the 
region of interest in the current project. Crossover sites fell within hairpin-like 
structures, with the majority showing unpaired nucleotide sequences which would 
seem favourable for acceptor templates. Unfortunately, most analysis was carried out 
 -188-
on a large segment of RNA sequence with extensive secondary structure, suggesting 
that all crossover sites were located amid this secondary structure. This analysis 
predated more accurate and current RNA folding methods and would be better 
served with smaller fragments for analysis. The only conserved secondary RNA 
structure in this region is the CRE, which was not evident within the potential folding 
figure in this publication. 
 
There was no evidence for the occurrence of multiple crossover events within the 
regions, although this could not be discounted for the remainder of the unsequenced 
genome. Recombination seemed to occur in preferred locations (5’ end of 2A or 2B) 
as the crossover sites were not evenly distributed throughout the region, but it was 
difficult to identify factors relating to nucleotide or amino acid sequences that 
provided evidence for preferences to those sites. The region of recombination was 
relatively unstructured as a whole, but contained several potential local RNA 
structures and sequence motifs (such as stem loops and homopolymers) that did not 
correlate strongly with junction sites.  
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CHAPTER SIX: Construction of RNA Partners for Co-transfections  
6.1 Introduction 
Chapter four demonstrated proof of concept by using two RNA molecules to create 
recombinant species C viruses comprising sequences from PV1 and PV3 in vitro. A 
number of recombinant viruses were recovered in the absence of any background 
full-length parental PV1 or PV3 viruses. These isolated, recombinant species C 
viruses contained sequence similarities to recombinant clinical isolates obtained from 
humans (Cuervo et al., 2001; Georgescu et al., 1994) and suggested that this 
approach could be used to simulate intraspecies recombination events that may arise 
in vivo. The new model described in chapter four may also be expanded to study 
virus recombination between different species of enterovirus (i.e. interspecies 
recombination). A review of the literature suggests that interspecies recombination is 
limited to viruses of the same host species and tropism, those that share close 
phylogenetic relationships, and happen to be circulating concurrently (Bolanaki et 
al., 2007; Yozwiak et al., 2010). These mostly host related restrictions make it 
difficult to determine if virus recombination between species is possible at the 
genomic level. The method described in chapter four used naked RNA transfected in 
vitro in order to bypass cell entry processes which would otherwise restrict viral 
tropism (such as the need for specific host cell receptors).  
  
The method relied on two defective virus sequences (herein described as “partners”) 
that could recombine within a single host cell to create viable progeny virus. 
Defective virus genomes were derived from plasmids encoding several forms of 
enterovirus cDNA, such as subgenomic replicons and full-length virus cDNA 
containing a mutated CRE sequence. Mutating the CRE would limit virus RNA 
replication to the negative-strand, meaning it would be semi-replication competent. 
The construction of full-length virus cDNA clones and their derivatives are discussed 
in chapters one and four.  
 
Echovirus 30 (E30) belongs to species B enteroviruses and is the major cause of 
meningitis in both children and adults (Khetsuriani et al., 2006; Rice et al., 1995). 
Surges of E30 transmission correlate with distinct new genomic lineages which 
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usually replace older circulating ones. High frequencies of E30 detection and 
isolation occur over large geographical areas and phylogenetic analysis of strains 
suggests that E30 sequence diversity differs between the structural and non-structural 
regions of the genome. Recombination with unidentified species B viruses, evident in 
the non-structural regions (McWilliam Leitch et al., 2009; Mirand et al., 2007) may 
play an important role during outbreaks of E30. The outbreak patterns of circulation 
and continuous dynamic changes to genomic lineage make it an ideal virus to study 
further by incorporation into recombination experiments. To date there have been no 
publications identified describing the construction of a full-length infectious clone or 
subgenomic replicon for E30. 
 
Chapter four described the use of defective virus RNA partners in co-transfection 
experiments for generating recombinant viruses for further characterisation. The aim 
here was to incorporate E30 RNA into such experiments by constructing either a 
defective full-length clone with mutated CRE, or a subgenomic replicon for E30. 
Both forms of virus RNA would fit the requirements to generate infectious virus 
during co-transfections with other virus RNA partners.  
 
Three E30 isolates were provided by Professor Peter Simmonds (Centre for 
Infectious Diseases, University of Edinburgh) and had been obtained as part of an 
ongoing geographical and evolutionary epidemiological study of E30 transmission 
worldwide over an eight year period (McWilliam Leitch et al., 2009). Because of the 
nature of the molecular study, only small regions of the E30 genome (VP1 and 
3Dpol) had been sequenced. As the complete E30 virus sequence was unknown, the 
complete genome could be amplified by long distance PCR using oligonucleotides 
targeted to the conserved 5’ and 3’ ends of enterovirus genomes (Lindberg et al., 
1997). A general strategy for the construction of an E30 infectious clone into pRiboI 
vector using restriction enzymes for ligations is outlined in figure 6.1.  
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 Figure 6.1 Overview of proposed E30 full-length infectious clone construction. 
Virus RNA is extracted from virus cultured in RD cells. Virus cDNA is synthesised 
from RNA and complete genome amplified by PCR using conserved enterovirus 
oligonucleotides with inserted restriction sites. Virus amplicon and pRiboI are 
digested and ligated together to form a full-length clone for E30. This will be tested 
for infectivity at a later date.  
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Plasmids containing insert of the correct size would be further characterised for 
infectivity. Ribonucleic acid transcribed in vitro from cloned virus cDNA would be 
transfected into susceptible cells and assessed for the generation of viable virus 
particles. A full-length E30 cDNA clone capable of generating virus would be 
sequenced in its entirety and used for additional cloning strategies.  
  
Aims 
The aim was to construct species B RNA partners for co-transfections to make 
populations of recombinant viruses in cell culture. This would allow the study of 
interspecies recombination as species C and D RNA partners were already available. 
The intent was two-fold. Firstly, in order to design E30 RNA partners, this 
necessitated the initial construction of a full-length infectious E30 cDNA. With the 
aid of a full-length E30 cDNA clone, it would be easier to construct a subgenomic 
replicon or mutate the CRE by modifying the plasmid by molecular cloning 
techniques. Secondly, to mutate the CRE in the full-length pT7E7 infectious clone in 
order to inhibit virus production yet allow synthesis of negative RNA strands, as 
previously demonstrated by Goodfellow et al., 2000 for the pT7FLC/SL3 construct. 
These two aims were necessary in order to complete a larger objective which was 
performed and discussed in chapter four; to integrate species B partners with species 
C and D partners as part of interspecies co-transfection experiments to determine if it 
was technically possible to generate chimeric interspecies viruses by bypassing host 
cell receptors and cell entry in vitro.  
_____________________________________________________________ 
 
6.2 Generation of a Full-length Infectious E30 cDNA 
Amplification of E30 genome by RT-PCR 
Isolates Fi13 (Finland), GB27, and GB37 (both Great Britain) were amplified by 
passage in RD cells. Ribonucleic acid was extracted from tissue culture using the 
RNAeasy Mini kit (Qiagen) according to the manufacturer’s instructions. Reverse 
transcription was performed using Superscript II Reverse Transcriptase (Invitrogen) 
and the oligonucleotide MJREV containing an extended T region (table 2.3), with a 
longer extension step of 50 min at 46°C. This was necessary to ensure complete 
transcription to the extreme 5’ end of the genome. The E30 genome was amplified by 
PCR using conditions optimised during supervision of an undergraduate student 
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project (Megan Jackson). Briefly, the forward oligonucleotide (E30-1FClaI) 
(table 2.3) contained the first 27 bases corresponding to those of the start of E30 (as 
determined by sequences in GenBank) as well as a ClaI restriction site to aid in 
subsequent cloning into the pRiboI vector (Herold & Andino, 2000). The reverse 
oligonucleotide used was the same as that used for RT (MJREV), and included a run 
of 29 thymine bases in order to incorporate a longer and more stable poly(A)-tail at 
the 3’ end of the virus transcript. The KOD polymerase (Novagen) was effective in 
amplifying the entire E30 genome with cDNA produced, and was applied using 
30 cycles with an annealing temperature of 61°C and a 6 min extension incubation. 
The higher annealing temperature was required for priming the longer 
oligonucleotides to template and was optimised by gradient PCR (data not shown). 
A 5-6 min extension incubation was recommended by the polymerase manufacturer. 
The outcome was an amplicon of approximately 7.5 kbp (figure 6.2A), with smaller 
non-specific bands evident at 3 kbp and 1.7 kbp.  
 
Restriction digestions to determine restriction enzyme sites in virus sequence 
As these virus isolates had not been previously sequenced, it was important to 
determine which restriction enzymes could digest the virus sequence for future 
cloning procedures. A SalI digest produced a similar banding pattern to the original 
PCR product, indicating the absence of SalI sites within the virus genome. This did 
not exclude SalI sites from the genome altogether, as one might exist near the ends of 
the genome which makes visualisation of products difficult on an agarose gel. Single 
(not shown) and double digests with SmaI and SalI showed the existence of at least 
three SmaI sites limiting the use of the pRiboI vector (figure 6.2B). Digestions were 
incomplete, as full-length product (~7.5 kbp) remained. Strains Fi13 and GB37 
indicated the presence of five gel bands (~7.5 kbp, faint ~5.75kbp doublet, ~4.5 kbp, 
~2.5 kbp, and ~0.85 kbp) meaning that three possible SmaI sites existed if undigested 
band fragments were taken into account. The strain GB27 digest contained five gel 
bands, but the extra band at approximately 1.7 kbp was evident in the original PCR 
product. With regards to pRiboI, the 5’ terminus of virus cDNA could only be cloned 
immediately following the cis-acting hammerhead ribozyme using the single SmaI 
site contained within the ribozyme cDNA (Herold & Andino, 2000).  
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 Figure 6.2 Amplification and restriction digests of E30 cDNA. (A) Agarose gel of 
full-length E30 RT-PCR product, stained with ethidium bromide. PCR was 
performed in duplicate per strain; -ve indicates PCR control with no template (H2O). 
(B) Restriction enzyme digests to confirm cut sites present in the virus sample. Left 
gel indicates the presence of several SmaI or SalI sites within the virus sequence, 
while the right gel shows that one EcoRV site (E) is present in virus strain GB27. 
The three strains of E30 (Fi13, GB27, and GB37) do not contain ClaI restriction sites 
(C) (see text).  
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Virus cDNA containing several SmaI sites would make this difficult to achieve. 
Single digests with ClaI and EcoRV showed that the viruses most likely did not 
contain a ClaI site (figure 6.2B), but indicated the existence of an EcoRV site within 
E30 virus strain GB27 (two extra bands appear in lane at ~6.5 kbp and 1.25 kbp). 
Multiple EcoRI restriction sites were detected in all strains (data not shown).  
 
To conclude, cloning could not easily be performed using available restriction sites 
in pRiboI because such sites were present in the virus genomes and would increase 
the complexity of cloning required.  
 
Cloning of full-length RT-PCR product into pGEM®-T Easy vector 
As the sequence (and therefore restriction sites) was unknown for the virus isolates, 
it was apparent that blunt-end cloning would be a useful method for ligating full-
length virus PCR product into a single vector without the need for restriction digests.  
Full-length amplicon could be cloned directly into linearised vectors if the DNA 
polymerase used during PCR generated single A overhangs attached to the 3’ end of 
amplified fragments. An amplicon with 3’-A overhangs can be ligated directly into 
linear vectors containing single 3’ terminal T overhangs at insertion sites. These A 
and T overhangs flanking amplicon and vector respectively, improve the efficiency 
of ligation by providing compatible bases for attachment. 
 
A full-length virus amplicon was therefore purified from 1% agarose gel in order to 
remove non-specific PCR product using the DNA Extraction Kit (Fermentas). To 
increase ligation efficiency, the purified amplicon was further modified to 
incorporate 3’A residues using the Taq polymerase kit (Fermentas) and cleaned using 
a High Pure PCR Clean Up Micro Kit (Roche) in order to remove excess dATPs that 
could interfere with cloning. Full-length PCR product (with 3’ A overhangs) for all 
three E30 strains were cloned into linearised pGEM®-T Easy vector using the kit 
supplied by Promega. The 3015 bp pGEM®-T easy vector contains a single 3’ T 
extension at each end to aid in efficient ligation, and includes T7 and SP6 RNA 
polymerase promoters that flank the multiple cloning site (MCS). A diagrammatic 
representation of this cloning method is shown in (figure 6.3A). 
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Figure 6.3 Construction of pT7E30 full-length infection clone for E30. (A) The 
entire amplified genome of E30 (strains Fi13, GB27, and GB37) was separately 
cloned into linearised commercial vector pGEM®-T Easy. The 5’ MCS begins with 
a T7 promoter, and the 3’ MCS ends with an SP6 promoter in reverse orientation. 
(B) As this was blunt-ended cloning, virus cDNA could be inserted in either 
orientation. To reorientate the genome in order to use T7 promoter, the plasmid was 
digested with BstZI and re-ligated with all components present, therefore removing 
the genome and small flanking MCS. Resulting clones were analysed for correct T7 
orientation by sequence analysis. 
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This cloning strategy proved to be inefficient, with only six clones containing the 
appropriately sized DNA recovered from several hundred clones for all three strains. 
One clone was recovered for strain Fi13, three clones for strain GB27, and two full-
length clones for strain GB37. Single and double digests were performed with ClaI 
and SalI on all six plasmids to confirm the presence of virus sequence of correct 
length and of these, only three plasmids contained the entire virus sequence, one for 
each strain. The double digest displayed two DNA bands on the agarose gel, the 
smaller (3015 bp) representing the vector backbone, and larger band (~7500 bp) 
being virus cDNA. As this was essentially achieved by blunt-end ligation, the 
orientation of virus sequence in the plasmid was also determined by restriction 
digestion using Sal I alone. A single Sal I site was present in the vector 3’ end of the 
MCS (when linear) and this digest would determine whether the virus was in reverse 
(a SalI site at each end of virus) or in the correct orientation with both SalI sites at 
the 3’ end of the virus (figure 6.3A).  
 
The orientation of virus cDNA in pGEM®-T Easy was determined in order to 
establish which promoter (T7 or SP6) would be required to transcribe RNA from 
cDNA. The insertion site in pGEM®-T Easy was flanked by either a T7 or SP6 
promoter. As such, all three strains of E30 were cloned in reverse with regard to the 
T7 promoter (3’ to 5’) and would require the SP6 promoter for transcription. The use 
of the standardised T7 promoter was preferred and therefore, the virus sequence was 
digested out of the vector with BstZI to remove the virus sequence in its entirety 
from the backbone before re-ligating it back in the opposite direction (figure 6.3B). 
A BstZI restriction site was located on either side of the inserted virus cDNA in the 
MCS and was not present in the virus (data not shown). The virus cDNA and vector 
backbone was gel extracted from 1% agarose and religated together once the vector 
was dephosphorylated with alkaline phosphatase in order to remove 5’ phosphate 
groups to prevent religation to itself. The cloning process was repeated and plasmids 
were isolated with the desired orientation of insert using the T7 promoter for RNA 
transcription. These new clones were designated pT7E30 Fi13 (15.6, 15.7, 15.16), 
pT7E30 GB27 (27.29), and pT7E30 GB37 (2.44). The numbers in parenthesis 
indicated clone numbers belonging to each strain.  
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Sequence analysis of E30 GB37 cDNA 
As one clone from those above proved to be infectious (details in the following 
section), it was sequenced in its entirety. The pT7E30 GB37 (2.44) cDNA sequence, 
which was 7428 nt long excluding the A tail, contained an open reading frame of 
2194 amino acids, had a 5’ NCR of 743 nt, and was followed by a shorter 3’ NCR 
containing 103 nt and poly(A)29 tract. The nucleotide identity of E30 GB37 was 
compared to four full-length E30 genomes available in GenBank (figure 6.4A). It 
shared between 81.2-84.4% nucleotide identity with the database strains, including 
two separate submissions for prototype strain Bastianni (accession numbers 
AF162711 and AF311938). The E30 GB37 strain appeared as a more recently 
evolved strain from the prototype, as is evident from the phylogenetic tree calculated 
using ClustalW in MegAlign (DNASTAR Lasergene®)(figure 6.4B).  
 
Full genome sequencing of non-infectious clones pT7E30 GB27 (27.29) and pT7E30 
Fi13 (15.6) was performed to characterise the particular strains of E30 and identify 
potential mutations that could be corrected at a later date. Clone pT7E30 GB27 
(27.29) contained a T deletion at nt position 6463 (AATCT[T]AGGCT) that resulted 
in the introduction of a stop codon at amino acid 2166. Virus sequence in pT7E30 
Fi13 (15.6) contained three mutations to render this non-infectious. It contained an 
inserted A at nt position 4363 (AGCTG[A]AAGCA), an encoded stop codon at nt 
position 4908 (TTTCTAACAAT), and a G deletion at nt position 6926 
(CCTAC[G]GAGAC). The mutations listed above could be corrected by single 
rounds of site-directed mutagenesis in the future.  
 
RNA transfections and recovery of infectious E30 progeny 
In order to determine whether the full-length E30 clones were capable of generating 
infectious virus, clones pT7E30 Fi13 (15.6, 15.7, 15.16), pT7E30 GB27 (27.29), and 
pT7E30 GB37 (2.44) were linearised with SalI (a unique site located downstream of 
the poly(A)-tail), ethanol precipitated to remove excess enzyme, and transcribed 
using T7 RNA Polymerase Kit (Fermentas)(figure 6.5A). Rhabdomyosarcoma cells 
were transfected with 2 µg RNA using Lipofectamine 2000 (Invitrogen) and 
incubated for 48 hrs. Transfection supernatant was removed and the viable virus 
identified and quantified using plaque assays. Supernatant was serially diluted in  
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Figure 6.4 Phylogenetic analysis of cloned E30 strain GB37. Nucleotide 
sequences of E30 strains from GenBank were aligned with pT7E30 GB37 sequence 
using ClustalW in MegAlign software (DNASTAR Lasergene®). This produced (A) 
a table outlining percent identity and divergence for all five sequences, and (B) a 
phylogenetic tree to describe evolutionary distances.  
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 Figure 6.5 Recovery of infectious E30 from RNA transfections. (A) Ethidium 
bromide stained 1% agarose gel showing RNA transcription product of pT7E30 
clones from T7 promoter. (B) Plaque assays of serially diluted transfection 
supernatant on RD cells showing infectious virus generated from pT7E30 GB37 
(2.44) RNA, but not pT7E30 Fi13 (15.16) clone. The remaining clones were negative 
(plates not shown). 
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medium before using it to inoculate fresh RD monolayers. Once overlay plaque 
media was added to each well, plates were incubated at 37°C until CPE was evident 
in the cells. Only one clone demonstrated CPE after 48 hrs (pT7E30 GB37 (2.44)) 
(figure 6.5B). Infectious virus was recovered after transfections with clone pT7E30 
GB37 (2.44), but not for the remaining clones (figure 6.5B). 
 
Growth characteristics of cloned E30 GB37 
To determine the stability of clone pT7E30 GB37(2.44), (designated as 
pT7E30GB37 henceforth), infectious virus generated from the full-length clone was 
serially passaged five times through RD cells. A fresh monolayer of RD cells was 
infected with RNA transfection supernatant containing E30 GB37 virus from the 
infectious clone and cultures were harvested after 24 hrs or when cells displayed 
>50% CPE. A quarter of the previously harvested supernatant was used for each 
subsequent inoculum. There were no observable changes in plaque phenotype 
between passages 1 to 5, with the initial passage yielding 7.2 x 105 PFU/ml and the 
fifth passage yielding 3.6 x 107 PFU/ml (figure 6.6A).  
 
Replication kinetics of the original isolate and virus recovered from RNA 
transfection was compared in single-step growth experiments performed in 12-well 
plates to determine the kinetics of virus growth (PFU over time) as a measure of viral 
fitness. Briefly, RD cells were infected at an MOI of 5 for 30-60 mins before cells 
were washed twice with sterile PBS and incubated with fresh medium. Supernatant 
was harvested at various time points over a 24 hr period and virus titre was 
determined by plaque assay. Despite irregularities in wild-type E30 GB37 titres at 
11 and 24 hrs (possibly due to aliquoting errors at the time of infection), virus 
recovered after 1 and 5 passages displayed similar growth kinetics to the original 
isolate (figure 6.6B). This experiment indicated that clone-derived virus (p1) had a 
slightly lower rate of growth, (lower by approximately one log10) from 4 to 9 hrs, but 
at later time points was at least as good as p5 E30 GB37. The early ‘lag’ in growth of 
p1 virus may have been the result of inserted nts between the T7 promoter and 
beginning of the 5’ NCR, which could affect replication and packaging efficiency 
until insertions are gradually removed through repeated passage. Any nt changes 
introduced in virus sequence during subsequent passages were not investigated 
further due to time restraints.  
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Figure 6.6 Growth characteristics of infectious full-length pT7E30 GB37 clone. 
(A) Plaque phenotypes of clone-derived E30 GB37 after 1 or 5 passages through RD 
cells. Cells were infected with 10-fold dilutions of virus and plated with plaque assay 
overlay medium. Cells were stained and photographed 72 hrs post-infection. (B) 
Growth kinetics comparing clone-derived E30 GB37 (passages 1 and 5) to original 
isolate. RD cells were infected at an MOI of 5; inoculum was removed after 30-60 
mins and replacement medium removed at various time points from 2 to 24 hrs.  
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In summary, virus generated from the pT7E30 GB37 infectious clone had similar 
phenotypic and growth kinetics to wild-type GB37 from which it was derived. This 
meant that clone-derived virus clearly represented the wild-type virus isolated from a 
patient. The infectious clone was not characterised further (e.g. specific infectivity of 
clone-derived RNA) due to time constraints.  
 
Construction of an E30 subgenomic virus replicon 
Attempts were made to construct a luciferase encoded subgenomic replicon in a 
pRiboI vector backbone using full-length pT7E30 GB37 virus cDNA as template. 
The strategy is outlined in figure 6.7. Briefly, cloning was performed in two major 
steps: insertion of E30 5’ NCR and the luciferase gene into pRiboI vector using the 
unique SmaI site in the vector ribozyme sequence, followed by insertion of the 3’ end 
of the E30 genome downstream of the luciferase gene. The E30 5’ NCR was 
amplified from pT7E30 GB37 plasmid using oligonucleotides RiboSmaIE30F and 
E305UTRSacIR (table 2.3). The luciferase gene was amplified from pT7Rep3-L 
(PV3 subgenomic replicon encoding luciferase) using oligonucleotides SacILucF and 
BstZ17ISmaILucR. Both PCR products were double digested with SmaI and SacI 
and ligated into the unique SmaI site in pRiboI in a triple ligation (figure 6.7). In the 
final stage, the 3’ end of E30 (non-structurals and 3’ NCR) was amplified using 
oligonucleotides E30-2551F and MJREV to produce a PCR product of 
approximately 5 kbp. This and a correct pRiboI/5’ NCR/luciferase backbone from 
the previous step was double digested with BstZ17I and SalI and subsequently 
ligated together. This step exploited the unique BstZ17I site in pT7E30 GB37 at nt 
position 3150, and the unique SalI sites in the pRiboI vector and SalI site 
incorporated at the 3’ terminus of the PCR product. Although apparently complete 
constructs were recovered and confirmed by restriction digests, all clones tested gave 
low luciferase readings, comparable to controls in the presence of guanidine 
hydrochloride. Unfortunately, these results were not explored further due to time 
limitations.  
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 Figure 6.7 Overview of construction of E30 subgenomic replicon encoding 
luciferase. All three cDNA fragments were amplified from plasmids by PCR using 
oligonucleotides discussed in the text. Restriction sites used for cloning were 
incorporated into PCR product via oligonucleotides encoding these sites. 
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6.3 Generation of a Full-length E7 CRE Mutant cDNA 
Mutating CRE region in full-length infectious E7 plasmid by site-directed 
mutagenesis 
The second aim was to construct a species B enterovirus RNA partner for use in 
interspecies recombination experiments. Echovirus type 7 was chosen to represent a 
species B partner because both a full-length infectious clone and subgenomic 
replicon was available at the time. The CRE is present and highly conserved in the 
enteroviruses and is located in the E7 strain Wallace at position 4390 to 4450 
according to complete genome sequence in GenBank (AY302559). The species B E7 
partner was modified by mutating the CRE in full-length infectious clone pT7E7 in 
order to disrupt the ability of this clone to generate E7 virus particles while still 
allowing for negative-strand RNA synthesis. The aim was to disrupt the conserved 
secondary RNA structure of the CRE stem loop with point mutations in the nt 
sequence. The wild-type RNA structure of E7 CRE is presented in figure 6.8A and 
was predicted in silico using MFOLD (Zuker, 1989). Seven synonymous mutations 
were incorporated into the CRE sequence and were designed to disrupt the structure 
from forming. Most point mutations occurred at the third-base position of codons to 
avoid changing the translated 2C product and mimicked those used in early CRE 
studies (Goodfellow et al., 2000). Figure 6.8B shows substitutions in the stem loop at 
the following nt positions: 4402 (C→T), 4405 (A→C), 4408 (G→A), 4412 (C→T), 
4414 (G→A), 4419 (A→G), and 4429 (T→C), and further illustrates how these 
changes were predicted to affect the overall shape of the CRE to prevent RNA 
synthesis.  
 
Initially, a portion of the 2C coding region (spanning the CRE) was removed from 
pT7E7 by digestion using restriction enzyme PstI (4332 and 6434 nts) and was 
subcloned into the unique PstI site in pUC19. Attempts were made to mutate the 
CRE by using a site-directed mutagenesis kit (Stratagene) following the 
manufacturer’s instructions. Unfortunately this was unsuccessful as no inserts with 
mutated CREs were recovered. One interpretation of this result suggested that this 
method was ineffective due to the length of oligonucleotides and the large number of 
mutations contained within them. An alternative approach was therefore used where 
a pT7E7ΔCRE mutant was constructed by overlapping PCR mutagenesis, as outlined  
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 Figure 6.8 Predicted secondary structure of wild-type and mutagenised E7 CRE 
stem loop. (A) Wild-type CRE stem loop generated by an MFOLD program run by 
Burnet Institute website (software originally created by Zuker and Stiegler, 1981). 
(B) Predicted secondary structure of mutagenised CRE. Seven mutations introduced 
are boxed. 
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 in figure 6.9. The same oligonucleotides were applied to incorporate the 
aforementioned nt mutations. 
 
Briefly, the CRE was amplified in two fragments in order to incorporate the 
necessary mutations into the oligonucleotides. Oligonucleotides E7-3782F and 
E7RcreMUT were used to amplify one fragment from plasmid pT7E7 while 
E7FcreMUT and M13R amplified the remaining fragment from the initial subclone 
in pUC19 described above. The fragments contained overlapping sequence 
(mutatedCRE) and acted as template to construct the larger amplicon. Both 
fragments were purified from agarose gel, the DNA quantified, and incorporated into 
an initial ‘5 cycle’ PCR performed without oligonucleotides in order to complete 
amplicons with precise ds ends. This PCR product was used as template and subject 
to final assembly amplification using Taq DNA Polymerase with standard conditions 
(figure 6.10A). Column-purified product was digested with PstI, gel-purified and 
ligated into phosphatase treated PstI digested pGEM®-T Easy vector. This vector 
was used to aid in the sequencing of cloned fragments with the use of T7 and SP6 
oligonucleotide regions flanking the insertion site, see below. Mutations introduced 
to the CRE also incorporated a unique SwaI site which was used to screen plasmid 
DNA minipreps (figure 6.10B). Sequencing was used to confirm integrity of the 
fragment before it was rebuilt into the full-length infectious pT7E7 plasmid to 
generate pT7E7ΔCRE. Once again, the unique SwaI site in mutated CRE was used to 
confirm its presence in pT7E7ΔCRE, and orientation of the reinserted fragment was 
later determined by sequencing. 
 
Sequence analysis of CRE overlapping PCR fragment in pGEM®-T Easy 
The following seven mutations to the CRE were confirmed in the full-length 
genome, at nt positions: 4402 (C→T), 4405 (A→C), 4408 (G→A), 4412 (C→T), 
4414 (G→A), 4419 (A→G), and 4429 (T→C). Two further mutations were located 
in the fragment, and these occurred at nt positions: 4590 (C→T) and 5993 (G→A). 
Both were responsible for amino acid changes from threonine to isoleucine and from 
alanine to threonine, respectively. As the initially cloned E7 fragment had not been  
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 Figure 6.9 Strategy for mutagenising CRE in full-length infectious clone pT7E7. 
(A) The CRE region was amplified in two fragments using oligonucleotides 
containing the seven nt changes required to alter the CRE sequence. The second 
fragment (E7FcreMUT to M13R) was amplified from the original subclone 
constructed in pUC19 (see text). (B) Overlapping PCR performed to join both CRE 
fragments generated in (A). The ~ 2618 bp fragment was digested with PstI and 
subcloned into pGEM®T-Easy to confirm mutagenesis by sequence analysis. The 
CRE fragment was digested from the shuttle vector and rebuilt in the pT7E7 
backbone using the PstI sites again. 
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Figure 6.10 Overlapping PCR of E7 CRE fragments. (A) Agarose gel photo 
showing ‘5 cycle’ PCR product (lane 1) complete with both fragments amplified 
separately and added to the reaction to create precise ds amplicons. Lane 2 shows the 
result of the final assembly PCR (overlapping PCR) which used lane 1 product as 
template. The large band highlighted in lane 2 is the combined overlapping product 
of both fragments. (B) Digestion of E7ΔCRE/pGEM®-T Easy clones to confirm 
presence of introduced SwaI site. All clones are positive for SwaI and therefore have 
a mutated CRE sequence. 
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 sequenced prior to mutagenesis, it was not apparent whether the two mutations were 
already present in the E7 genome.  
 
RNA transfections and recovery of revertant virus to confirm stability of CRE 
mutations 
It was important that the introduced mutations could not revert to their original nts by 
continuous passage resulting in restored infectivity to clone-derived RNA. This 
would no longer be a viable partner in the interspecies recombination experiments. 
Previous studies of PV3 CRE have shown that a treble mutant in the stem loop  
 (2Cmut6) destroyed replication of full-length genomes and function was only 
restored after three repeated blind passages, which resulted in reversion of at least  
one of the three mutations (Goodfellow et al., 2000). There was no reason to believe 
that the conserved CRE would behave differently for E7, and there should be no 
detectable revertants, as too many would be required simultaneously to restore 
infectivity. Integrity of the seven mutations in the 2C section of the CRE was tested 
by serial passage of the non-viable RNA through RD cells.  
 
Several pT7E7ΔCRE clones, together with wild-type pT7E7, were linearised with 
NotI and transcribed into RNA as described in Materials and Methods. Briefly, 2 µg 
of clone-derived RNA was transfected into cells and supernatant harvested 48 hrs 
later. A portion of supernatant was inoculated onto fresh RD monolayers for 30 mins, 
removed and cells washed twice with sterile PBS, before serum-free medium was 
added to the cells. Supernatant was again removed 48 hrs post-transfection and the 
process repeated five times. Wild-type pT7E7 supernatant was not passaged in this 
way as it provided a positive control for RNA transfections. Supernatant harvested 
from transfections (p0) and p5 infections was diluted in serial 10-fold increments and 
plaqued onto fresh RD monolayers. It should be noted that no CPE was observed 
during these stages. Plaques were not detected in supernatant at passages 0 or 5 in the 
pT7E7ΔCRE clones, indicating that they remained non-infectious (data not shown). 
It has been reported that the 2C loop can accommodate a small number of variations 
in the region, but the non-viable clone would have to overcome the majority of the 
seven introduced mutations to restore infectivity (Goodfellow et al., 2000). 
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6.4 Discussion 
A full-length infectious clone of E30 strain GB37 was constructed (pT7E30 GB37) 
and its complete nucleotide sequence determined. This was the first reported 
infectious clone for E30. Although this plasmid does not contain a ribozyme for 
more efficient RNA processing from plasmid, the clone-derived RNA produced 
infectious virus with similar growth characteristics to wild-type strain GB37 in a 
single-step growth curve and was therefore deemed suitable for the project’s 
requirements. Although the specific infectivity for clone-derived virus RNA in RD 
cells was not calculated, it was estimated to be lower than that calculated for naked 
PV RNA in HeLa cells of around 106 PFU/µg RNA (Crotty et al., 2001) based on the 
cloning strategy used. There was approximately 70 nt of extraneous sequence located 
between the T7 promoter and the start of the virus, which would reduce early virus 
infectivity as has been shown in studies with PV (Herold & Andino., 2000). Herold 
and Andino showed that replication of PV was more efficient when the 5’ end of the 
RNA was cleaved precisely by a cis-acting hammerhead ribozyme (Herold & 
Andino, 2000). This could be overcome by subcloning the E30 virus sequence into a 
pRiboI vector (a pBluescript II derived cloning vector with a hammerhead ribozyme 
situated adjacent to the T7 promoter).  
 
Cloning of full-length E30 RT-PCR product proved to be an inefficient process 
which is evident with only one viable infectious clone recovered. A DNA 
polymerase was used with rapid amplification and proof reading ability, and this 
provided adequate quantities of PCR product. The KOD polymerase possesses strong 
3’-5’ exonuclease activity and is reported to have an error rate of approximately 1 in 
106 (Nishioka et al., 2001). The polymerase forms a mix of blunt and 3’ A ends on 
PCR product which should be ideal for cloning in T-vectors such as pGEM®-T 
Easy.  
 
Only six full-length E30 clones were obtained over several repeated cloning 
experiments. It is likely that several factors contributed to this low efficiency, 
including the low rate of 3’ A additions to amplicon during and after PCR, and 
decreased efficiencies in further cloning steps. Transformation efficiencies are 
reported to decrease as the size of plasmid increases and this is a probable reason for 
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the low number of clones obtained4. Promega literature suggests that an empty 
vector the same size as that used in the present study (pGEM®-T Easy at 3015 bp) 
yields approximately 60 times more colonies per microgram of transformed DNA
than 13.6 kbp plasmids, and this is even lower for transformations using chemic
competent cells. Competition was therefore created between empty vector (3015 bp) 
and vector containing virus cDNA (3015 + 7515 = 10530 bp) for insertion into E. 
coli, and this would have been compounded by the lower proportion of constructs in 
the ligation mix. As mentioned, this could have been caused by the inefficient 
addition of A nts to 3’ ends of amplicon by the polymerases used, thereby reducing 
ligated fragments prior to transformation.  
 
ally 
                                                
 
The non-infectious E30 clones (strains Fi13 and GB27) contained several 
insertions/deletions upon sequencing and these are likely to have destroyed the 
genomes’ function. The E30 clones could be repaired at a later date using site-
directed mutagenesis or overlapping PCR to generate repaired infectious clones 
representing the remaining E30 strains. These would provide a useful model to study 
recombination between E30 strains in the future. 
 
Due to time restraints, attempts to construct a luciferase-encoding subgenomic 
replicon for E30 were not successful. Attempts were also made to mutagenise the 
CRE to inhibit the generation of viable virus from clone-derived virus RNA, but this 
was not completed. The latter project was performed in the same manner as that 
described for constructing pT7E7ΔCRE. An E30 subgenomic replicon and full-
length CRE mutant would have made valuable species B partners for in vitro 
recombination experiments using co-transfections.   
 
The construction of a full-length semi-replicating E7 clone was successful and could 
constitute one RNA partner in co-transfection experiments to generate recombinant 
viruses in cell culture. The modification of the replication element was stable during 
continuous RNA replication cycles and is unlikely to restore its infectivity in the long 
term based on data from 5 serial passages. The secondary structure of the CRE was 
completely disrupted from forming by mutagenesis so that it no longer presented as a 
 
4 (http://www.promega.com/enotes/faqspeak/0107/fq0030.htm) 
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stem loop. The CRE is involved in templating the uridylylation of VPg and is 
therefore required for the initiation of virus RNA synthesis. Disrupting the CRE 
structure meant that the two adenosines located at the CRE terminal loop could not 
function as a template for the addition of two uridylate residues to VPg, hence 
leading to inhibition of the formation of VPg-pUpU. As this modified VPg-pUpU is 
required as a primer for virus 3Dpol, and is linked to the 5’-end of the positive- and 
negative-strand genomes. Any disruptions to this process would therefore negatively 
affect replication. As negative-strand RNA synthesis was not affected, this provided 
an ideal species B partner for recombination experiments presented in this thesis.  
 
Due to time restraints, the replication ability (negative-strand synthesis) of 
pT7E7ΔCRE was not investigated. Instead, this new RNA partner was incorporated 
into a co-transfection assay with homologous pT7E7luc subgenomic replicon (refer 
to chapter four). Viable recombinant E7 was recovered, demonstrating semi-
replication of pT7E7ΔCRE in cell culture and the use of this model in the study of 
intraserotypic recombination events in both species B and species C picornaviruses. 
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CHAPTER SEVEN: General Discussion 
7.1 Current Understanding  
There are wide ranging implications of enterovirus evolution, particularly when 
recombination events contribute to the emergence of modified viruses associated 
with disease outbreaks. Outbreaks of non-wild-type PV are usually caused by 
recombination in low OPV vaccinated populations, and it is not clear which 
circulating enteroviruses will contribute to future outbreaks.  
 
Although it has been thoroughly investigated in several virus systems, little is known 
about the underlying molecular mechanisms of recombination between positive-
sense single stranded RNA viruses. A better understanding of these processes has 
been advanced in this study by the development of an experimental method for the 
generation of recombinant PVs. This method is beneficial for studying recombinant 
viruses because there are no competing parental-type viruses in the progeny, and the 
assay is not restricted by certain aspects of natural viral tropism, such as susceptible 
cell type and infection into the cell post-attachment. These characteristics allow the 
method to capture initial recombination events prior to further virus propagation.  
 
During this project, an assay was developed that produces populations of natural PV 
recombinants that leads to replication competent viruses. The system only allows for 
recombination events to occur in the genome region following VP1 and before the 
CRE, which is the location of commonly detected sites ‘in the wild’.  
The work presented in this thesis established general rules for recombination as 
observed in individual recombinant PVs: 
• The majority of junction sites are imprecise with insertions up to ~ 500 nts, in 
the 2A and 2B coding regions. 
• A minority of junction sites are precise, but usually located in the 2C coding 
region. 
• Template switching appears to be a sequence independent event, since inserts 
contain non-virus sequence derived from the luciferase reporter gene. 
• Template switching occurs independently of local RNA motifs, such as 
strings of As or AUs, potential stem loop structures, and palindromes. 
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• Recombinants contain a complete 2A and/or 2B coding region from one or 
other parent. The generation of chimeric 2A and 2B coding regions are rare in 
initial recombinants recovered, and only appear after subsequent serial 
passage.  
• Template switching is localised to regions, and not evenly distributed 
throughout the entire targeted region. As a consequence of the above. 
• Imprecise junction sites do not show deletions of sequence, only insertions. 
• Recombination is at least a two stage process, with initial template switching 
occurring in a ‘promiscuous’ and unpredictable manner (conforming to the 
general ‘rules’ above), while further rounds of replication correct imprecise 
crossover junctions to reflect wild-type virus genome length.  
 
The question of whether PV RdRp switches templates at preferred sites in the viral 
genome was explored by King in 1988, who analysed the crossover sites of 
approximately 50 reported interserotypic recombinants for poliovirus (King, 1988). 
King suggested that secondary structure was not involved in polymerase pausing, by 
stating that “most ssRNAs are extensively folded” naturally, which is in agreement 
with data presented in this project. Although previous reports had concluded that 
poliovirus recombination occurred in more general regions and not by a site-specific 
mechanism (Kirkegaard & Baltimore, 1986), King found a strong bias for the 
occurrence of precise crossover sites immediately after AA dinucleotides (two-thirds 
of those analysed), indicating a site-specific selectivity. It was not clear from the 
report whether this pertained to donor, acceptor, or both templates. Of the nine 
precise crossover sites identified in this study (figure 5.13), only one virus, 
PV3(3640-54)PV1, contained an adjacent 3’ AA dinucleotide on the donor template. 
It is difficult to conclude from this result without applying a larger dataset to this 
analysis. It was striking to discover, however, that 67% of crossover sites in this 
project occurred next to dipurine sequences (AA, AG, GA, or GG) on the donor 
strand. The significance of this finding could be investigated further with more 
experimental data.     
 
The nature of imprecise recombinant PVs may reflect restrictions imposed on the 
viruses during packaging. Imprecise recombinants contained inserted sequence up to 
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513 nt in length, and these genomes (now ~ 8 kb) could be approaching the 
theoretical packaging limit for capsid protein shells. Of current picornaviruses, 
FMDV has the largest genome at ~8.2 kb, and this is contained within similar sized 
particles to PV (~30 nm) (Fox et al., 1987). Teterina and colleagues successfully 
inserted a ~ 700 nt sequence encoding a fluorescent protein tag into 2Apro of PV, and 
this increased the genome length to just over 8.1 kb (Teterina et al., 2010). But like 
the recombinants generated in this project, the fluorescently tagged virus was only 
stable for four passages before deletions appeared in the non-virus sequence. It is 
possible that longer genomes can only be packaged in larger particles, and longer 
recombinant PVs may be approaching the theoretical packaging limit for the 
conserved particle size, therefore imposing a selection pressure on the size of insert 
and final genome length. 
 
There are many steps in the virus life cycle that lead to the generation of a viable 
recombinant virus, and there are equally numerous constraints imposed by the host 
and virus itself that could impact on this occurring. The possible constraints at each 
level of the virus life cycle are described in figure 7.1. It is not known what 
proportion of cells in the host are co-infected, or the proportion of virus RNA 
partners that reside within the same replication complex. This relates directly to the 
MOI and would also be limited to the number of sites in which replication complexes 
can be established within an infected cell. When looking at a subset of partners that 
have made it through early selection as just mentioned, a rough probability of 
successful template switches can be calculated. Those recombinants with forward 
crossovers will not survive since they contain deletions, and crossovers that are too 
far back (> 513 nt, the maximum observed in this study) may be too long for 
successful packaging. If the location of template switching is evenly distributed 
throughout the genome, each nt position would have 1/7440 chance of being the 
location of a junction site (PV1 Mahoney genome contains 7440 nt), but this is not 
the case. This is also influenced by the location in the genome where recombination 
occurs, as its clear that it rarely occurs in the capsid region, which is approximately 
1/3 of the genome. This means that ~4800 nt would be accessible in the donor 
template, and ~5300 nt in the acceptor template (including up to ~500 nt insertion). If 
a virus can only tolerate a 513 nt insert, then there are theoretically 513/4800 
possible junction sites in the genome. Subsequently, only 1/3 will be translated in 
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 Figure 7.1 Production (and restrictions) of a viable recombinant RNA virus. The 
steps necessary to generate a recombinant and viable RNA virus in a host, and the 
constraints imposed at each stage by a combination of virus and host. (This model is 
adapted from Worobey & Holmes, 1999). 
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frame, meaning that ~2% (513/5300 x 4800/7440 x 1/3 x 100%) of recombinant 
genomes will fulfil all the ‘rules’. This small subset of successful recombinants must 
then prove viable at all subsequent steps of the life cycle. In a simplified way, this 
demonstrates the low frequency of recombination events that must occur in the host.  
 
Many restrictions can be imposed on the creation of a viable replication-competent 
recombinant virus, from both the host and virus itself. Considering the number of 
restrictions that could impact on the generation of recombinant viruses, it is not 
surprising that intra- and interspecies recombinants are rarely identified, and why 
interspecies viruses were not recovered during this project. At the amino acid level, 
chimeric virus proteins containing both CVA21 and PV sequence were not observed 
in isolated recombinants. Such junctions may have occurred during replication, but 
were later selected against during protein processing or morphogenesis. Similarly, 
since the construction of the recombinant CVA21/PV full-length cDNAs by Dr. 
Claire Blanchard, it is now known that direct interactions between proteins VP3 and 
2CATPase are vital for virus morphogenesis (refer to chapter four).  
 
This method has highlighted the promiscuous nature of early recombination events 
between two closely related viruses. Recombinant genomes may have been generated 
between input RNA species within the cell, but might not have been functional at 
later stages of the life cycle. Only a few interspecies recombinants have been 
identified from natural isolates (Bolanaki et al., 2007; Yozwiak et al., 2010), and 
only small regions of genome are replaced (e.g. 5’ NCR or 3D) compared to 
significant portions of genome aimed for in these experiments (Smura et al., 2007). 
Chimeric PV genomes with an HRV2 2Apro did not generate viable virus, but those 
with a CVB4 2Apro did, suggesting that replacements with more closely related virus 
sequences will be more likely to conserve function (Lu et al., 1995). In another 
approach, Bell and colleagues replaced the 3Dpol coding sequence with that from 
CVB3 in a PV1 infectious clone. No infectious virus was produced from the 
chimeric RNA and no RNA synthesis occurred in transfected HeLa cells, indicating 
that these chimeric genome regions were not compatible for essential interactions 
(Bell et al., 1999). It seems that interspecies recombinants, with a junction site in the 
centre of the genome, have either remained undiscovered, or are not viable due to 
incompatibilities in RNA-RNA or RNA-protein interactions during replication. Such 
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sequence motifs required for these interactions are poorly defined and are difficult to 
identify, although they must be localised to the coding region, as NCR functions and 
the CRE are similar between species. This could explain the lack of chimeric viruses 
with different structural and non-structural coding regions during intra- and 
interspecies co-transfection experiments. 
7.2 Future experiments 
As this method for generating recombinant viruses has proven efficient and 
reproducible, it can be expanded upon to gain further insight into the influences of 
recombination at the virus and host levels. 
• If crossover junctions identified in this project are not dependent on sequence 
identity between RNA partners or local sequence/structure motifs, then it 
would be of interest to perform the same co-transfection, with PV1 replicon 
and PV3 CRE mutant, several times independently to determine whether 
recombination events follow the ‘general rules’ mentioned above. The 
observations above were obtained from a limited number of experiments, and 
it is inconclusive whether only a single host cell produces a virus with a 
distinct junction site that replicates well (reflected in the number of clones 
identified), or whether the same recombinant can be generated by more than 
one host cell in the population. Recombination junction sites from replicate 
assays can be compared to investigate this.  
• Resistance markers in mutagen-induced viruses have previously been applied 
in order to calculate recombination frequencies (Kirkegaard & Baltimore, 
1986; McCahon et al., 1977). Similar controlled experiments can be applied 
to the method in this project in order to accurately calculate recombination 
frequencies in relation to distance of RNA partner relatedness. Any 
influences of the distance between lesions in both RNA partners on 
recombination frequencies can also be determined. 
• Due to time restraints, it was not possible to incorporate different species B 
RNA partners into this method. The availability of a full-length infectious 
E30 clone makes it possible to construct a CRE mutant using either site-
directed mutagenesis or by overlapping PCR (as was the case for mutating 
CRE in pT7E7). Similarly, a portion of the capsid coding region can be 
removed by restriction digest followed by religation of flanking 5’ and 3’ 
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termini, to construct a replication competent E30 DI particle or a luciferase 
(or similar reporter) coding replicon. Co-transfections with E7 and E30 RNA 
partners can be performed to validate this method further and to determine 
whether both viruses will recombine in vitro.  
• Mechanistic studies of PV RdRp have uncovered an amino acid substitution 
resulting from a single nt change (G64S) in the 3Dpol encoding region that 
improves fidelity during replication (Pfeiffer & Kirkegaard, 2003) and 
reduces the elongation rate (Arnold et al., 2005). Both of these events may 
impact on the frequency of template switching by PV RdRp and can be 
determined experimentally by incorporating the G64S substitution into RNA 
partners prior to co-transfections. A less error-prone RdRp may reduce the 
frequency of template switching between RNA templates, and the opposite 
phenomenon can be investigated by decreasing RdRp fidelity. This could be 
achieved by performing recombination experiments in the presence of 
ribavirin. 
• As briefly mentioned above, the distance between engineered “lesions” 
contained within RNA partners can be altered by relocating the CRE to other 
regions of the genome with little impact on function (Goodfellow et al., 
2003). For example, a mutated CRE at opposing ends of each RNA partner 
genome will allow an even greater region for targeted recombination and may 
establish ‘hot spots’ outside the scope of this project.  
• There has been much interest in host and environmental factors contributing 
to RNA recombination, particularly involving plant viruses. Genome-wide 
screens representing ~95% of host genes have been performed with Tomato 
bushy stunt virus (TBSV) in a yeast model, to identify host genes affecting 
RNA recombination (Serviene et al., 2006; Serviene et al., 2005). 
Interestingly, at least two important pathways have been identified in yeast 
that directly affect virus replication and recombination in the presence of 
external chemical factors. In one study, it was reported that inactivation of 
yeast host Pmr1p, an ion pump that controls Ca2+/Mn2+ movement into the 
Golgi from the cytosol, led to an ~160-fold increase in TBSV recombination 
in yeast (Jaag et al., 2010). This involved deleting non-overlapping fragments 
of PMR1 gene (highly conserved gene that encodes Pmr1p) following by the 
initiation of TBSV RNA replication from expression plasmids. Analysis of 
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northern blots revealed the more efficient accumulation of RNA 
recombinants in deletion mutants compared than in wild-type yeast. In 
another study, it was demonstrated that the MET22/Xrn1 pathway 
(nucleotidases/ ribonucleases) regulates the frequency of TBSV RNA 
recombination and efficiency of virus replication in a yeast system (Jaag & 
Nagy, 2010). Not only did deletions of MET22 gene increase TBSV RNA 
replication and recombination, but the addition of either LiCl or NaCl was 
also shown to inhibit MET22p activity to produce similar outcomes. To 
conclude, it would be meaningful to identify similar genes/pathways in 
humans and determine whether such applied host and external factors could 
affect PV replication and recombination in the same manner. Preliminary 
searching has revealed that a human equivalent of the conserved PMR1 gene 
exists with a similar function, and is known as calcium-transporting ATPase 
type 2C member 1 (ATP2C1) (NCBI reference sequence NM_001199185). 
Likewise, human equivalents of MET22 gene encoding bisphosphate-3’-
nucleotidase can be identified and subsequently altered experimentally (with 
siRNA) to determine affects on PV replication and recombination 
efficiencies.  
• Observations in in vitro assays using cell lines do not always represent 
mechanisms in in vivo models. The experimental method presented in this 
thesis is an artificial system, as naked RNA is introduced directly into cells 
(bypassing natural virus infection stages), and RNA partners contain non-
virus sequence. It would be beneficial to apply this method to an animal 
model using transgenic mice that express PVR. A proposed experiment is to 
inject a solution containing two PV RNA partners directly into the spine 
(intrathecally) of mice. After a short period of time, tissue would be removed 
from different regions of the mouse, including from sites surrounding the 
injection location. Any viable recombinant PVs in mouse tissue can be 
initially identified by plaque assay, following by isolation of individual 
viruses for characterisation. If recombinant PV is recovered, crossover sites 
can be characterised according to the location of tissue they are derived from. 
Are recombinant PVs similar to those generated in vitro, and do they follow 
the same ‘general rules’? Do crossover sites change according to the distance 
from the initial injection site? The prediction would be that the further away 
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from the site of inoculation, the more precise the recombinants would be as 
those viruses can spread more efficiently. Such recombinants will have to 
overcome multiple host restrictions that are not present in an in vitro system; 
this may influence the frequency and nature of recombination.  
 
The work in this thesis contributes to our understanding of the underlying 
mechanisms involved in RNA recombination. Viruses must survive various 
constraints imposed by the infected host and by the virus itself, and they achieve this 
through rapid adaptation of their large population sizes and with the aid of 
recombination. 
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Appendix 1 Potential cleavage products of selected imprecise recombinants. The PV3 polyprotein and cleavage pattern is outlined at the top 
of the page. The central polyprotein region has been expanded to further depict the genome structure of several imprecise recombinants (outlined 
in table 5.1), together with known cleavage sites for virus proteases 2Apro and 3Cpro. Approximately 17 nt of the 3’ end of VP1 coding region 
remains after the luciferase gene in the pRLucWT (blue shading), in order to maintain 2Apro cleavage site. 
 
